Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
The formation or presence of a blood clot (THROMBUS) within a vein.
Agents that prevent clotting.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
Inflammation of a vein associated with a blood clot (THROMBUS).
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Bleeding or escape of blood from a vessel.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed)
Tight coverings for the foot and leg that are worn to aid circulation in the legs, and prevent the formation of EDEMA and DEEP VEIN THROMBOSIS. PNEUMATIC COMPRESSION STOCKINGS serve a similar purpose especially for bedridden patients, and following surgery.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.
Mechanical devices inserted in the inferior vena cava that prevent the migration of blood clots from deep venous thrombosis of the leg.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Instruments that generate intermittent forces, uniformed or graduated, to facilitate the emptying of VEINS. These devices are used to reduce limb EDEMA and prevent venous THROMBOEMBOLISM, such as deep vein thrombosis in the legs.
System established by the World Health Organization and the International Committee on Thrombosis and Hemostasis for monitoring and reporting blood coagulation tests. Under this system, results are standardized using the International Sensitivity Index for the particular test reagent/instrument combination used.
The return of a sign, symptom, or disease after a remission.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.
A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Formation and development of a thrombus or blood clot in the blood vessel.
A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
Fixed drug combinations administered orally for contraceptive purposes.
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Surgical removal of an obstructing clot or foreign material which has been transported from a distant vessel by the bloodstream. Removal of a clot at its original site is called THROMBECTOMY.
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
An absence or deficiency in PROTEIN C which leads to impaired regulation of blood coagulation. It is associated with an increased risk of severe or premature thrombosis. (Stedman's Med. Dict., 26th ed.)
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Material used for wrapping or binding any part of the body.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Radiographic visualization or recording of a vein after the injection of contrast medium.
A condition caused by one or more episodes of DEEP VEIN THROMBOSIS, usually the blood clots are lodged in the legs. Clinical features include EDEMA; PAIN; aching; heaviness; and MUSCLE CRAMP in the leg. When severe leg swelling leads to skin breakdown, it is called venous STASIS ULCER.
An autosomal dominant disorder showing decreased levels of plasma protein S antigen or activity, associated with venous thrombosis and pulmonary embolism. PROTEIN S is a vitamin K-dependent plasma protein that inhibits blood clotting by serving as a cofactor for activated PROTEIN C (also a vitamin K-dependent protein), and the clinical manifestations of its deficiency are virtually identical to those of protein C deficiency. Treatment with heparin for acute thrombotic processes is usually followed by maintenance administration of coumarin drugs for the prevention of recurrent thrombosis. (From Harrison's Principles of Internal Medicine, 12th ed, p1511; Wintrobe's Clinical Hematology, 9th ed, p1523)
The co-occurrence of pregnancy and a cardiovascular disease. The disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233)
A synthetic progestational hormone used often as the progestogenic component of combined oral contraceptive agents.
The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot.
An amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported.
Thiophenes are aromatic heterocyclic organic compounds containing a five-membered ring with four carbon atoms and one sulfur atom, which are found in various natural substances and synthesized for use in pharmaceuticals and agrochemicals.
Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of prothrombin to thrombin in conjunction with other cofactors.
A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.
Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both.
Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.
Double-layered inflatable suits which, when inflated, exert pressure on the lower part of the wearer's body. The suits are used to improve or stabilize the circulatory state, i.e., to prevent hypotension, control hemorrhage, and regulate blood pressure. The suits are also used by pilots under positive acceleration.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
The giving of drugs, chemicals, or other substances by mouth.
I'm sorry for any confusion, but "Austria" is a country located in Central Europe and it is not a medical term or concept. Therefore, it doesn't have a medical definition.
Pregnenes with one double bond or more than three double bonds which have undergone ring contractions or are lacking carbon-18 or carbon-19..
Oral contraceptives which owe their effectiveness to synthetic preparations.
Elements of limited time intervals, contributing to particular results or situations.
An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis.
The restriction of the MOVEMENT of whole or part of the body by physical means (RESTRAINT, PHYSICAL) or chemically by ANALGESIA, or the use of TRANQUILIZING AGENTS or NEUROMUSCULAR NONDEPOLARIZING AGENTS. It includes experimental protocols used to evaluate the physiologic effects of immobility.
Replacement of the knee joint.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
Ear-shaped appendage of either atrium of the heart. (Dorland, 28th ed)
Strips of elastic material used to apply pressure to body parts to control EDEMA and aid circulation.
A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Pyridine derivatives with one or more keto groups on the ring.
That branch of medicine dealing with the studies and effects of flight through the atmosphere or in space upon the human body and with the prevention or cure of physiological or psychological malfunctions arising from these effects. (from NASA Thesaurus)
Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues using a transducer placed in the esophagus.
Disease having a short and relatively severe course.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Surgical removal of an obstructing clot or foreign material from a blood vessel at the point of its formation. Removal of a clot arising from a distant site is called EMBOLECTOMY.
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.
Embolism or thrombosis involving blood vessels which supply intracranial structures. Emboli may originate from extracranial or intracranial sources. Thrombosis may occur in arterial or venous structures.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material.
Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.
The confinement of a patient in a hospital.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
Formation or presence of a blood clot (THROMBUS) in a blood vessel within the SKULL. Intracranial thrombosis can lead to thrombotic occlusions and BRAIN INFARCTION. The majority of the thrombotic occlusions are associated with ATHEROSCLEROSIS.
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
Replacement of the hip joint.
The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).
The vein accompanying the femoral artery in the same sheath; it is a continuation of the popliteal vein and becomes the external iliac vein.
Laboratory tests for evaluating the individual's clotting mechanism.
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Persons admitted to health facilities which provide board and room, for the purpose of observation, care, diagnosis or treatment.
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
A heparin fraction with a mean molecular weight of 4500 daltons. It is isolated from porcine mucosal heparin and used as an antithrombotic agent. (From Merck Index, 11th ed)
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
'Hospital Bed Capacity, 300 to 499' is a term used to describe healthcare facilities that have a bed capacity ranging between three hundred to four hundred and ninety-nine beds, which enables them to accommodate and manage a substantial number of patients while providing essential medical services.'
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Polysaccharides are complex carbohydrates consisting of long, often branched chains of repeating monosaccharide units joined together by glycosidic bonds, which serve as energy storage molecules (e.g., glycogen), structural components (e.g., cellulose), and molecular recognition sites in various biological systems.
Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).
Procedures used to treat and correct deformities, diseases, and injuries to the MUSCULOSKELETAL SYSTEM, its articulations, and associated structures.
Conformity in fulfilling or following official, recognized, or institutional requirements, guidelines, recommendations, protocols, pathways, or other standards.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Morpholines are organic compounds containing a morpholine ring, which is a saturated six-membered heterocycle made up of four carbon atoms and two oxygen atoms (OCC1CCO), often used as functional groups in pharmaceuticals, agrochemicals, and materials science due to their versatile chemical properties.
An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN.
A congenital disorder that is characterized by a triad of capillary malformations (HEMANGIOMA), venous malformations (ARTERIOVENOUS FISTULA), and soft tissue or bony hypertrophy of the limb. This syndrome is caused by mutations in the VG5Q gene which encodes a strong angiogenesis stimulator.
Hemorrhage following any surgical procedure. It may be immediate or delayed and is not restricted to the surgical wound.
The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Placement of an intravenous CATHETER in the subclavian, jugular, or other central vein.
The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs.
Compounds with a BENZENE fused to IMIDAZOLES.
Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.
Toluenes in which one hydrogen of the methyl group is substituted by an amino group. Permitted are any substituents on the benzene ring or the amino group.
A condition characterized by a chronically swollen limb, often a leg with stasis dermatitis and ulcerations. This syndrome can appear soon after phlebitis or years later. Postphlebitic syndrome is the result of damaged or incompetent venous valves in the limbs. Distended, tortuous VARICOSE VEINS are usually present. Leg pain may occur after long period of standing.
Azetidines are saturated, organic compounds containing a 4-membered ring with two carbon atoms and two nitrogen atoms (one as a secondary amine), which can be found in certain pharmaceuticals and natural substances, although they are less common than other cyclic amines.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Intrauterine devices that release contraceptive agents.
Blocking of a blood vessel in the SKULL by an EMBOLUS which can be a blood clot (THROMBUS) or other undissolved material in the blood stream. Most emboli are of cardiac origin and are associated with HEART DISEASES. Other non-cardiac sources of emboli are usually associated with VASCULAR DISEASES.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
A deficiency of blood coagulation factor V (known as proaccelerin or accelerator globulin or labile factor) leading to a rare hemorrhagic tendency known as Owren's disease or parahemophilia. It varies greatly in severity. Factor V deficiency is an autosomal recessive trait. (Dorland, 27th ed)
Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.
Radiography of blood vessels after injection of a contrast medium.
The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION.
Oral contraceptives which owe their effectiveness to hormonal preparations.
The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.
Blocking of a blood vessel by an embolus which can be a blood clot or other undissolved material in the blood stream.
The term "United States" in a medical context often refers to the country where a patient or study participant resides, and is not a medical term per se, but relevant for epidemiological studies, healthcare policies, and understanding differences in disease prevalence, treatment patterns, and health outcomes across various geographic locations.
The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
Pathological conditions involving the HEART including its structural and functional abnormalities.
Recording changes in electrical impedance between electrodes placed on opposite sides of a part of the body, as a measure of volume changes in the path of the current. (Stedman, 25th ed)
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.
Injection of an anesthetic into the nerves to inhibit nerve transmission in a specific part of the body.
Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.
The chambers of the heart, to which the BLOOD returns from the circulation.
A weight-carrying structure for navigation of the air that is supported either by its own buoyancy or by the dynamic action of the air against its surfaces. (Webster, 1973)
Procedure to accelerate the ability of a patient to walk or move about by reducing the time to AMBULATION. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
The vitamin K-dependent cofactor of activated PROTEIN C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S; (PROTEIN S DEFICIENCY); can lead to recurrent venous and arterial thrombosis.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Pipecolic acids are cyclic amino acids, specifically a derivative of L-lysine, that can function as an indicator of certain metabolic disorders such as lysinuric protein intolerance and maple syrup urine disease.
A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.
The use of chemical compounds to prevent the development of a specific disease.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with MESTRANOL.
## I'm sorry for any confusion, but "Japan" is not a medical term or concept. It is a country located in Asia, known as Nihon-koku or Nippon-koku in Japanese, and is renowned for its unique culture, advanced technology, and rich history. If you have any questions related to medical topics, I would be happy to help answer them!
Postmortem examination of the body.
Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.
A condition caused by dysfunctions related to the SINOATRIAL NODE including impulse generation (CARDIAC SINUS ARREST) and impulse conduction (SINOATRIAL EXIT BLOCK). It is characterized by persistent BRADYCARDIA, chronic ATRIAL FIBRILLATION, and failure to resume sinus rhythm following CARDIOVERSION. This syndrome can be congenital or acquired, particularly after surgical correction for heart defects.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
The venous trunk which receives blood from the lower extremities and from the pelvic and abdominal organs.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The valve between the left atrium and left ventricle of the heart.
I'm sorry for any confusion, but "Massachusetts" is a geographical location and not a medical term or concept. It is a state located in the northeastern region of the United States. If you have any medical questions or terms you would like me to define, please let me know!
Formation or presence of a blood clot (THROMBUS) in the SUPERIOR SAGITTAL SINUS or the inferior sagittal sinus. Sagittal sinus thrombosis can result from infections, hematological disorders, CRANIOCEREBRAL TRAUMA; and NEUROSURGICAL PROCEDURES. Clinical features are primarily related to the increased intracranial pressure causing HEADACHE; NAUSEA; and VOMITING. Severe cases can evolve to SEIZURES or COMA.
Surgery which could be postponed or not done at all without danger to the patient. Elective surgery includes procedures to correct non-life-threatening medical problems as well as to alleviate conditions causing psychological stress or other potential risk to patients, e.g., cosmetic or contraceptive surgery.
I'm sorry for any confusion, but "Denmark" is not a medical term and does not have a medical definition. It is a country located in northern Europe. If you have any questions related to medicine or health, I would be happy to try to help answer them.
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.
Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).
Measures aimed at providing appropriate supportive and rehabilitative services to minimize morbidity and maximize quality of life after a long-term disease or injury is present.
Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).
An approach of practicing medicine with the goal to improve and evaluate patient care. It requires the judicious integration of best research evidence with the patient's values to make decisions about medical care. This method is to help physicians make proper diagnosis, devise best testing plan, choose best treatment and methods of disease prevention, as well as develop guidelines for large groups of patients with the same disease. (from JAMA 296 (9), 2006)
Specific practices for the prevention of disease or mental disorders in susceptible individuals or populations. These include HEALTH PROMOTION, including mental health; protective procedures, such as COMMUNICABLE DISEASE CONTROL; and monitoring and regulation of ENVIRONMENTAL POLLUTANTS. Primary prevention is to be distinguished from SECONDARY PREVENTION and TERTIARY PREVENTION.
A subnormal level of BLOOD PLATELETS.
The vein formed by the union of the anterior and posterior tibial veins; it courses through the popliteal space and becomes the femoral vein.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
The study of chance processes or the relative frequency characterizing a chance process.
Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases. (Taber, 18th ed.)
Cardiac manifestation of systemic rheumatological conditions, such as RHEUMATIC FEVER. Rheumatic heart disease can involve any part the heart, most often the HEART VALVES and the ENDOCARDIUM.
The region of the lower limb in animals, extending from the gluteal region to the FOOT, and including the BUTTOCKS; HIP; and LEG.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
Prosthesis, usually heart valve, composed of biological material and whose durability depends upon the stability of the material after pretreatment, rather than regeneration by host cell ingrowth. Durability is achieved 1, mechanically by the interposition of a cloth, usually polytetrafluoroethylene, between the host and the graft, and 2, chemically by stabilization of the tissue by intermolecular linking, usually with glutaraldehyde, after removal of antigenic components, or the use of reconstituted and restructured biopolymers.
The hemodynamic and electrophysiological action of the LEFT ATRIUM.
A measurement of the time needed for FIBRINOLYSIS to occur.
Condition in which the plasma levels of homocysteine and related metabolites are elevated (>13.9 µmol/l). Hyperhomocysteinemia can be familial or acquired. Development of the acquired hyperhomocysteinemia is mostly associated with vitamins B and/or folate deficiency (e.g., PERNICIOUS ANEMIA, vitamin malabsorption). Familial hyperhomocysteinemia often results in a more severe elevation of total homocysteine and excretion into the urine, resulting in HOMOCYSTINURIA. Hyperhomocysteinemia is a risk factor for cardiovascular and neurodegenerative diseases, osteoporotic fractures and complications during pregnancy.
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Bleeding within the SKULL induced by penetrating and nonpenetrating traumatic injuries, including hemorrhages into the tissues of CEREBRUM; BRAIN STEM; and CEREBELLUM; as well as into the epidural, subdural and subarachnoid spaces of the MENINGES.
A platelet-specific protein which is released when platelets aggregate. Elevated plasma levels have been reported after deep venous thrombosis, pre-eclampsia, myocardial infarction with mural thrombosis, and myeloproliferative disorders. Measurement of beta-thromboglobulin in biological fluids by radioimmunoassay is used for the diagnosis and assessment of progress of thromboembolic disorders.
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
The inferior part of the lower extremity between the KNEE and the ANKLE.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
Extracellular vesicles generated by the shedding of CELL MEMBRANE blebs.

Outcome of pregnancy in women with congenital shunt lesions. (1/1606)

OBJECTIVE: To evaluate the outcome of pregnancy in women with congenital shunt lesions. SETTING: Retrospective study in a tertiary care centre. METHODS: Pregnancy history was obtained by a standardised questionnaire and medical records were reviewed. PATIENTS: 175 women were identified, at a mean (SD) age of 42 (14) years. Pregnancies occurred in 126 women: 50 with an atrial septal defect, 22 with a ventricular septal defect, 22 with an atrioventricular septal defect, 19 with tetralogy of Fallot, and 13 with other complex shunt lesions. RESULTS: 309 pregnancies were reported by 126 woman (2.5 (1.6) pregnancies per woman). The shortening fraction of the systemic ventricle was 40 (8)%, and 98% were in New York Heart Association class I-II at last follow up. Spontaneous abortions occurred in 17% of pregnancies (abortion rate, 0.4 (0.9) per woman). Gestational age of the 241 newborn infants was 8.8 (0.8) months. There were no maternal deaths related to pregnancy. Pre-eclampsia and embolic events were observed in 1.3% and 0.6%, respectively of all pregnancies. Women with complex shunt lesions more often underwent caesarean section (70% v 15-30%, p = 0.005) and gave birth to smaller babies for equivalent gestation (2577 (671) g v 3016 (572) to 3207 (610) g, p < 0.05). The recurrence risk of congenital heart disease was 2.5%. CONCLUSIONS: The outcome of pregnancy is favourable in women with congenital shunt lesions if their functional class and their systolic ventricular function are good. Such patients can be reassured.  (+info)

Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. (2/1606)

The reported incidence of thromboembolism in children with acute lymphoblastic leukemia (ALL) treated with L-asparaginase, vincristine, and prednisone varies from 2.4% to 11.5%. The present study was designed to prospectively evaluate the role of the TT677 methylenetetrahydrofolate reductase (MTHFR) genotype, the prothrombin G20210A mutation, the factor V G1691A mutation, deficiencies of protein C, protein S, antithrombin, and increased lipoprotein (a) concentrations in leukemic children treated according to the ALL-Berlin-Frankfurt-Muenster (BFM) 90/95 study protocols with respect to the onset of vascular events. Three hundred and one consecutive leukemic children were enrolled in this study. Fifty-five of these 301 subjects investigated had one established single prothrombotic risk factor: 20 children showed the TT677 MTHFR genotype; 5 showed the heterozygous prothrombin G20210A variant; 11 were carriers of the factor V G1691A mutation (heterozygous, n = 10; homozygous, n = 1); 4 showed familial protein C, 4 protein S, and 2 antithrombin type I deficiency; 9 patients were suffering from familially increased lipoprotein (a) [Lp(a)] concentrations (>30 mg/dL). In addition, combined prothrombotic defects were found in a further 10 patients: the FV mutation was combined with the prothrombin G20210A variant (n = 1), increased Lp(a) (n = 3), protein C deficiency (n = 1), and homozygosity for the C677T MTHFR gene mutation (n = 1). Lp(a) was combined with protein C deficiency (n = 2) and the MTHFR TT 677 genotype (n = 2). Two hundred eighty-nine of the 301 patients were available for thrombosis-free survival analysis. In 32 (11%) of these 289 patients venous thromboembolism occurred. The overall thrombosis-free survival in patients with at least one prothrombotic defect was significantly reduced compared with patients without a prothrombotic defect within the hemostatic system (P <.0001). In addition, a clear-cut positive correlation (P <.0001) was found between thrombosis and the use of central lines. However, because the prothrombotic defects diagnosed in the total childhood population studied were all found within the prevalences reported for healthy Caucasian individuals, the interaction between prothrombotic risk factors, ALL treatment, and further environmental factors is likely to cause thrombotic manifestations.  (+info)

Bileaflet mechanical prostheses for aortic valve replacement in patients younger than 65 years and 65 years of age or older: major thromboembolic and hemorrhagic complications. (3/1606)

OBJECTIVE: To determine major thromboembolic and hemorrhagic complications and predictive risk factors associated with aortic valve replacement (AVR), using bileaflet mechanical prostheses (CarboMedics and St. Jude Medical). DESIGN: A case series. SETTING: Cardiac surgical services at the teaching institutions of the University of British Columbia. PATIENTS AND METHODS: Patients 2 age groups who had undergone AVR between 1989 and 1994 were studied. Group 1 comprised 384 patients younger than 65 years. Group 2 comprised 215 patients 65 years of age and older. RESULTS: The linearized rates of major thromboembolism (TE) occurring after AVR were 1.54%/patient-year for group 1 and 3.32%/patient-year for group 2; the rates for major TE occurring more than 30 days after AVR were 1.13%/patient-year for group 1 and 1.55%/patient-year for group 2. The crude rates for major TE occurring within 30 days of AVR were 1.04% for group 1 and 3.72% for group 2. The death rate from major TE in group 1 was 0.31%/patient-year and in group 2 was 0.88%/patient-year. Of the major TE events occurring within 30 days, 100% of patients in both age groups were inadequately anticoagulated at the time of the event, and for events occurring more than 30 days after AVR, 45% in group 1 and 57% in group 2 were inadequately anticoagulated (INR less than 2.0). The overall linearized rates of major hemorrhage were 1.54%/patient-year for group 1 and 2.21%/patient-year for group 2. There were no cases of prosthesis thrombosis in either group. The mean (and standard error) overall freedom from major TE for group 1 patients at 5 years was 95.6% (1.4%) and with exclusion of early events was 96.7% (1.3%); for group 2 patients the rates were 90.0% (3.2%) and 93.7% (3.0%), respectively. The mean (and SE) overall freedom from major and fatal TE and hemorrhage for group 1 patients was 90.1% (2.3%) and with exclusion of early events was 91.2% (2.3%); for group 2 patients the rates were 87.9% (3.1%) and 92.5% (2.9%), respectively. The 5-year rate for freedom from valve-related death for group 1 patients was 96.3% (2.1%) and for group 2 patients was 97.2% (1.2%). CONCLUSION: The thromboembolic and hemorrhagic complications after AVR with bileaflet mechanical prostheses occur more frequently and result in more deaths in patients 65 years of age and older than in patients years younger than 65 years.  (+info)

Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. (4/1606)

The inherited thrombophilias--deficiencies of protein C, protein S, and antithrombin III--and the prothrombotic polymorphisms factor V G1691A and factor II G20210A predispose patients toward venous thromboembolism (VTE). The aim of this study was to determine the prevalence of single and combined prothrombotic factors in patients with idiopathic VTE and to estimate the associated risks. The study group consisted of 162 patients referred for work-up of thrombophilia after documented VTE. The controls were 336 consecutively admitted patients. In all subjects factor V G1691A, factor II G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T were analyzed by specific polymerase chain reactions and restriction enzymes. Activities of antithrombin III and protein C, free protein S antigen, and lupus anticoagulant were determined in a subset of 109 patients who were not receiving oral anticoagulants. The prevalences of heterozygotes and homozygotes for factor V G1691A and factor II G20210A among patients and controls were 40.1% versus 3.9% and 18.5% versus 5.4%, respectively (P=0.0001). The prevalence of homozygotes for MTHFR C677T in patients was 22.8% and in controls, 14.3% (P=0.025). Heterozygous and homozygous factor V G1691A, factor II G20210A, and homozygous MTHFR C677T were found to be independent risk factors for VTE, with odds ratios of 16.3, 3.6, and 2.1, respectively. Two or more polymorphisms were detected in 27 of 162 patients (16.7%) and in 3 of 336 controls (0.9%). Logistic regression analysis disclosed odds ratios of 58.6 (confidence interval [CI], 22.1 to 155.2) for joint occurrence of factor V and factor II polymorphisms, of 35.0 (CI, 14.5 to 84.7) for factor V and MTHFR polymorphisms, and of 7.7 (CI, 3.0 to 19.6) for factor II and MTHFR polymorphisms. Among 109 patients in whom a complete thrombophilic work-up was performed, 74% had at least 1 underlying defect. These data indicate that in most patients referred for evaluation of thrombophilia due to idiopathic VTE, 1 or more underlying genetic predispositions were discernible. The presence of >1 of the prothrombotic polymorphisms was associated with a substantial risk of VTE.  (+info)

Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. (5/1606)

BACKGROUND: The long-term prognosis for patients with pulmonary embolism (PE) is dependent on the underlying disease, degree of pulmonary hypertension (PH), and degree of right ventricular (RV) dysfunction. A precise description of the time course of pulmonary artery pressure (PAsP)/RV function is therefore of importance for the early identification of persistent PH/RV dysfunction in patients treated for acute PE. Other objectives were to identify variables associated with persistent PH/RV dysfunction and to analyze the 5-year survival rate for patients alive 1 month after inclusion. METHODS AND RESULTS: Echocardiography Doppler was performed in 78 patients with acute PE at the time of diagnosis and repeatedly during the next year. A 5-year survival analysis was made. The PAsP decreased exponentially until the beginning of a stable phase, which was 50 mm Hg at the time of diagnosis of acute PE was associated with persistent PH after 1 year. The 5-year mortality rate was associated with underlying disease. Only patients with persistent PH in the stable phase required pulmonary thromboendarterectomy within 5 years. CONCLUSIONS: An echocardiography Doppler investigation performed 6 weeks after diagnosis of acute PE can identify patients with persistent PH/RV dysfunction and may be of value in planning the follow-up and care of these patients.  (+info)

In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. (6/1606)

OBJECTIVES: The purpose of this study was to target acoustically reflective liposomes to atherosclerotic plaques in vivo for ultrasound image enhancement. BACKGROUND: We have previously demonstrated the development of acoustically reflective liposomes that can be conjugated for site-specific acoustic enhancement. This study evaluates the ability of liposomes coupled to antibodies specific for different components of atherosclerotic plaques and thrombi to target and enhance ultrasonic images in vivo. METHODS: Liposomes were prepared with phospholipids and cholesterol using a dehydration/ rehydration method. Antibodies were thiolated for liposome conjugation with N-succinimidyl 3-(2-pyridyldithio) propionate resulting in a thioether linkage between the protein and the phospholipid. Liposomes were conjugated to antifibrinogen or anti-intercellular adhesion molecule-1 (anti-ICAM-1). In a Yucatan miniswine model, atherosclerosis was developed by crush injury of one carotid and one femoral artery and ingestion of a hypercholesterolemic diet. After full plaque development the arteries were imaged (20-MHz intravascular ultrasound catheter and 7.5-MHz transvascular linear probe) after injection of saline, unconjugated liposomes and antibody conjugated liposomes. RESULTS: Conjugated liposomes retained their acoustically reflective properties and provided ultrasonic image enhancement of their targeted structures. Liposomes conjugated to antifibrinogen attached to thrombi and fibrous portions of the atheroma, whereas liposomes conjugated to anti-ICAM-1 attached to early atheroma. CONCLUSIONS: Our data demonstrate that this novel acoustic agent can provide varying targeting with different antibodies with retention of intravascular and transvascular acoustic properties.  (+info)

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. (7/1606)

BACKGROUND: Patients who have a first episode of venous thromboembolism in the absence of known risk factors for thrombosis (idiopathic thrombosis) are often treated with anticoagulant therapy for three months. Such patients may benefit from longer treatment, however, because they appear to have an increased risk of recurrence after anticoagulant therapy is stopped. METHODS: In this double-blind study, we randomly assigned patients who had completed 3 months of anticoagulant therapy for a first episode of idiopathic venous thromboembolism to continue receiving warfarin, with the dose adjusted to achieve an international normalized ratio of 2.0 to 3.0, or to receive placebo for a further 24 months. Our goal was to determine the effects of extended anticoagulant therapy on rates of recurrent symptomatic venous thromboembolism and bleeding. RESULTS: A prespecified interim analysis of efficacy led to the early termination of the trial after 162 patients had been enrolled and followed for an average of 10 months. Of 83 patients assigned to continue to receive placebo, 17 had a recurrent episode of venous thromboembolism (27.4 percent per patient-year), as compared with 1 of 79 patients assigned to receive warfarin (1.3 percent per patient-year, P<0.001). Warfarin resulted in a 95 percent reduction in the risk of recurrent venous thromboembolism (95 percent confidence interval, 63 to 99 percent). Three patients assigned to the warfarin group had nonfatal major bleeding (two had gastrointestinal bleeding and one genitourinary bleeding), as compared with none of those assigned to the placebo group (3.8 vs. 0 percent per patient-year, P=0.09). CONCLUSIONS: Patients with a first episode of idiopathic venous thromboembolism should be treated with anticoagulant agents for longer than three months.  (+info)

Arterial thromboembolism in patients with sick sinus syndrome: prediction from pacing mode, atrial fibrillation, and echocardiographic findings. (8/1606)

OBJECTIVE: To evaluate whether thromboembolism in sick sinus syndrome can be predicted by pacing mode, atrial fibrillation, or echocardiographic findings. METHODS: Patients were randomised to single chamber atrial (n = 110) or ventricular (n = 115) pacing. They were divided into subgroups with and without brady-tachy syndrome at time of randomisation. The occurrence of atrial fibrillation and thromboembolism during follow up were investigated and compared with echocardiographic findings. RESULTS: The annual risk of thromboembolism was 5.8% in patients with brady-tachy syndrome randomised to ventricular pacing, 3.2% in patients without brady-tachy syndrome randomised to ventricular pacing, 3% in patients with brady-tachy syndrome randomised to atrial pacing, and 1.5% in patients without brady-tachy syndrome randomised to atrial pacing. In atrial paced patients without brady-tachy syndrome at randomisation and without atrial fibrillation during follow up, the annual risk of thromboembolism was 1.4%. Left atrial size measured by M mode echocardiography was of no value in predicting thromboembolism. CONCLUSIONS: Arterial thromboembolism in patients with sick sinus syndrome is very common and is associated primarily with brady-tachy syndrome at randomisation and with ventricular pacing. The risk of thromboembolism is small in atrial paced patients in whom atrial fibrillation has never been documented.  (+info)

Venous Thromboembolism (VTE) is a medical condition that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is a blood clot that forms in the deep veins, usually in the legs, while PE occurs when a clot breaks off and travels to the lungs, blocking a pulmonary artery or one of its branches. This condition can be life-threatening if not diagnosed and treated promptly.

The medical definition of Venous Thromboembolism is:

"The formation of a blood clot (thrombus) in a deep vein, most commonly in the legs, which can then dislodge and travel to the lungs, causing a potentially life-threatening blockage of the pulmonary artery or one of its branches (pulmonary embolism). VTE is a complex disorder resulting from an interplay of genetic and environmental factors that affect the balance between thrombosis and fibrinolysis."

Some common risk factors for VTE include immobility, surgery, trauma, cancer, hormonal therapy, pregnancy, advanced age, and inherited or acquired thrombophilia. Symptoms of DVT may include swelling, pain, warmth, and redness in the affected limb, while symptoms of PE can range from shortness of breath and chest pain to coughing up blood or even sudden death. Diagnosis typically involves a combination of clinical assessment, imaging studies (such as ultrasound, CT scan, or MRI), and laboratory tests (such as D-dimer). Treatment usually includes anticoagulation therapy to prevent further clot formation and reduce the risk of recurrence.

Thromboembolism is a medical condition that refers to the obstruction of a blood vessel by a thrombus (blood clot) that has formed elsewhere in the body and then been transported by the bloodstream to a narrower vessel, where it becomes lodged. This process can occur in various parts of the body, leading to different types of thromboembolisms:

1. Deep Vein Thrombosis (DVT): A thrombus forms in the deep veins, usually in the legs or pelvis, and then breaks off and travels to the lungs, causing a pulmonary embolism.
2. Pulmonary Embolism (PE): A thrombus formed elsewhere, often in the deep veins of the legs, dislodges and travels to the lungs, blocking one or more pulmonary arteries. This can lead to shortness of breath, chest pain, and potentially life-threatening complications if not treated promptly.
3. Cerebral Embolism: A thrombus formed in another part of the body, such as the heart or carotid artery, dislodges and travels to the brain, causing a stroke or transient ischemic attack (TIA).
4. Arterial Thromboembolism: A thrombus forms in an artery and breaks off, traveling to another part of the body and blocking blood flow to an organ or tissue, leading to potential damage or loss of function. Examples include mesenteric ischemia (intestinal damage due to blocked blood flow) and retinal artery occlusion (vision loss due to blocked blood flow in the eye).

Prevention, early detection, and appropriate treatment are crucial for managing thromboembolism and reducing the risk of severe complications.

A pulmonary embolism (PE) is a medical condition that occurs when a blood clot, often formed in the deep veins of the legs (deep vein thrombosis), breaks off and travels to the lungs, blocking one or more pulmonary arteries. This blockage can lead to various symptoms such as shortness of breath, chest pain, rapid heart rate, and coughing up blood. In severe cases, it can cause life-threatening complications like low oxygen levels, hypotension, and even death if not promptly diagnosed and treated with anticoagulant medications or thrombolytic therapy to dissolve the clot.

Venous thrombosis is a medical condition characterized by the formation of a blood clot (thrombus) in the deep veins, often in the legs (deep vein thrombosis or DVT), but it can also occur in other parts of the body such as the arms, pelvis, or lungs (pulmonary embolism).

The formation of a venous thrombus can be caused by various factors, including injury to the blood vessel wall, changes in blood flow, and alterations in the composition of the blood. These factors can lead to the activation of clotting factors and platelets, which can result in the formation of a clot that blocks the vein.

Symptoms of venous thrombosis may include swelling, pain, warmth, and redness in the affected area. In some cases, the clot can dislodge and travel to other parts of the body, causing potentially life-threatening complications such as pulmonary embolism.

Risk factors for venous thrombosis include advanced age, obesity, smoking, pregnancy, use of hormonal contraceptives or hormone replacement therapy, cancer, recent surgery or trauma, prolonged immobility, and a history of previous venous thromboembolism. Treatment typically involves the use of anticoagulant medications to prevent further clotting and dissolve existing clots.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

Low-molecular-weight heparin (LMWH) is a type of heparin used as an anticoagulant, which refers to a group of medications that prevent the formation of blood clots. Heparin is a naturally occurring substance in the body, and low-molecular-weight heparins are obtained through the depolymerization of standard heparin.

LMWH has a lower molecular weight than standard heparin, which results in several pharmacological differences. LMWHs have a more predictable dose response, longer half-life, and higher bioavailability when administered subcutaneously compared to standard heparin. They also exhibit greater anti-factor Xa activity relative to their antithrombin (anti-IIa) activity, which contributes to their anticoagulant effects.

LMWHs are used for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and other thromboembolic disorders. Common LMWHs include enoxaparin, dalteparin, tinzaparin, and nadroparin.

It is essential to monitor the patient's kidney function when using LMWH since they are primarily cleared by the kidneys. In patients with renal impairment, dose adjustments or alternative anticoagulants may be necessary to reduce the risk of bleeding complications.

Thrombophilia is a medical condition characterized by an increased tendency to form blood clots (thrombi) due to various genetic or acquired abnormalities in the coagulation system. These abnormalities can lead to a hypercoagulable state, which can cause thrombosis in both veins and arteries. Commonly identified thrombophilias include factor V Leiden mutation, prothrombin G20210A mutation, antithrombin deficiency, protein C deficiency, and protein S deficiency.

Acquired thrombophilias can be caused by various factors such as antiphospholipid antibody syndrome (APS), malignancies, pregnancy, oral contraceptive use, hormone replacement therapy, and certain medical conditions like inflammatory bowel disease or nephrotic syndrome.

It is essential to diagnose thrombophilia accurately, as it may influence the management of venous thromboembolism (VTE) events and guide decisions regarding prophylactic anticoagulation in high-risk situations.

Thrombophlebitis is a medical condition characterized by the inflammation and clotting of blood in a vein, usually in the legs. The term thrombophlebitis comes from two words: "thrombo" which means blood clot, and "phlebitis" which refers to inflammation of the vein.

The condition can occur in superficial or deep veins. Superficial thrombophlebitis affects the veins just below the skin's surface, while deep vein thrombophlebitis (DVT) occurs in the deeper veins. DVT is a more serious condition as it can lead to complications such as pulmonary embolism if the blood clot breaks off and travels to the lungs.

Symptoms of thrombophlebitis may include redness, warmth, pain, swelling, or discomfort in the affected area. In some cases, there may be visible surface veins that are hard, tender, or ropy to touch. If left untreated, thrombophlebitis can lead to chronic venous insufficiency and other long-term complications. Treatment typically involves medications such as anticoagulants, antiplatelet agents, or thrombolytics, along with compression stockings and other supportive measures.

Warfarin is a anticoagulant medication that works by inhibiting the vitamin K-dependent activation of several coagulation factors (factors II, VII, IX, and X). This results in prolonged clotting times and reduced thrombus formation. It is commonly used to prevent and treat blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Warfarin is also known by its brand names Coumadin and Jantoven.

It's important to note that warfarin has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic one is small. Therefore, it requires careful monitoring of the patient's coagulation status through regular blood tests (INR) to ensure that the dosage is appropriate and to minimize the risk of bleeding complications.

Hemorrhage is defined in the medical context as an excessive loss of blood from the circulatory system, which can occur due to various reasons such as injury, surgery, or underlying health conditions that affect blood clotting or the integrity of blood vessels. The bleeding may be internal, external, visible, or concealed, and it can vary in severity from minor to life-threatening, depending on the location and extent of the bleeding. Hemorrhage is a serious medical emergency that requires immediate attention and treatment to prevent further blood loss, organ damage, and potential death.

Fibrin(ogen) degradation products (FDPs) are a group of proteins that result from the breakdown of fibrinogen and fibrin, which are key components of blood clots. This process occurs during the normal physiological process of fibrinolysis, where clots are dissolved to maintain blood flow.

FDPs can be measured in the blood as a marker for the activation of the coagulation and fibrinolytic systems. Elevated levels of FDPs may indicate the presence of a disorder that causes abnormal clotting or bleeding, such as disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of cancer.

It is important to note that FDPs are not specific to any particular disorder and their measurement should be interpreted in conjunction with other clinical and laboratory findings.

Enoxaparin is a low molecular weight heparin (LMWH) medication that is used as an anticoagulant to prevent and treat blood clots. It works by binding to and inhibiting the activity of factor Xa, a clotting factor in the blood. This helps to reduce the risk of clot formation and can help to prevent conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Enoxaparin is typically given by injection under the skin (subcutaneously) and is available under the brand names Lovenox and Clexane, among others. It is important to follow the instructions of a healthcare professional when using enoxaparin, as it can increase the risk of bleeding.

Compression stockings are a specialized type of hosiery that applies pressure to your legs, promoting better blood flow. They are tightest at the ankle and gradually become less constrictive up the leg. This gradient compression helps to counteract the force of gravity and promote venous return, reducing the pooling of blood in the lower extremities.

Compression stockings are often used to help prevent or treat various conditions related to poor circulation, including:

1. Varicose veins: Enlarged, swollen, and twisting veins that are easily visible just under the surface of the skin.
2. Deep vein thrombosis (DVT): A blood clot that forms in the deep veins, usually in the legs. Compression stockings can help reduce the risk of DVT after certain surgeries or during long periods of immobilization.
3. Edema: Swelling in the legs and ankles due to fluid buildup.
4. Chronic venous insufficiency: A condition where the veins have difficulty returning blood from the legs back to the heart, leading to symptoms like leg pain, swelling, and skin changes.
5. Post-thrombotic syndrome (PTS): A long-term complication of DVT characterized by chronic leg pain, swelling, and skin ulcers. Compression stockings can help manage symptoms and prevent further complications.

There are different levels of compression available, ranging from mild (15-20 mmHg) to extra firm (50-60 mmHg). Your healthcare provider will recommend the appropriate level based on your specific condition and needs. It is essential to wear compression stockings correctly for them to be effective and avoid skin irritation or other complications.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Factor V, also known as proaccelerin or labile factor, is a protein involved in the coagulation cascade, which is a series of chemical reactions that leads to the formation of a blood clot. Factor V acts as a cofactor for the activation of Factor X to Factor Xa, which is a critical step in the coagulation cascade.

When blood vessels are damaged, the coagulation cascade is initiated to prevent excessive bleeding. During this process, Factor V is activated by thrombin, another protein involved in coagulation, and then forms a complex with activated Factor X and calcium ions on the surface of platelets or other cells. This complex converts prothrombin to thrombin, which then converts fibrinogen to fibrin to form a stable clot.

Deficiency or dysfunction of Factor V can lead to bleeding disorders such as hemophilia B or factor V deficiency, while mutations in the gene encoding Factor V can increase the risk of thrombosis, as seen in the Factor V Leiden mutation.

Vena cava filters are medical devices that are implanted into the inferior vena cava, which is the largest vein in the body that returns blood from the lower half of the body to the heart. These filters are designed to trap blood clots that form in the deep veins of the legs (deep vein thrombosis or DVT) and prevent them from traveling to the lungs (pulmonary embolism or PE), which can be a life-threatening condition.

The filter is typically implanted using a catheter-based procedure, and it has legs or arms that extend out to trap the blood clots as they flow through the vein. Over time, the trapped clots may dissolve on their own or become organized and incorporated into the wall of the vein.

Vena cava filters are typically used in patients who are at high risk for PE but cannot take anticoagulation medication or have failed anticoagulation therapy. However, there is some controversy surrounding the use of these devices due to concerns about their long-term safety and effectiveness.

Heparin is defined as a highly sulfated glycosaminoglycan (a type of polysaccharide) that is widely present in many tissues, but is most commonly derived from the mucosal tissues of mammalian lungs or intestinal mucosa. It is an anticoagulant that acts as an inhibitor of several enzymes involved in the blood coagulation cascade, primarily by activating antithrombin III which then neutralizes thrombin and other clotting factors.

Heparin is used medically to prevent and treat thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and certain types of heart attacks. It can also be used during hemodialysis, cardiac bypass surgery, and other medical procedures to prevent the formation of blood clots.

It's important to note that while heparin is a powerful anticoagulant, it does not have any fibrinolytic activity, meaning it cannot dissolve existing blood clots. Instead, it prevents new clots from forming and stops existing clots from growing larger.

Intermittent Pneumatic Compression (IPC) devices are medical devices that use inflatable garments to apply controlled pressure in a rhythmic, intermittent manner to the extremities of the body, most commonly used on the legs. These devices are designed to help improve venous and lymphatic flow, reduce edema (swelling), and prevent the formation of blood clots (deep vein thrombosis) in patients who are at risk.

The IPC device typically consists of a pump, hoses, and an air-filled garment that covers the affected limb. The pump regulates the pressure and inflation pattern, while the garment applies pressure to the limb. The compression cycle usually starts with low pressure and gradually increases to a peak pressure before decreasing again. This process is repeated at regular intervals, providing intermittent compression that mimics natural muscle contractions and helps promote blood flow.

IPC devices are often used in clinical settings such as hospitals and rehabilitation centers, but they can also be prescribed for home use. They are commonly recommended for patients who have undergone surgery, experienced trauma, or have conditions that increase their risk of developing blood clots, such as prolonged immobilization, varicose veins, or certain medical disorders.

It is essential to follow the healthcare provider's instructions when using IPC devices and report any discomfort, pain, or unusual symptoms during treatment.

The International Normalized Ratio (INR) is a standardized measurement of the prothrombin time (PT), which is the time it takes for blood to clot. The INR is used to monitor and regulate the effects of anticoagulant medications, such as warfarin, that affect the blood's ability to clot.

The INR is calculated by dividing the patient's PT by a control value (the PT of normal, healthy blood), raised to the power of a sensitivity factor called the International Sensitivity Index (ISI). The ISI is specific to the thromboplastin reagent used in the PT assay.

The INR provides a consistent and comparable way to monitor anticoagulation therapy across different laboratories, regardless of the thromboplastin reagent used. This helps ensure that patients receive appropriate doses of anticoagulant medications and reduces the risk of bleeding or clotting complications.

In general, an INR range of 2.0 to 3.0 is recommended for most people taking anticoagulants for conditions such as atrial fibrillation, deep vein thrombosis, or pulmonary embolism. However, the target INR range may vary depending on individual patient factors and medical indications.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

Prothrombin is a protein present in blood plasma, and it's also known as coagulation factor II. It plays a crucial role in the coagulation cascade, which is a complex series of reactions that leads to the formation of a blood clot.

When an injury occurs, the coagulation cascade is initiated to prevent excessive blood loss. Prothrombin is converted into its active form, thrombin, by another factor called factor Xa in the presence of calcium ions, phospholipids, and factor Va. Thrombin then catalyzes the conversion of fibrinogen into fibrin, forming a stable clot.

Prothrombin levels can be measured through a blood test, which is often used to diagnose or monitor conditions related to bleeding or coagulation disorders, such as liver disease or vitamin K deficiency.

Fibrinolytic agents are medications that dissolve or break down blood clots by activating plasminogen, which is converted into plasmin. Plasmin is a proteolytic enzyme that degrades fibrin, the structural protein in blood clots. Fibrinolytic agents are used medically to treat conditions such as acute ischemic stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction (heart attack) by restoring blood flow in occluded vessels. Examples of fibrinolytic agents include alteplase, reteplase, and tenecteplase. It is important to note that these medications carry a risk of bleeding complications and should be administered with caution.

Vitamin K is a fat-soluble vitamin that plays a crucial role in blood clotting and bone metabolism. It is essential for the production of several proteins involved in blood clotting, including factor II (prothrombin), factor VII, factor IX, and factor X. Additionally, Vitamin K is necessary for the synthesis of osteocalcin, a protein that contributes to bone health by regulating the deposition of calcium in bones.

There are two main forms of Vitamin K: Vitamin K1 (phylloquinone), which is found primarily in green leafy vegetables and some vegetable oils, and Vitamin K2 (menaquinones), which is produced by bacteria in the intestines and is also found in some fermented foods.

Vitamin K deficiency can lead to bleeding disorders such as hemorrhage and excessive bruising. While Vitamin K deficiency is rare in adults, it can occur in newborns who have not yet developed sufficient levels of the vitamin. Therefore, newborns are often given a Vitamin K injection shortly after birth to prevent bleeding problems.

In epidemiology, the incidence of a disease is defined as the number of new cases of that disease within a specific population over a certain period of time. It is typically expressed as a rate, with the number of new cases in the numerator and the size of the population at risk in the denominator. Incidence provides information about the risk of developing a disease during a given time period and can be used to compare disease rates between different populations or to monitor trends in disease occurrence over time.

Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, obstructing the flow of blood through the circulatory system. When a clot forms in an artery, it can cut off the supply of oxygen and nutrients to the tissues served by that artery, leading to damage or tissue death. If a thrombus forms in the heart, it can cause a heart attack. If a thrombus breaks off and travels through the bloodstream, it can lodge in a smaller vessel, causing blockage and potentially leading to damage in the organ that the vessel supplies. This is known as an embolism.

Thrombosis can occur due to various factors such as injury to the blood vessel wall, abnormalities in blood flow, or changes in the composition of the blood. Certain medical conditions, medications, and lifestyle factors can increase the risk of thrombosis. Treatment typically involves anticoagulant or thrombolytic therapy to dissolve or prevent further growth of the clot, as well as addressing any underlying causes.

Activated Protein C (APC) resistance is a condition in which the body's natural anticoagulant system is impaired, leading to an increased risk of thrombosis or blood clot formation. APC is an enzyme that plays a crucial role in regulating blood coagulation by inactivating clotting factors Va and VIIIa.

APC resistance is most commonly caused by a genetic mutation in the Factor V gene, known as Factor V Leiden. This mutation results in the production of a variant form of Factor V called Factor V Leiden, which is resistant to APC-mediated inactivation. As a result, the body's ability to regulate blood clotting is impaired, leading to an increased risk of thrombosis.

APC resistance can be measured by performing a functional assay that compares the activity of APC in normal plasma versus plasma from a patient with suspected APC resistance. The assay measures the rate of inactivation of Factor Va by APC, and a reduced rate of inactivation indicates APC resistance.

It is important to note that not all individuals with APC resistance will develop thrombosis, and other factors such as age, obesity, pregnancy, oral contraceptive use, and smoking can increase the risk of thrombosis in individuals with APC resistance.

Oral combined contraceptives, also known as "the pill," are a type of hormonal birth control that contain a combination of synthetic estrogen and progestin. These hormones work together to prevent ovulation (the release of an egg from the ovaries), thicken cervical mucus to make it harder for sperm to reach the egg, and thin the lining of the uterus to make it less likely for a fertilized egg to implant.

Combined oral contraceptives come in various brands and forms, such as monophasic, biphasic, and triphasic pills. Monophasic pills contain the same amount of hormones in each active pill, while biphasic and triphasic pills have varying amounts of hormones in different phases of the cycle.

It is important to note that oral combined contraceptives do not protect against sexually transmitted infections (STIs) and should be used in conjunction with condoms for safer sex practices. Additionally, there are potential risks and side effects associated with oral combined contraceptives, including an increased risk of blood clots, stroke, and heart attack, especially in women who smoke or have certain medical conditions. It is essential to consult a healthcare provider before starting any hormonal birth control method to determine if it is safe and appropriate for individual use.

Postoperative complications refer to any unfavorable condition or event that occurs during the recovery period after a surgical procedure. These complications can vary in severity and may include, but are not limited to:

1. Infection: This can occur at the site of the incision or inside the body, such as pneumonia or urinary tract infection.
2. Bleeding: Excessive bleeding (hemorrhage) can lead to a drop in blood pressure and may require further surgical intervention.
3. Blood clots: These can form in the deep veins of the legs (deep vein thrombosis) and can potentially travel to the lungs (pulmonary embolism).
4. Wound dehiscence: This is when the surgical wound opens up, which can lead to infection and further complications.
5. Pulmonary issues: These include atelectasis (collapsed lung), pneumonia, or respiratory failure.
6. Cardiovascular problems: These include abnormal heart rhythms (arrhythmias), heart attack, or stroke.
7. Renal failure: This can occur due to various reasons such as dehydration, blood loss, or the use of certain medications.
8. Pain management issues: Inadequate pain control can lead to increased stress, anxiety, and decreased mobility.
9. Nausea and vomiting: These can be caused by anesthesia, opioid pain medication, or other factors.
10. Delirium: This is a state of confusion and disorientation that can occur in the elderly or those with certain medical conditions.

Prompt identification and management of these complications are crucial to ensure the best possible outcome for the patient.

Dalteparin is a low molecular weight heparin (LMWH) medication that is used as an anticoagulant to prevent and treat blood clots. It works by binding to an enzyme called antithrombin III and enhancing its ability to inhibit clotting factors in the blood.

Dalteparin is available under the brand name Fragmin and is administered subcutaneously (under the skin) once or twice a day, depending on the indication and dosage prescribed by a healthcare professional. Common side effects of dalteparin include bleeding, bruising, pain at the injection site, and elevated liver enzymes.

As with all medications, it is important to use dalteparin only under the supervision of a healthcare provider and to follow their instructions carefully.

An embolectomy is a surgical procedure to remove an embolus, which is a blockage in a blood vessel caused by a clot or air bubble that has traveled from another part of the body. During an embolectomy, the surgeon makes an incision in the affected blood vessel and removes the embolus using specialized surgical instruments. This procedure is often performed as an emergency treatment to restore blood flow and prevent tissue damage in the affected area of the body.

Atrial fibrillation (A-tre-al fi-bru-la'shun) is a type of abnormal heart rhythm characterized by rapid and irregular beating of the atria, the upper chambers of the heart. In this condition, the electrical signals that coordinate heartbeats don't function properly, causing the atria to quiver instead of contracting effectively. As a result, blood may not be pumped efficiently into the ventricles, which can lead to blood clots, stroke, and other complications. Atrial fibrillation is a common type of arrhythmia and can cause symptoms such as palpitations, shortness of breath, fatigue, and dizziness. It can be caused by various factors, including heart disease, high blood pressure, age, and genetics. Treatment options include medications, electrical cardioversion, and surgical procedures to restore normal heart rhythm.

Risk assessment in the medical context refers to the process of identifying, evaluating, and prioritizing risks to patients, healthcare workers, or the community related to healthcare delivery. It involves determining the likelihood and potential impact of adverse events or hazards, such as infectious diseases, medication errors, or medical devices failures, and implementing measures to mitigate or manage those risks. The goal of risk assessment is to promote safe and high-quality care by identifying areas for improvement and taking action to minimize harm.

Protein C deficiency is a genetic disorder that affects the body's ability to control blood clotting. Protein C is a protein in the blood that helps regulate the formation of blood clots. When blood clots form too easily or do not dissolve properly, they can block blood vessels and lead to serious medical conditions such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

People with protein C deficiency have lower than normal levels of this protein in their blood, which can increase their risk of developing abnormal blood clots. The condition is usually inherited and present from birth, but it may not cause any symptoms until later in life, such as during pregnancy, after surgery, or due to other factors that increase the risk of blood clots.

Protein C deficiency can be classified into two types: type I and type II. Type I deficiency is characterized by lower than normal levels of both functional and immunoreactive protein C in the blood. Type II deficiency is characterized by normal or near-normal levels of immunoreactive protein C, but reduced functional activity.

Protein C deficiency can be diagnosed through blood tests that measure the level and function of protein C in the blood. Treatment may include anticoagulant medications to prevent blood clots from forming or dissolve existing ones. Regular monitoring of protein C levels and careful management of risk factors for blood clots are also important parts of managing this condition.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Hematologic pregnancy complications refer to disorders related to the blood and blood-forming tissues that occur during pregnancy. These complications can have serious consequences for both the mother and the fetus if not properly managed. Some common hematologic pregnancy complications include:

1. Anemia: A condition characterized by a decrease in the number of red blood cells or hemoglobin in the blood, which can lead to fatigue, weakness, and shortness of breath. Iron-deficiency anemia is the most common type of anemia during pregnancy.
2. Thrombocytopenia: A condition characterized by a decrease in the number of platelets (cells that help blood clot) in the blood. Mild thrombocytopenia is relatively common during pregnancy, but severe thrombocytopenia can increase the risk of bleeding during delivery.
3. Gestational thrombotic thrombocytopenic purpura (GTTP): A rare but serious disorder that can cause blood clots to form in small blood vessels throughout the body, leading to a decrease in the number of platelets and red blood cells. GTTP can cause serious complications such as stroke, kidney failure, and even death if not promptly diagnosed and treated.
4. Disseminated intravascular coagulation (DIC): A condition characterized by abnormal clotting and bleeding throughout the body. DIC can be triggered by various conditions such as severe infections, pregnancy complications, or cancer.
5. Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: A serious complication of pregnancy that can cause damage to the liver and lead to bleeding. HELLP syndrome is often associated with preeclampsia, a condition characterized by high blood pressure and damage to organs such as the liver and kidneys.

It's important for pregnant women to receive regular prenatal care to monitor for these and other potential complications, and to seek prompt medical attention if any concerning symptoms arise.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

A bandage is a medical dressing or covering applied to a wound, injury, or sore with the intention of promoting healing or preventing infection. Bandages can be made of a variety of materials such as gauze, cotton, elastic, or adhesive tape and come in different sizes and shapes to accommodate various body parts. They can also have additional features like fasteners, non-slip surfaces, or transparent windows for monitoring the condition of the wound.

Bandages serve several purposes, including:

1. Absorbing drainage or exudate from the wound
2. Protecting the wound from external contaminants and bacteria
3. Securing other medical devices such as catheters or splints in place
4. Reducing swelling or promoting immobilization of the affected area
5. Providing compression to control bleeding or prevent fluid accumulation
6. Relieving pain by reducing pressure on sensitive nerves or structures.

Proper application and care of bandages are essential for effective wound healing and prevention of complications such as infection or delayed recovery.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Phlebography is a medical imaging technique used to visualize and assess the veins, particularly in the legs. It involves the injection of a contrast agent into the veins, followed by X-ray imaging to capture the flow of the contrast material through the veins. This allows doctors to identify any abnormalities such as blood clots, blockages, or malformations in the venous system.

There are different types of phlebography, including ascending phlebography (where the contrast agent is injected into a foot vein and travels up the leg) and descending phlebography (where the contrast agent is injected into a vein in the groin or neck and travels down the leg).

Phlebography is an invasive procedure that requires careful preparation and monitoring, and it is typically performed by radiologists or vascular specialists. It has largely been replaced by non-invasive imaging techniques such as ultrasound and CT angiography in many clinical settings.

Postthrombotic syndrome (PTS), also known as postphlebitic syndrome, is a chronic complication that can occur after deep vein thrombosis (DVT). It's characterized by a combination of symptoms including pain, swelling, cramping, itching, and skin changes in the affected limb. PTS happens when the damaged valves in the veins are unable to properly move blood back to the heart, leading to venous hypertension and fluid accumulation in the lower extremities.

The symptoms of PTS can vary in severity, but they often worsen with prolonged standing or sitting. In some cases, patients may develop open sores (ulcers) on the skin, particularly around the ankles. The risk of developing PTS is higher in individuals who have experienced a recurrent DVT, those with more extensive clotting, and those who do not receive appropriate anticoagulation therapy after their initial DVT diagnosis.

Preventive measures such as early mobilization, use of compression stockings, and maintaining adequate anticoagulation can help reduce the risk of developing PTS following a DVT.

Protein S deficiency is a genetic disorder that affects the body's ability to coagulate blood properly. Protein S is a naturally occurring protein in the blood that helps regulate the clotting process by deactivating clotting factors when they are no longer needed. When Protein S levels are too low, it can lead to an increased risk of abnormal blood clots forming within blood vessels, a condition known as thrombophilia.

There are three types of Protein S deficiency: Type I (quantitative deficiency), Type II (qualitative deficiency), and Type III (dysfunctional protein). These types refer to the amount or function of Protein S in the blood. In Type I, there is a decrease in both free and total Protein S levels. In Type II, there is a decrease in functional Protein S despite normal total Protein S levels. In Type III, there is a decrease in free Protein S with normal total Protein S levels.

Protein S deficiency can be inherited or acquired. Inherited forms of the disorder are caused by genetic mutations and are usually present from birth. Acquired forms of Protein S deficiency can develop later in life due to certain medical conditions, such as liver disease, vitamin K deficiency, or the use of certain medications that affect blood clotting.

Symptoms of Protein S deficiency may include recurrent blood clots, usually in the legs (deep vein thrombosis) or lungs (pulmonary embolism), skin discoloration, pain, and swelling in the affected area. In severe cases, it can lead to complications such as chronic leg ulcers, pulmonary hypertension, or damage to the heart or lungs.

Diagnosis of Protein S deficiency typically involves blood tests to measure Protein S levels and function. Treatment may include anticoagulant medications to prevent blood clots from forming or growing larger. Lifestyle modifications such as regular exercise, maintaining a healthy weight, and avoiding smoking can also help reduce the risk of blood clots in people with Protein S deficiency.

Cardiovascular complications in pregnancy refer to conditions that affect the heart and blood vessels, which can arise during pregnancy, childbirth, or after delivery. These complications can be pre-existing or new-onset and can range from mild to severe, potentially threatening the life of both the mother and the fetus. Some examples of cardiovascular complications in pregnancy include:

1. Hypertension disorders: This includes chronic hypertension (high blood pressure before pregnancy), gestational hypertension (high blood pressure that develops after 20 weeks of pregnancy), and preeclampsia/eclampsia (a pregnancy-specific disorder characterized by high blood pressure, proteinuria, and potential organ damage).

2. Cardiomyopathy: A condition in which the heart muscle becomes weakened, leading to an enlarged heart and reduced pumping efficiency. Peripartum cardiomyopathy is a specific type that occurs during pregnancy or in the months following delivery.

3. Arrhythmias: Irregularities in the heart's rhythm, such as tachycardia (rapid heartbeat) or bradycardia (slow heartbeat), can occur during pregnancy and may require medical intervention.

4. Valvular heart disease: Pre-existing valve disorders, like mitral stenosis or aortic insufficiency, can worsen during pregnancy due to increased blood volume and cardiac output. Additionally, new valve issues might develop during pregnancy.

5. Venous thromboembolism (VTE): Pregnancy increases the risk of developing blood clots in the veins, particularly deep vein thrombosis (DVT) or pulmonary embolism (PE).

6. Ischemic heart disease: Although rare, coronary artery disease and acute coronary syndrome can occur during pregnancy, especially in women with risk factors such as obesity, diabetes, or smoking history.

7. Heart failure: Severe cardiac dysfunction leading to fluid accumulation, shortness of breath, and reduced exercise tolerance may develop due to any of the above conditions or other underlying heart diseases.

Early recognition, monitoring, and appropriate management of these cardiovascular complications in pregnancy are crucial for maternal and fetal well-being.

Acenocoumarol is an anticoagulant medication that is used to prevent and treat blood clots. It works by inhibiting the formation of vitamin K-dependent clotting factors, which are necessary for normal blood coagulation. This results in a prolonged bleeding time and reduced risk of blood clots.

Acenocoumarol is a coumarin derivative and is available under various brand names, including Sintrom and Nicoumalone. It is typically administered orally in the form of tablets and its effects are monitored through regular blood tests to ensure that the dosage is appropriate and that the risk of bleeding complications is minimized.

Common side effects of acenocoumarol include easy bruising, nosebleeds, and skin rashes. It may also interact with a variety of other medications, including antibiotics, antifungals, and certain herbal supplements, so it is important to inform your healthcare provider of all medications and supplements you are taking before starting acenocoumarol therapy.

It is important to note that acenocoumarol has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic dose is relatively small. Therefore, it is essential to follow your healthcare provider's instructions carefully when taking this medication and to have regular blood tests to monitor its effects on your coagulation status.

Desogestrel is a synthetic form of progestin, which is a female sex hormone. It is used in various forms of hormonal contraception such as birth control pills, patches, and vaginal rings to prevent pregnancy. Desogestrel works by preventing ovulation (the release of an egg from the ovaries), thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant.

Desogestrel is also used in some hormone replacement therapies (HRT) to treat symptoms of menopause such as hot flashes and vaginal dryness. It may be prescribed alone or in combination with estrogen.

Like all hormonal contraceptives, desogestrel has potential side effects, including irregular menstrual bleeding, headaches, mood changes, breast tenderness, and nausea. In rare cases, it may also increase the risk of blood clots, stroke, or heart attack. It is important to discuss the risks and benefits of desogestrel with a healthcare provider before using it.

Blood coagulation, also known as blood clotting, is a complex process that occurs in the body to prevent excessive bleeding when a blood vessel is damaged. This process involves several different proteins and chemical reactions that ultimately lead to the formation of a clot.

The coagulation cascade is initiated when blood comes into contact with tissue factor, which is exposed after damage to the blood vessel wall. This triggers a series of enzymatic reactions that activate clotting factors, leading to the formation of a fibrin clot. Fibrin is a protein that forms a mesh-like structure that traps platelets and red blood cells to form a stable clot.

Once the bleeding has stopped, the coagulation process is regulated and inhibited to prevent excessive clotting. The fibrinolytic system degrades the clot over time, allowing for the restoration of normal blood flow.

Abnormalities in the blood coagulation process can lead to bleeding disorders or thrombotic disorders such as deep vein thrombosis and pulmonary embolism.

Beta-alanine is a non-essential amino acid, which means that it is not required in the diet because the body can produce it from other amino acids. It is produced in the liver and is also found in some foods such as meat, poultry, and fish.

Beta-alanine plays a role in the production of carnosine, a dipeptide molecule that helps to regulate muscle pH and improve muscle function during high-intensity exercise. When muscles contract during intense exercise, they produce hydrogen ions, which can cause the muscle pH to decrease (become more acidic), leading to fatigue and reduced muscle function. Carnosine acts as a buffer against this acidity, helping to maintain optimal muscle pH levels and improve performance during high-intensity exercise.

Beta-alanine supplements have been shown to increase carnosine levels in muscles, which may lead to improved athletic performance, particularly in activities that require short bursts of intense effort, such as weightlifting or sprinting. However, more research is needed to fully understand the effects and potential benefits of beta-alanine supplementation.

It's important to note that while beta-alanine supplements are generally considered safe for most people, they can cause a tingling sensation in the skin (paresthesia) when taken in high doses. This is a harmless side effect and typically subsides within an hour or so of taking the supplement.

Thiophenes are organic compounds that contain a heterocyclic ring made up of four carbon atoms and one sulfur atom. The structure of thiophene is similar to benzene, with the benzene ring being replaced by a thiophene ring. Thiophenes are aromatic compounds, which means they have a stable, planar ring structure and delocalized electrons.

Thiophenes can be found in various natural sources such as coal tar, crude oil, and some foods like onions and garlic. They also occur in certain medications, dyes, and pesticides. Some thiophene derivatives have been synthesized and studied for their potential therapeutic uses, including anti-inflammatory, antiviral, and antitumor activities.

In the medical field, thiophenes are used in some pharmaceuticals as building blocks to create drugs with various therapeutic effects. For example, tipepidine, a cough suppressant, contains a thiophene ring. Additionally, some anesthetics and antipsychotic medications also contain thiophene moieties.

It is important to note that while thiophenes themselves are not typically considered medical terms, they play a role in the chemistry of various pharmaceuticals and other medical-related compounds.

Androstenes are a group of steroidal compounds that are produced and released by the human body. They are classified as steroids because they contain a characteristic carbon skeleton, called the sterane ring, which consists of four fused rings arranged in a specific structure. Androstenes are derived from cholesterol and are synthesized in the gonads (testes and ovaries), adrenal glands, and other tissues.

The term "androstene" refers specifically to compounds that contain a double bond between the 5th and 6th carbon atoms in the sterane ring. This double bond gives these compounds their characteristic chemical properties and distinguishes them from other steroidal compounds.

Androstenes are important in human physiology because they serve as precursors to the synthesis of sex hormones, such as testosterone and estrogen. They also have been found to play a role in the regulation of various bodily functions, including sexual behavior, mood, and cognition.

Some examples of androstenes include androstenedione, which is a precursor to both testosterone and estrogen; androstenediol, which can be converted into either testosterone or estrogen; and androsterone, which is a weak androgen that is produced in the body as a metabolite of testosterone.

It's worth noting that androstenes are sometimes referred to as "pheromones" because they have been found to play a role in chemical communication between individuals of the same species. However, this use of the term "pheromone" is controversial and not universally accepted, as it has been difficult to demonstrate conclusively that humans communicate using chemical signals in the same way that many other animals do.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Factor Xa is a serine protease that plays a crucial role in the coagulation cascade, which is a series of reactions that lead to the formation of a blood clot. It is one of the activated forms of Factor X, a pro-protein that is converted to Factor Xa through the action of other enzymes in the coagulation cascade.

Factor Xa functions as a key component of the prothrombinase complex, which also includes calcium ions, phospholipids, and activated Factor V (also known as Activated Protein C or APC). This complex is responsible for converting prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a stable clot.

Inhibitors of Factor Xa are used as anticoagulants in the prevention and treatment of thromboembolic disorders such as deep vein thrombosis and pulmonary embolism. These drugs work by selectively inhibiting Factor Xa, thereby preventing the formation of the prothrombinase complex and reducing the risk of clot formation.

Levonorgestrel is a synthetic form of the natural hormone progesterone, which is used in various forms of birth control and emergency contraceptives. It works by preventing ovulation (the release of an egg from the ovaries), thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant.

Medically, Levonorgestrel is classified as a progestin and is available in various forms, including oral tablets, intrauterine devices (IUDs), and emergency contraceptive pills. It may also be used to treat endometriosis, irregular menstrual cycles, and heavy menstrual bleeding.

It's important to note that while Levonorgestrel is a highly effective form of birth control when used correctly, it does not protect against sexually transmitted infections (STIs). Therefore, condoms should still be used during sexual activity if there is any risk of STI transmission.

Oral contraceptives, also known as "birth control pills," are medications taken by mouth to prevent pregnancy. They contain synthetic hormones that mimic the effects of natural hormones estrogen and progesterone in a woman's body, thereby preventing ovulation, fertilization, or implantation of a fertilized egg in the uterus.

There are two main types of oral contraceptives: combined pills, which contain both estrogen and progestin, and mini-pills, which contain only progestin. Combined pills work by preventing ovulation, thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant. Mini-pills work mainly by thickening cervical mucus and changing the lining of the uterus.

Oral contraceptives are highly effective when used correctly, but they do not protect against sexually transmitted infections (STIs). It is important to use them consistently and as directed by a healthcare provider. Side effects may include nausea, breast tenderness, headaches, mood changes, and irregular menstrual bleeding. In rare cases, oral contraceptives may increase the risk of serious health problems such as blood clots, stroke, or liver tumors. However, for most women, the benefits of using oral contraceptives outweigh the risks.

Practice guidelines, also known as clinical practice guidelines, are systematically developed statements that aim to assist healthcare professionals and patients in making informed decisions about appropriate health care for specific clinical circumstances. They are based on a thorough evaluation of the available scientific evidence, consensus of expert opinion, and consideration of patient preferences. Practice guidelines can cover a wide range of topics, including diagnosis, management, prevention, and treatment options for various medical conditions. They are intended to improve the quality and consistency of care, reduce unnecessary variations in practice, and promote evidence-based medicine. However, they should not replace clinical judgment or individualized patient care.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

In the context of medicine, risk is the probability or likelihood of an adverse health effect or the occurrence of a negative event related to treatment or exposure to certain hazards. It is usually expressed as a ratio or percentage and can be influenced by various factors such as age, gender, lifestyle, genetics, and environmental conditions. Risk assessment involves identifying, quantifying, and prioritizing risks to make informed decisions about prevention, mitigation, or treatment strategies.

"Gravity suits" is not a recognized medical term. However, in the context of space medicine and space travel, gravity suits, also known as g-suits or anti-G suits, are specialized garments worn by pilots and astronauts to prevent or reduce the negative effects of high gravitational forces (G-forces) on their bodies during high-speed maneuvers or while re-entering the Earth's atmosphere.

These suits work by applying pressure to specific areas of the body, typically around the lower abdomen and legs, to prevent the pooling of blood in those areas due to the increased G-forces. This helps maintain adequate blood flow to the brain and other vital organs, reducing the risk of loss of consciousness (G-induced Loss of Consciousness or G-LOC) and other symptoms associated with high G-forces such as blackouts, vision impairment, and disorientation.

It's important to note that gravity suits are not used as a medical treatment for any specific condition but rather as a protective measure during space travel and high-performance aviation.

A cohort study is a type of observational study in which a group of individuals who share a common characteristic or exposure are followed up over time to determine the incidence of a specific outcome or outcomes. The cohort, or group, is defined based on the exposure status (e.g., exposed vs. unexposed) and then monitored prospectively to assess for the development of new health events or conditions.

Cohort studies can be either prospective or retrospective in design. In a prospective cohort study, participants are enrolled and followed forward in time from the beginning of the study. In contrast, in a retrospective cohort study, researchers identify a cohort that has already been assembled through medical records, insurance claims, or other sources and then look back in time to assess exposure status and health outcomes.

Cohort studies are useful for establishing causality between an exposure and an outcome because they allow researchers to observe the temporal relationship between the two. They can also provide information on the incidence of a disease or condition in different populations, which can be used to inform public health policy and interventions. However, cohort studies can be expensive and time-consuming to conduct, and they may be subject to bias if participants are not representative of the population or if there is loss to follow-up.

Oral administration is a route of giving medications or other substances by mouth. This can be in the form of tablets, capsules, liquids, pastes, or other forms that can be swallowed. Once ingested, the substance is absorbed through the gastrointestinal tract and enters the bloodstream to reach its intended target site in the body. Oral administration is a common and convenient route of medication delivery, but it may not be appropriate for all substances or in certain situations, such as when rapid onset of action is required or when the patient has difficulty swallowing.

I'm sorry for any confusion, but "Austria" is not a medical term or concept. It is a country located in central Europe, known officially as the Republic of Austria. It is not a medical condition, treatment, or related term. If you have any questions about a medical issue, I would be happy to try to help answer those for you!

Norpregnenes are a class of steroids that are produced by the metabolism of progesterone and other pregnanes. They are characterized by the absence of a double bond between carbons 4 and 5, and the presence of a ketone group at carbon 3. Some examples of norpregnenes include dehydroepiandrosterone (DHEA), androstenedione, and pregnenolone. These steroids are important intermediates in the biosynthesis of various hormones, including cortisol, aldosterone, androgens, and estrogens. They play a role in various physiological processes such as sexual development, immune function, and stress response.

Oral contraceptives, also known as "birth control pills," are synthetic hormonal medications that are taken by mouth to prevent pregnancy. They typically contain a combination of synthetic versions of the female hormones estrogen and progesterone, which work together to inhibit ovulation (the release of an egg from the ovaries), thicken cervical mucus (making it harder for sperm to reach the egg), and thin the lining of the uterus (making it less likely that a fertilized egg will implant).

There are several different types of oral contraceptives, including combination pills, progestin-only pills, and extended-cycle pills. Combination pills contain both estrogen and progestin, while progestin-only pills contain only progestin. Extended-cycle pills are a type of combination pill that are taken for 12 weeks followed by one week of placebo pills, which can help reduce the frequency of menstrual periods.

It's important to note that oral contraceptives do not protect against sexually transmitted infections (STIs), so it's still important to use barrier methods like condoms if you are at risk for STIs. Additionally, oral contraceptives can have side effects and may not be suitable for everyone, so it's important to talk to your healthcare provider about the potential risks and benefits before starting to take them.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Antithrombin III (ATIII) deficiency is a genetic disorder that affects the body's ability to regulate blood clotting. ATIII is a protein produced in the liver that inhibits the activity of thrombin and other coagulation factors, preventing excessive clot formation.

People with ATIII deficiency have lower than normal levels of this protein, which can lead to an increased risk of developing abnormal blood clots (thrombosis) in veins, particularly deep vein thrombosis (DVT) and pulmonary embolism (PE). These clots can cause serious complications, including damage to the affected veins, organ damage, and even death.

ATIII deficiency can be classified into two types: type I and type II. Type I is characterized by a quantitative decrease in ATIII levels, while type II is characterized by a qualitative defect that results in reduced functional activity of the protein.

The condition is usually inherited in an autosomal dominant manner, meaning that a person has a 50% chance of inheriting the gene mutation from an affected parent. However, some cases may occur spontaneously due to new mutations in the ATIII gene. Treatment for ATIII deficiency typically involves anticoagulation therapy with medications such as heparin or warfarin to prevent blood clots from forming.

Immobilization is a medical term that refers to the restriction of normal mobility or motion of a body part, usually to promote healing and prevent further injury. This is often achieved through the use of devices such as casts, splints, braces, slings, or traction. The goal of immobilization is to keep the injured area in a fixed position so that it can heal properly without additional damage. It may be used for various medical conditions, including fractures, dislocations, sprains, strains, and soft tissue injuries. Immobilization helps reduce pain, minimize swelling, and protect the injured site from movement that could worsen the injury or impair healing.

Arthroplasty, replacement, knee is a surgical procedure where the damaged or diseased joint surface of the knee is removed and replaced with an artificial joint or prosthesis. The procedure involves resurfacing the worn-out ends of the femur (thigh bone) and tibia (shin bone) with metal components, and the back of the kneecap with a plastic button. This surgery is usually performed to relieve pain and restore function in patients with severe knee osteoarthritis, rheumatoid arthritis, or traumatic injuries that have damaged the joint beyond repair. The goal of knee replacement surgery is to improve mobility, reduce pain, and enhance the quality of life for the patient.

Subcutaneous injection is a route of administration where a medication or vaccine is delivered into the subcutaneous tissue, which lies between the skin and the muscle. This layer contains small blood vessels, nerves, and connective tissues that help to absorb the medication slowly and steadily over a period of time. Subcutaneous injections are typically administered using a short needle, at an angle of 45-90 degrees, and the dose is injected slowly to minimize discomfort and ensure proper absorption. Common sites for subcutaneous injections include the abdomen, thigh, or upper arm. Examples of medications that may be given via subcutaneous injection include insulin, heparin, and some vaccines.

The atrial appendage, also known as the left atrial appendage (LAA), is a small, ear-shaped structure that is located on the upper left chamber of the heart (left atrium). It has a unique muscular structure and plays a role in the normal functioning of the heart. However, it is best known for its association with atrial fibrillation, a common type of irregular heart rhythm. In people with atrial fibrillation, blood clots can form in the LAA, which can then travel to other parts of the body and cause strokes. For this reason, one treatment option for atrial fibrillation is to close off or remove the LAA to reduce the risk of stroke.

Compression bandages are medical devices used to apply pressure on a part of the body, typically on limbs such as arms or legs. They are often used in the treatment of venous disorders, lymphatic disorders, and wounds, including venous ulcers, leg edema, and chronic swelling. The compression helps to promote better blood flow, reduce swelling, and aid in the healing process by helping to prevent fluid buildup in the tissues. They are usually made from elastic materials that allow for adjustable levels of compression and can be wrapped around the affected area in a specific manner to ensure proper fit and effectiveness. It is important to receive proper instruction on the application and removal of compression bandages to ensure they are used safely and effectively.

Protein C is a vitamin K-dependent protease that functions as an important regulator of coagulation and inflammation. It is a plasma protein produced in the liver that, when activated, degrades clotting factors Va and VIIIa to limit thrombus formation and prevent excessive blood clotting. Protein C also has anti-inflammatory properties by inhibiting the release of pro-inflammatory cytokines and reducing endothelial cell activation. Inherited or acquired deficiencies in Protein C can lead to an increased risk of thrombosis, a condition characterized by abnormal blood clot formation within blood vessels.

Aspirin is the common name for acetylsalicylic acid, which is a medication used to relieve pain, reduce inflammation, and lower fever. It works by inhibiting the activity of an enzyme called cyclooxygenase (COX), which is involved in the production of prostaglandins, hormone-like substances that cause inflammation and pain. Aspirin also has an antiplatelet effect, which means it can help prevent blood clots from forming. This makes it useful for preventing heart attacks and strokes.

Aspirin is available over-the-counter in various forms, including tablets, capsules, and chewable tablets. It is also available in prescription strengths for certain medical conditions. As with any medication, aspirin should be taken as directed by a healthcare provider, and its use should be avoided in children and teenagers with viral infections due to the risk of Reye's syndrome, a rare but serious condition that can affect the liver and brain.

Pyridones are a class of organic compounds that contain a pyridone ring, which is a heterocyclic ring consisting of a six-membered ring with five carbon atoms and one nitrogen atom, with one oxygen atom attached to the nitrogen atom by a double bond. Pyridones can be found in various natural sources, including plants and microorganisms, and they also have important applications in the pharmaceutical industry as building blocks for drug design and synthesis. Some drugs that contain pyridone rings include antihistamines, anti-inflammatory agents, and antiviral agents.

Aerospace medicine is a branch of medicine that deals with the health and safety of pilots, astronauts, and passengers during space travel or aircraft flight. It involves studying the effects of various factors such as altitude, weightlessness, radiation, noise, vibration, and temperature extremes on the human body, and developing measures to prevent or mitigate any adverse effects.

Aerospace medicine also encompasses the diagnosis and treatment of medical conditions that occur during space travel or aircraft flight, as well as the development of medical standards and guidelines for pilot and astronaut selection, training, and fitness for duty. Additionally, it includes research into the physiological and psychological challenges of long-duration space missions and the development of countermeasures to maintain crew health and performance during such missions.

Transesophageal echocardiography (TEE) is a type of echocardiogram, which is a medical test that uses sound waves to create detailed images of the heart. In TEE, a special probe containing a transducer is passed down the esophagus (the tube that connects the mouth to the stomach) to obtain views of the heart from behind. This allows for more detailed images of the heart structures and function compared to a standard echocardiogram, which uses a probe placed on the chest. TEE is often used in patients with poor image quality from a standard echocardiogram or when more detailed images are needed to diagnose or monitor certain heart conditions. It is typically performed by a trained cardiologist or sonographer under the direction of a cardiologist.

An acute disease is a medical condition that has a rapid onset, develops quickly, and tends to be short in duration. Acute diseases can range from minor illnesses such as a common cold or flu, to more severe conditions such as pneumonia, meningitis, or a heart attack. These types of diseases often have clear symptoms that are easy to identify, and they may require immediate medical attention or treatment.

Acute diseases are typically caused by an external agent or factor, such as a bacterial or viral infection, a toxin, or an injury. They can also be the result of a sudden worsening of an existing chronic condition. In general, acute diseases are distinct from chronic diseases, which are long-term medical conditions that develop slowly over time and may require ongoing management and treatment.

Examples of acute diseases include:

* Acute bronchitis: a sudden inflammation of the airways in the lungs, often caused by a viral infection.
* Appendicitis: an inflammation of the appendix that can cause severe pain and requires surgical removal.
* Gastroenteritis: an inflammation of the stomach and intestines, often caused by a viral or bacterial infection.
* Migraine headaches: intense headaches that can last for hours or days, and are often accompanied by nausea, vomiting, and sensitivity to light and sound.
* Myocardial infarction (heart attack): a sudden blockage of blood flow to the heart muscle, often caused by a buildup of plaque in the coronary arteries.
* Pneumonia: an infection of the lungs that can cause coughing, chest pain, and difficulty breathing.
* Sinusitis: an inflammation of the sinuses, often caused by a viral or bacterial infection.

It's important to note that while some acute diseases may resolve on their own with rest and supportive care, others may require medical intervention or treatment to prevent complications and promote recovery. If you are experiencing symptoms of an acute disease, it is always best to seek medical attention to ensure proper diagnosis and treatment.

Vascular neoplasms are a type of tumor that develops from cells that line the blood vessels or lymphatic vessels. These tumors can be benign (non-cancerous) or malignant (cancerous). Benign vascular neoplasms, such as hemangiomas and lymphangiomas, are usually harmless and may not require treatment unless they cause symptoms or complications. Malignant vascular neoplasms, on the other hand, are known as angiosarcomas and can be aggressive, spreading to other parts of the body and potentially causing serious health problems.

Angiosarcomas can develop in any part of the body but are most commonly found in the skin, particularly in areas exposed to radiation or chronic lymph edema. They can also occur in the breast, liver, spleen, and heart. Treatment for vascular neoplasms depends on the type, location, size, and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

A thrombectomy is a medical procedure that involves the removal of a blood clot (thrombus) from a blood vessel. This is typically performed to restore blood flow in cases where the clot is causing significant blockage, which can lead to serious complications such as tissue damage or organ dysfunction.

During a thrombectomy, a surgeon makes an incision and accesses the affected blood vessel, often with the help of imaging guidance. Specialized tools are then used to extract the clot, after which the blood vessel is usually repaired. Thrombectomies can be performed on various blood vessels throughout the body, including those in the brain, heart, lungs, and limbs.

This procedure may be recommended for patients with deep vein thrombosis (DVT), pulmonary embolism (PE), or certain types of stroke, depending on the specific circumstances and the patient's overall health. It is generally considered when anticoagulation therapy or clot-dissolving medications are not sufficient or appropriate to treat the blood clot.

Antithrombins are substances that prevent the formation or promote the dissolution of blood clots (thrombi). They include:

1. Anticoagulants: These are medications that reduce the ability of the blood to clot. Examples include heparin, warfarin, and direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran.
2. Thrombolytic agents: These are medications that break down existing blood clots. Examples include alteplase, reteplase, and tenecteplase.
3. Fibrinolytics: These are a type of thrombolytic agent that specifically target fibrin, a protein involved in the formation of blood clots.
4. Natural anticoagulants: These are substances produced by the body to regulate blood clotting. Examples include antithrombin III, protein C, and protein S.

Antithrombins are used in the prevention and treatment of various thromboembolic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (heart attack). It is important to note that while antithrombins can help prevent or dissolve blood clots, they also increase the risk of bleeding, so their use must be carefully monitored.

1. Intracranial Embolism: This is a medical condition that occurs when a blood clot or other particle (embolus) formed elsewhere in the body, travels through the bloodstream and lodges itself in the intracranial blood vessels, blocking the flow of blood to a part of the brain. This can lead to various neurological symptoms such as weakness, numbness, speech difficulties, or even loss of consciousness, depending on the severity and location of the blockage.

2. Intracranial Thrombosis: This is a medical condition that occurs when a blood clot (thrombus) forms within the intracranial blood vessels. The clot can partially or completely obstruct the flow of blood, leading to various symptoms such as headache, confusion, seizures, or neurological deficits, depending on the severity and location of the thrombosis. Intracranial thrombosis can occur due to various factors including atherosclerosis, hypertension, diabetes, and other medical conditions that increase the risk of blood clot formation.

A case-control study is an observational research design used to identify risk factors or causes of a disease or health outcome. In this type of study, individuals with the disease or condition (cases) are compared with similar individuals who do not have the disease or condition (controls). The exposure history or other characteristics of interest are then compared between the two groups to determine if there is an association between the exposure and the disease.

Case-control studies are often used when it is not feasible or ethical to conduct a randomized controlled trial, as they can provide valuable insights into potential causes of diseases or health outcomes in a relatively short period of time and at a lower cost than other study designs. However, because case-control studies rely on retrospective data collection, they are subject to biases such as recall bias and selection bias, which can affect the validity of the results. Therefore, it is important to carefully design and conduct case-control studies to minimize these potential sources of bias.

Blood coagulation factors, also known as clotting factors, are a group of proteins that play a crucial role in the blood coagulation process. They are essential for maintaining hemostasis, which is the body's ability to stop bleeding after injury.

There are 13 known blood coagulation factors, and they are designated by Roman numerals I through XIII. These factors are produced in the liver and are normally present in an inactive form in the blood. When there is an injury to a blood vessel, the coagulation process is initiated, leading to the activation of these factors in a specific order.

The coagulation cascade involves two pathways: the intrinsic and extrinsic pathways. The intrinsic pathway is activated when there is damage to the blood vessel itself, while the extrinsic pathway is activated by tissue factor released from damaged tissues. Both pathways converge at the common pathway, leading to the formation of a fibrin clot.

Blood coagulation factors work together in a complex series of reactions that involve activation, binding, and proteolysis. When one factor is activated, it activates the next factor in the cascade, and so on. This process continues until a stable fibrin clot is formed.

Deficiencies or abnormalities in blood coagulation factors can lead to bleeding disorders such as hemophilia or thrombosis. Hemophilia is a genetic disorder that affects one or more of the coagulation factors, leading to excessive bleeding and difficulty forming clots. Thrombosis, on the other hand, occurs when there is an abnormal formation of blood clots in the blood vessels, which can lead to serious complications such as stroke or pulmonary embolism.

A heart valve prosthesis is a medical device that is implanted in the heart to replace a damaged or malfunctioning heart valve. The prosthetic valve can be made of biological tissue (such as from a pig or cow) or artificial materials (such as carbon or polyester). Its function is to allow for the proper directional flow of blood through the heart, opening and closing with each heartbeat to prevent backflow of blood.

There are several types of heart valve prostheses, including:

1. Mechanical valves: These are made entirely of artificial materials and have a longer lifespan than biological valves. However, they require the patient to take blood-thinning medication for the rest of their life to prevent blood clots from forming on the valve.
2. Bioprosthetic valves: These are made of biological tissue and typically last 10-15 years before needing replacement. They do not require the patient to take blood-thinning medication, but there is a higher risk of reoperation due to degeneration of the tissue over time.
3. Homografts or allografts: These are human heart valves that have been donated and preserved for transplantation. They have similar longevity to bioprosthetic valves and do not require blood-thinning medication.
4. Autografts: In this case, the patient's own pulmonary valve is removed and used to replace the damaged aortic valve. This procedure is called the Ross procedure and has excellent long-term results, but it requires advanced surgical skills and is not widely available.

The choice of heart valve prosthesis depends on various factors, including the patient's age, overall health, lifestyle, and personal preferences.

Puerperal disorders are a group of medical conditions that can affect women during the period following childbirth, also known as the puerperium. The puerperium typically lasts for six to eight weeks after delivery. These disorders can be complications of childbirth or postpartum infections and include:

1. Puerperal fever: This is a febrile illness that occurs during the puerperium, usually caused by a bacterial infection. The most common causative organisms are group A streptococcus, Staphylococcus aureus, and Escherichia coli.

2. Puerperal sepsis: This is a severe form of puerperal fever characterized by the presence of bacteria in the blood (bacteremia) and widespread inflammation throughout the body. It can lead to organ failure and even death if not treated promptly with antibiotics.

3. Puerperal endometritis: This is an infection of the lining of the uterus (endometrium) that occurs during the puerperium. Symptoms may include fever, abdominal pain, and foul-smelling vaginal discharge.

4. Puerperal mastitis: This is an inflammation of the breast tissue that can occur during lactation, often caused by a bacterial infection. It is more common in women who are breastfeeding but can also occur in non-lactating women.

5. Puerperal psychosis: This is a rare but serious mental health disorder that can occur after childbirth. It is characterized by symptoms such as delusions, hallucinations, and disorganized thinking.

6. Puerperal thromboembolism: This is a blood clot that forms during the puerperium, usually in the deep veins of the legs (deep vein thrombosis) or in the lungs (pulmonary embolism). It can be a serious complication of childbirth and requires prompt medical attention.

Overall, puerperal disorders are a significant cause of maternal morbidity and mortality worldwide, particularly in low-income countries where access to healthcare is limited. Prompt diagnosis and treatment are essential for improving outcomes and reducing the risk of long-term complications.

Hospitalization is the process of admitting a patient to a hospital for the purpose of receiving medical treatment, surgery, or other health care services. It involves staying in the hospital as an inpatient, typically under the care of doctors, nurses, and other healthcare professionals. The length of stay can vary depending on the individual's medical condition and the type of treatment required. Hospitalization may be necessary for a variety of reasons, such as to receive intensive care, to undergo diagnostic tests or procedures, to recover from surgery, or to manage chronic illnesses or injuries.

Partial Thromboplastin Time (PTT) is a medical laboratory test that measures the time it takes for blood to clot. It's more specifically a measure of the intrinsic and common pathways of the coagulation cascade, which are the series of chemical reactions that lead to the formation of a clot.

The test involves adding a partial thromboplastin reagent (an activator of the intrinsic pathway) and calcium to plasma, and then measuring the time it takes for a fibrin clot to form. This is compared to a control sample, and the ratio of the two times is calculated.

The PTT test is often used to help diagnose bleeding disorders or abnormal blood clotting, such as hemophilia or disseminated intravascular coagulation (DIC). It can also be used to monitor the effectiveness of anticoagulant therapy, such as heparin. Prolonged PTT results may indicate a bleeding disorder or an increased risk of bleeding, while shortened PTT results may indicate a hypercoagulable state and an increased risk of thrombosis.

Intracranial thrombosis refers to the formation of a blood clot (thrombus) within the intracranial vessels, which supply blood to the brain. This condition can occur in any of the cerebral arteries or veins and can lead to serious complications such as ischemic stroke, transient ischemic attack (TIA), or venous sinus thrombosis.

The formation of an intracranial thrombus can be caused by various factors, including atherosclerosis, cardiac embolism, vasculitis, sickle cell disease, hypercoagulable states, and head trauma. Symptoms may vary depending on the location and extent of the thrombosis but often include sudden onset of headache, weakness or numbness in the face or limbs, difficulty speaking or understanding speech, vision changes, and loss of balance or coordination.

Diagnosis of intracranial thrombosis typically involves imaging studies such as computed tomography (CT) angiography, magnetic resonance angiography (MRA), or digital subtraction angiography (DSA). Treatment options may include anticoagulation therapy, thrombolysis, endovascular intervention, or surgical intervention, depending on the underlying cause and severity of the condition.

A stroke, also known as cerebrovascular accident (CVA), is a serious medical condition that occurs when the blood supply to part of the brain is interrupted or reduced, leading to deprivation of oxygen and nutrients to brain cells. This can result in the death of brain tissue and cause permanent damage or temporary impairment to cognitive functions, speech, memory, movement, and other body functions controlled by the affected area of the brain.

Strokes can be caused by either a blockage in an artery that supplies blood to the brain (ischemic stroke) or the rupture of a blood vessel in the brain (hemorrhagic stroke). A transient ischemic attack (TIA), also known as a "mini-stroke," is a temporary disruption of blood flow to the brain that lasts only a few minutes and does not cause permanent damage.

Symptoms of a stroke may include sudden weakness or numbness in the face, arm, or leg; difficulty speaking or understanding speech; vision problems; loss of balance or coordination; severe headache with no known cause; and confusion or disorientation. Immediate medical attention is crucial for stroke patients to receive appropriate treatment and prevent long-term complications.

Hip arthroplasty, also known as hip replacement surgery, is a medical procedure where the damaged or diseased joint surfaces of the hip are removed and replaced with artificial components. These components typically include a metal or ceramic ball that replaces the head of the femur (thigh bone), and a polyethylene or ceramic socket that replaces the acetabulum (hip socket) in the pelvis.

The goal of hip arthroplasty is to relieve pain, improve joint mobility, and restore function to the hip joint. This procedure is commonly performed in patients with advanced osteoarthritis, rheumatoid arthritis, hip fractures, or other conditions that cause significant damage to the hip joint.

There are several types of hip replacement surgeries, including traditional total hip arthroplasty, partial (hemi) hip arthroplasty, and resurfacing hip arthroplasty. The choice of procedure depends on various factors, such as the patient's age, activity level, overall health, and the extent of joint damage.

After surgery, patients typically require rehabilitation to regain strength, mobility, and function in the affected hip. With proper care and follow-up, most patients can expect significant pain relief and improved quality of life following hip arthroplasty.

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies in the blood. These antibodies are directed against phospholipids, a type of fat molecule found in cell membranes and plasma lipoproteins. The presence of these antibodies can lead to abnormal blood clotting, which can cause serious complications such as stroke, heart attack, deep vein thrombosis, and pulmonary embolism.

APS can occur either on its own (primary APS) or in conjunction with other autoimmune disorders, such as systemic lupus erythematosus (secondary APS). The exact cause of APS is not fully understood, but it is believed to involve a combination of genetic and environmental factors.

Symptoms of APS can vary widely depending on the location and severity of the blood clots. They may include:

* Recurrent miscarriages or stillbirths
* Blood clots in the legs, lungs, or other parts of the body
* Skin ulcers or lesions
* Headaches, seizures, or stroke-like symptoms
* Kidney problems
* Heart valve abnormalities

Diagnosis of APS typically involves blood tests to detect the presence of antiphospholipid antibodies. Treatment may include medications to prevent blood clots, such as anticoagulants and antiplatelet agents, as well as management of any underlying autoimmune disorders.

The femoral vein is the large vein that runs through the thigh and carries oxygen-depleted blood from the lower limbs back to the heart. It is located in the femoral triangle, along with the femoral artery and nerve. The femoral vein begins at the knee as the popliteal vein, which then joins with the deep vein of the thigh to form the femoral vein. As it moves up the leg, it is joined by several other veins, including the great saphenous vein, before it becomes the external iliac vein at the inguinal ligament in the groin.

Blood coagulation tests, also known as coagulation studies or clotting tests, are a series of medical tests used to evaluate the blood's ability to clot. These tests measure the functioning of various clotting factors and regulatory proteins involved in the coagulation cascade, which is a complex process that leads to the formation of a blood clot to prevent excessive bleeding.

The most commonly performed coagulation tests include:

1. Prothrombin Time (PT): Measures the time it takes for a sample of plasma to clot after the addition of calcium and tissue factor, which activates the extrinsic pathway of coagulation. The PT is reported in seconds and can be converted to an International Normalized Ratio (INR) to monitor anticoagulant therapy.
2. Activated Partial Thromboplastin Time (aPTT): Measures the time it takes for a sample of plasma to clot after the addition of calcium, phospholipid, and a contact activator, which activates the intrinsic pathway of coagulation. The aPTT is reported in seconds and is used to monitor heparin therapy.
3. Thrombin Time (TT): Measures the time it takes for a sample of plasma to clot after the addition of thrombin, which directly converts fibrinogen to fibrin. The TT is reported in seconds and can be used to detect the presence of fibrin degradation products or abnormalities in fibrinogen function.
4. Fibrinogen Level: Measures the amount of fibrinogen, a protein involved in clot formation, present in the blood. The level is reported in grams per liter (g/L) and can be used to assess bleeding risk or the effectiveness of fibrinogen replacement therapy.
5. D-dimer Level: Measures the amount of D-dimer, a protein fragment produced during the breakdown of a blood clot, present in the blood. The level is reported in micrograms per milliliter (µg/mL) and can be used to diagnose or exclude venous thromboembolism (VTE), such as deep vein thrombosis (DVT) or pulmonary embolism (PE).

These tests are important for the diagnosis, management, and monitoring of various bleeding and clotting disorders. They can help identify the underlying cause of abnormal bleeding or clotting, guide appropriate treatment decisions, and monitor the effectiveness of therapy. It is essential to interpret these test results in conjunction with a patient's clinical presentation and medical history.

Factor VIII is a protein in the blood that is essential for normal blood clotting. It is also known as antihemophilic factor (AHF). Deficiency or dysfunction of this protein results in hemophilia A, a genetic disorder characterized by prolonged bleeding and easy bruising. Factor VIII works together with other proteins to help form a clot and stop bleeding at the site of an injury. It acts as a cofactor for another clotting factor, IX, in the so-called intrinsic pathway of blood coagulation. Intravenous infusions of Factor VIII concentrate are used to treat and prevent bleeding episodes in people with hemophilia A.

Premedication is the administration of medication before a medical procedure or surgery to prevent or manage pain, reduce anxiety, minimize side effects of anesthesia, or treat existing medical conditions. The goal of premedication is to improve the safety and outcomes of the medical procedure by preparing the patient's body in advance. Common examples of premedication include administering antibiotics before surgery to prevent infection, giving sedatives to help patients relax before a procedure, or providing medication to control acid reflux during surgery.

A randomized controlled trial (RCT) is a type of clinical study in which participants are randomly assigned to receive either the experimental intervention or the control condition, which may be a standard of care, placebo, or no treatment. The goal of an RCT is to minimize bias and ensure that the results are due to the intervention being tested rather than other factors. This design allows for a comparison between the two groups to determine if there is a significant difference in outcomes. RCTs are often considered the gold standard for evaluating the safety and efficacy of medical interventions, as they provide a high level of evidence for causal relationships between the intervention and health outcomes.

Blood coagulation disorders, also known as bleeding disorders or clotting disorders, refer to a group of medical conditions that affect the body's ability to form blood clots properly. Normally, when a blood vessel is injured, the body's coagulation system works to form a clot to stop the bleeding and promote healing.

In blood coagulation disorders, there can be either an increased tendency to bleed due to problems with the formation of clots (hemorrhagic disorder), or an increased tendency for clots to form inappropriately even without injury, leading to blockages in the blood vessels (thrombotic disorder).

Examples of hemorrhagic disorders include:

1. Hemophilia - a genetic disorder that affects the ability to form clots due to deficiencies in clotting factors VIII or IX.
2. Von Willebrand disease - another genetic disorder caused by a deficiency or abnormality of the von Willebrand factor, which helps platelets stick together to form a clot.
3. Liver diseases - can lead to decreased production of coagulation factors, increasing the risk of bleeding.
4. Disseminated intravascular coagulation (DIC) - a serious condition where clotting and bleeding occur simultaneously due to widespread activation of the coagulation system.

Examples of thrombotic disorders include:

1. Factor V Leiden mutation - a genetic disorder that increases the risk of inappropriate blood clot formation.
2. Antithrombin III deficiency - a genetic disorder that impairs the body's ability to break down clots, increasing the risk of thrombosis.
3. Protein C or S deficiencies - genetic disorders that lead to an increased risk of thrombosis due to impaired regulation of the coagulation system.
4. Antiphospholipid syndrome (APS) - an autoimmune disorder where the body produces antibodies against its own clotting factors, increasing the risk of thrombosis.

Treatment for blood coagulation disorders depends on the specific diagnosis and may include medications to manage bleeding or prevent clots, as well as lifestyle changes and monitoring to reduce the risk of complications.

Antithrombin III is a protein that inhibits the formation of blood clots (thrombi) in the body. It does this by inactivating several enzymes involved in coagulation, including thrombin and factor Xa. Antithrombin III is produced naturally by the liver and is also available as a medication for the prevention and treatment of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. It works by binding to and neutralizing excess clotting factors in the bloodstream, thereby reducing the risk of clot formation.

Platelet aggregation inhibitors are a class of medications that prevent platelets (small blood cells involved in clotting) from sticking together and forming a clot. These drugs work by interfering with the ability of platelets to adhere to each other and to the damaged vessel wall, thereby reducing the risk of thrombosis (blood clot formation).

Platelet aggregation inhibitors are often prescribed for people who have an increased risk of developing blood clots due to various medical conditions such as atrial fibrillation, coronary artery disease, peripheral artery disease, stroke, or a history of heart attack. They may also be used in patients undergoing certain medical procedures, such as angioplasty and stenting, to prevent blood clot formation in the stents.

Examples of platelet aggregation inhibitors include:

1. Aspirin: A nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits the enzyme cyclooxygenase, which is involved in platelet activation and aggregation.
2. Clopidogrel (Plavix): A P2Y12 receptor antagonist that selectively blocks ADP-induced platelet activation and aggregation.
3. Prasugrel (Effient): A third-generation thienopyridine P2Y12 receptor antagonist, similar to clopidogrel but with faster onset and greater potency.
4. Ticagrelor (Brilinta): A direct-acting P2Y12 receptor antagonist that does not require metabolic activation and has a reversible binding profile.
5. Dipyridamole (Persantine): An antiplatelet agent that inhibits platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels in platelets, which leads to decreased platelet reactivity.
6. Iloprost (Ventavis): A prostacyclin analogue that inhibits platelet aggregation and causes vasodilation, often used in the treatment of pulmonary arterial hypertension.
7. Cilostazol (Pletal): A phosphodiesterase III inhibitor that increases cAMP levels in platelets, leading to decreased platelet activation and aggregation, as well as vasodilation.
8. Ticlopidine (Ticlid): An older P2Y12 receptor antagonist with a slower onset of action and more frequent side effects compared to clopidogrel or prasugrel.

An inpatient, in medical terms, refers to a person who has been admitted to a hospital or other healthcare facility for the purpose of receiving medical treatment and who is expected to remain there for at least one night. Inpatients are typically cared for by a team of healthcare professionals, including doctors, nurses, and therapists, and may receive various treatments, such as medications, surgeries, or rehabilitation services.

Inpatient care is generally recommended for patients who require close monitoring, frequent assessments, or intensive medical interventions that cannot be provided in an outpatient setting. The length of stay for inpatients can vary widely depending on the nature and severity of their condition, as well as their individual treatment plan.

Antiphospholipid antibodies are a type of autoantibody that targets and binds to certain proteins found in the blood that attach to phospholipids (a type of fat molecule). These antibodies are associated with an increased risk of developing antiphospholipid syndrome, a disorder characterized by abnormal blood clotting.

There are several types of antiphospholipid antibodies, including:

1. Lupus anticoagulant: This type of antiphospholipid antibody can interfere with blood clotting tests and may increase the risk of thrombosis (blood clots) in both arteries and veins.
2. Anticardiolipin antibodies: These antibodies target a specific phospholipid called cardiolipin, which is found in the inner membrane of mitochondria. High levels of anticardiolipin antibodies are associated with an increased risk of thrombosis and pregnancy complications such as recurrent miscarriage.
3. Anti-β2 glycoprotein I antibodies: These antibodies target a protein called β2 glycoprotein I, which binds to negatively charged phospholipids on the surface of cells. High levels of anti-β2 glycoprotein I antibodies are associated with an increased risk of thrombosis and pregnancy complications.

The exact mechanism by which antiphospholipid antibodies cause blood clotting is not fully understood, but it is thought to involve the activation of platelets, the inhibition of natural anticoagulants, and the promotion of inflammation. Antiphospholipid syndrome can be treated with medications that thin the blood or prevent clots from forming, such as aspirin, warfarin, or heparin.

Thrombolytic therapy, also known as thrombolysis, is a medical treatment that uses medications called thrombolytics or fibrinolytics to dissolve or break down blood clots (thrombi) in blood vessels. These clots can obstruct the flow of blood to vital organs such as the heart, lungs, or brain, leading to serious conditions like myocardial infarction (heart attack), pulmonary embolism, or ischemic stroke.

The goal of thrombolytic therapy is to restore blood flow as quickly and efficiently as possible to prevent further damage to the affected organ and potentially save lives. Commonly used thrombolytic drugs include alteplase (tPA), reteplase, and tenecteplase. It's essential to administer these medications as soon as possible after the onset of symptoms for optimal treatment outcomes. However, there are risks associated with thrombolytic therapy, such as an increased chance of bleeding complications, which must be carefully weighed against its benefits in each individual case.

The double-blind method is a study design commonly used in research, including clinical trials, to minimize bias and ensure the objectivity of results. In this approach, both the participants and the researchers are unaware of which group the participants are assigned to, whether it be the experimental group or the control group. This means that neither the participants nor the researchers know who is receiving a particular treatment or placebo, thus reducing the potential for bias in the evaluation of outcomes. The assignment of participants to groups is typically done by a third party not involved in the study, and the codes are only revealed after all data have been collected and analyzed.

Nadroparin is defined as a low molecular weight heparin (LMWH) drug, which is used as an anticoagulant. It is derived from unfractionated heparin and works by inhibiting the activity of coagulation factor Xa and to a lesser extent, thrombin. Nadroparin is commonly used for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the management of unstable angina and non-Q wave myocardial infarction.

The drug is administered subcutaneously, and its anticoagulant effect is monitored by measuring the activated partial thromboplastin time (APTT) or anti-Xa activity. The half-life of nadroparin is approximately 4 hours, and it has a lower risk of heparin-induced thrombocytopenia (HIT) compared to unfractionated heparin.

It's important to note that the use of nadroparin or any other anticoagulant medication should be under the supervision of a healthcare professional, and patients should be closely monitored for bleeding risks and other potential adverse effects.

"Age factors" refer to the effects, changes, or differences that age can have on various aspects of health, disease, and medical care. These factors can encompass a wide range of issues, including:

1. Physiological changes: As people age, their bodies undergo numerous physical changes that can affect how they respond to medications, illnesses, and medical procedures. For example, older adults may be more sensitive to certain drugs or have weaker immune systems, making them more susceptible to infections.
2. Chronic conditions: Age is a significant risk factor for many chronic diseases, such as heart disease, diabetes, cancer, and arthritis. As a result, age-related medical issues are common and can impact treatment decisions and outcomes.
3. Cognitive decline: Aging can also lead to cognitive changes, including memory loss and decreased decision-making abilities. These changes can affect a person's ability to understand and comply with medical instructions, leading to potential complications in their care.
4. Functional limitations: Older adults may experience physical limitations that impact their mobility, strength, and balance, increasing the risk of falls and other injuries. These limitations can also make it more challenging for them to perform daily activities, such as bathing, dressing, or cooking.
5. Social determinants: Age-related factors, such as social isolation, poverty, and lack of access to transportation, can impact a person's ability to obtain necessary medical care and affect their overall health outcomes.

Understanding age factors is critical for healthcare providers to deliver high-quality, patient-centered care that addresses the unique needs and challenges of older adults. By taking these factors into account, healthcare providers can develop personalized treatment plans that consider a person's age, physical condition, cognitive abilities, and social circumstances.

'Hospital Bed Capacity, 3

A "Drug Administration Schedule" refers to the plan for when and how a medication should be given to a patient. It includes details such as the dose, frequency (how often it should be taken), route (how it should be administered, such as orally, intravenously, etc.), and duration (how long it should be taken) of the medication. This schedule is often created and prescribed by healthcare professionals, such as doctors or pharmacists, to ensure that the medication is taken safely and effectively. It may also include instructions for missed doses or changes in the dosage.

Polysaccharides are complex carbohydrates consisting of long chains of monosaccharide units (simple sugars) bonded together by glycosidic linkages. They can be classified based on the type of monosaccharides and the nature of the bonds that connect them.

Polysaccharides have various functions in living organisms. For example, starch and glycogen serve as energy storage molecules in plants and animals, respectively. Cellulose provides structural support in plants, while chitin is a key component of fungal cell walls and arthropod exoskeletons.

Some polysaccharides also have important roles in the human body, such as being part of the extracellular matrix (e.g., hyaluronic acid) or acting as blood group antigens (e.g., ABO blood group substances).

Phlebitis is a medical term that refers to the inflammation of a vein, usually occurring in the legs. The inflammation can be caused by blood clots (thrombophlebitis) or other conditions that cause irritation and swelling in the vein's lining. Symptoms may include redness, warmth, pain, and swelling in the affected area. In some cases, phlebitis may lead to serious complications such as deep vein thrombosis (DVT) or pulmonary embolism (PE), so it is essential to seek medical attention if you suspect you have this condition.

Orthopedic procedures are surgical or nonsurgical methods used to treat musculoskeletal conditions, including injuries, deformities, or diseases of the bones, joints, muscles, ligaments, and tendons. These procedures can range from simple splinting or casting to complex surgeries such as joint replacements, spinal fusions, or osteotomies (cutting and repositioning bones). The primary goal of orthopedic procedures is to restore function, reduce pain, and improve the quality of life for patients.

Guideline adherence, in the context of medicine, refers to the extent to which healthcare professionals follow established clinical practice guidelines or recommendations in their daily practice. These guidelines are systematically developed statements designed to assist practitioners and patient decisions about appropriate health care for specific clinical circumstances. Adherence to evidence-based guidelines can help improve the quality of care, reduce unnecessary variations in practice, and promote optimal patient outcomes. Factors that may influence guideline adherence include clinician awareness, familiarity, agreement, self-efficacy, outcome expectancy, and the complexity of the recommendation.

Disseminated Intravascular Coagulation (DIC) is a complex medical condition characterized by the abnormal activation of the coagulation cascade, leading to the formation of blood clots in small blood vessels throughout the body. This process can result in the consumption of clotting factors and platelets, which can then lead to bleeding complications. DIC can be caused by a variety of underlying conditions, including sepsis, trauma, cancer, and obstetric emergencies.

The term "disseminated" refers to the widespread nature of the clotting activation, while "intravascular" indicates that the clotting is occurring within the blood vessels. The condition can manifest as both bleeding and clotting complications, which can make it challenging to diagnose and manage.

The diagnosis of DIC typically involves laboratory tests that evaluate coagulation factors, platelet count, fibrin degradation products, and other markers of coagulation activation. Treatment is focused on addressing the underlying cause of the condition while also managing any bleeding or clotting complications that may arise.

Sulfinpyrazone is a medication that belongs to the class of drugs known as uricosurics. It works by increasing the amount of uric acid that is removed from the body through urine, which helps to lower the levels of uric acid in the blood. This makes it useful for the treatment of conditions such as gout and kidney stones that are caused by high levels of uric acid.

In addition to its uricosuric effects, sulfinpyrazone also has antiplatelet properties, which means that it can help to prevent blood clots from forming. This makes it useful for the prevention of heart attacks and strokes in people who are at risk.

Sulfinpyrazone is available by prescription and is typically taken by mouth in the form of tablets. It may be used alone or in combination with other medications, depending on the individual patient's needs and medical condition. As with any medication, sulfinpyrazone should be used under the supervision of a healthcare provider, and patients should follow their provider's instructions carefully to ensure safe and effective use.

I'm sorry for any confusion, but "Morpholines" is not a medical term. It is a chemical term that refers to a class of heterocyclic organic compounds containing one nitrogen atom and one oxygen atom in the ring. They are widely used as intermediates in the synthesis of various pharmaceuticals, agrochemicals, and dyes. If you have any questions about a medical issue or term, I'd be happy to try to help answer those for you!

Thrombin is a serine protease enzyme that plays a crucial role in the coagulation cascade, which is a complex series of biochemical reactions that leads to the formation of a blood clot (thrombus) to prevent excessive bleeding during an injury. Thrombin is formed from its precursor protein, prothrombin, through a process called activation, which involves cleavage by another enzyme called factor Xa.

Once activated, thrombin converts fibrinogen, a soluble plasma protein, into fibrin, an insoluble protein that forms the structural framework of a blood clot. Thrombin also activates other components of the coagulation cascade, such as factor XIII, which crosslinks and stabilizes the fibrin network, and platelets, which contribute to the formation and growth of the clot.

Thrombin has several regulatory mechanisms that control its activity, including feedback inhibition by antithrombin III, a plasma protein that inactivates thrombin and other serine proteases, and tissue factor pathway inhibitor (TFPI), which inhibits the activation of factor Xa, thereby preventing further thrombin formation.

Overall, thrombin is an essential enzyme in hemostasis, the process that maintains the balance between bleeding and clotting in the body. However, excessive or uncontrolled thrombin activity can lead to pathological conditions such as thrombosis, atherosclerosis, and disseminated intravascular coagulation (DIC).

Klippel-Trenaunay-Weber Syndrome (KTWS) is a rare and complex congenital vascular disorder that affects the development of blood vessels, soft tissues, and bones. It is also known as Klippel-Trenaunay syndrome or KTS.

The medical definition of KTWS includes the following features:
1. Port-wine stain (capillary malformation): A red or purple birthmark caused by an abnormal collection of blood vessels in the skin, often present at birth and usually affecting one limb or part of the body.
2. Venous and lymphatic abnormalities: Varicose veins, dilated veins, or abnormal vein patterns may be present, along with lymphatic malformations that can cause swelling in the affected area.
3. Soft tissue and bone hypertrophy: Overgrowth of soft tissues and bones in the affected limb or region, leading to asymmetry and sometimes functional impairment.
4. Other possible features: May include skin abnormalities, such as increased hair growth or changes in texture; joint deformities; and orthopedic problems, like scoliosis or hip dysplasia.

It is important to note that the severity of KTWS can vary significantly from person to person, ranging from mild symptoms to severe cases with significant functional impairment. The condition is not typically life-threatening but may require ongoing medical management and surveillance to address potential complications, such as infections, bleeding, or deep vein thrombosis.

Postoperative hemorrhage is a medical term that refers to bleeding that occurs after a surgical procedure. This condition can range from minor oozing to severe, life-threatening bleeding. Postoperative hemorrhage can occur soon after surgery or even several days later, as the surgical site begins to heal.

The causes of postoperative hemorrhage can vary, but some common factors include:

1. Inadequate hemostasis during surgery: This means that all bleeding was not properly controlled during the procedure, leading to bleeding after surgery.
2. Blood vessel injury: During surgery, blood vessels may be accidentally cut or damaged, causing bleeding after the procedure.
3. Coagulopathy: This is a condition in which the body has difficulty forming blood clots, increasing the risk of postoperative hemorrhage.
4. Use of anticoagulant medications: Medications that prevent blood clots can increase the risk of bleeding after surgery.
5. Infection: An infection at the surgical site can cause inflammation and bleeding.

Symptoms of postoperative hemorrhage may include swelling, pain, warmth, or discoloration around the surgical site, as well as signs of shock such as rapid heartbeat, low blood pressure, and confusion. Treatment for postoperative hemorrhage depends on the severity of the bleeding and may include medications to control bleeding, transfusions of blood products, or additional surgery to stop the bleeding.

Sudden death is a term used to describe a situation where a person dies abruptly and unexpectedly, often within minutes to hours of the onset of symptoms. It is typically caused by cardiac or respiratory arrest, which can be brought on by various medical conditions such as heart disease, stroke, severe infections, drug overdose, or trauma. In some cases, the exact cause of sudden death may remain unknown even after a thorough post-mortem examination.

It is important to note that sudden death should not be confused with "sudden cardiac death," which specifically refers to deaths caused by the abrupt loss of heart function (cardiac arrest). Sudden cardiac death is often related to underlying heart conditions such as coronary artery disease, cardiomyopathy, or electrical abnormalities in the heart.

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Central venous catheterization is a medical procedure in which a flexible tube called a catheter is inserted into a large vein in the body, usually in the neck (internal jugular vein), chest (subclavian vein), or groin (femoral vein). The catheter is threaded through the vein until it reaches a central location, such as the superior vena cava or the right atrium of the heart.

Central venous catheterization may be performed for several reasons, including:

1. To administer medications, fluids, or nutritional support directly into the bloodstream.
2. To monitor central venous pressure (CVP), which can help assess a patient's volume status and cardiac function.
3. To draw blood samples for laboratory tests.
4. To deliver chemotherapy drugs or other medications that may be harmful to peripheral veins.
5. To provide access for hemodialysis or other long-term therapies.

The procedure requires careful attention to sterile technique to minimize the risk of infection, and it is usually performed under local anesthesia with sedation or general anesthesia. Complications of central venous catheterization may include bleeding, infection, pneumothorax (collapsed lung), arterial puncture, and catheter-related bloodstream infections (CRBSI).

The pulmonary artery is a large blood vessel that carries deoxygenated blood from the right ventricle of the heart to the lungs for oxygenation. It divides into two main branches, the right and left pulmonary arteries, which further divide into smaller vessels called arterioles, and then into a vast network of capillaries in the lungs where gas exchange occurs. The thin walls of these capillaries allow oxygen to diffuse into the blood and carbon dioxide to diffuse out, making the blood oxygen-rich before it is pumped back to the left side of the heart through the pulmonary veins. This process is crucial for maintaining proper oxygenation of the body's tissues and organs.

Benzimidazoles are a class of heterocyclic compounds containing a benzene fused to a imidazole ring. They have a wide range of pharmacological activities and are used in the treatment of various diseases. Some of the benzimidazoles are used as antiparasitics, such as albendazole and mebendazole, which are effective against a variety of worm infestations. Other benzimidazoles have antifungal properties, such as thiabendazole and fuberidazole, and are used to treat fungal infections. Additionally, some benzimidazoles have been found to have anti-cancer properties and are being investigated for their potential use in cancer therapy.

Fibrinogen is a soluble protein present in plasma, synthesized by the liver. It plays an essential role in blood coagulation. When an injury occurs, fibrinogen gets converted into insoluble fibrin by the action of thrombin, forming a fibrin clot that helps to stop bleeding from the injured site. Therefore, fibrinogen is crucial for hemostasis, which is the process of stopping bleeding and starting the healing process after an injury.

Benzylamines are a class of organic compounds that consist of a benzene ring attached to an amine group. The amine group (-NH2) can be primary, secondary, or tertiary, depending on the number of hydrogen atoms bonded to the nitrogen atom. Benzylamines are used in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. They have a variety of biological activities and can act as central nervous system depressants, local anesthetics, and muscle relaxants. However, some benzylamines can also be toxic or carcinogenic, so they must be handled with care.

Postphlebitic syndrome, also known as postthrombotic syndrome or post-thrombotic limb, is a long-term complication that can occur after deep vein thrombosis (DVT). It's characterized by chronic venous insufficiency due to damage in the valves and walls of the affected veins. This results in impaired return of blood from the extremities back to the heart, leading to symptoms such as:

1. Swelling (edema) in the affected limb, usually the lower leg or calf.
2. Pain, aching, or cramping in the legs.
3. Heaviness or fatigue in the legs.
4. Skin changes like redness, warmth, or itchiness.
5. Development of venous ulcers or sores, particularly around the ankles.

The severity of postphlebitic syndrome can vary from mild to severe and may significantly impact a person's quality of life. Risk factors for developing this condition include having had a previous DVT, obesity, older age, lack of physical activity, and a family history of blood clotting disorders. Early diagnosis and appropriate management of deep vein thrombosis can help reduce the risk of developing postphlebitic syndrome.

Azetidines are a class of organic compounds that contain a 4-membered saturated ring with two carbon atoms and two nitrogen atoms. The general structure of an azetidine is R-CH2-CH2-N-R', where R and R' can be hydrogen atoms or any other organic substituents.

Azetidines are relatively rare in nature, but they have attracted significant interest in the field of medicinal chemistry due to their unique structure and potential as building blocks for drug design. Some azetidine-containing compounds have been developed as drugs for various therapeutic indications, such as antibiotics, antivirals, and anti-inflammatory agents.

It's worth noting that the term 'azetidines' can also refer to the class of pharmaceutical compounds that contain an azetidine ring in their structure.

The Predictive Value of Tests, specifically the Positive Predictive Value (PPV) and Negative Predictive Value (NPV), are measures used in diagnostic tests to determine the probability that a positive or negative test result is correct.

Positive Predictive Value (PPV) is the proportion of patients with a positive test result who actually have the disease. It is calculated as the number of true positives divided by the total number of positive results (true positives + false positives). A higher PPV indicates that a positive test result is more likely to be a true positive, and therefore the disease is more likely to be present.

Negative Predictive Value (NPV) is the proportion of patients with a negative test result who do not have the disease. It is calculated as the number of true negatives divided by the total number of negative results (true negatives + false negatives). A higher NPV indicates that a negative test result is more likely to be a true negative, and therefore the disease is less likely to be present.

The predictive value of tests depends on the prevalence of the disease in the population being tested, as well as the sensitivity and specificity of the test. A test with high sensitivity and specificity will generally have higher predictive values than a test with low sensitivity and specificity. However, even a highly sensitive and specific test can have low predictive values if the prevalence of the disease is low in the population being tested.

An intrauterine device (IUD) is a small, T-shaped birth control device that is inserted into the uterus to prevent pregnancy. A medicated IUD is a type of IUD that contains hormones, which are released slowly over time to provide additional benefits beyond just contraception.

There are two types of medicated IUDs available in the US market: levonorgestrel-releasing intrauterine system (LNG-IUS) and the copper intrauterine device (Cu-IUD). The LNG-IUS releases a progestin hormone called levonorgestrel, which thickens cervical mucus to prevent sperm from reaching the egg, thins the lining of the uterus to make it less likely for a fertilized egg to implant, and can also inhibit ovulation in some women. The Cu-IUD is non-hormonal and works by releasing copper ions that create a toxic environment for sperm, preventing them from reaching the egg.

Medicated IUDs are highly effective at preventing pregnancy, with typical use failure rates of less than 1% per year. They can remain in place for several years, depending on the brand, and can be removed at any time by a healthcare provider if a woman wants to become pregnant or experience side effects. Common side effects of medicated IUDs may include irregular menstrual bleeding, cramping, and spotting between periods, although these tend to improve over time.

An intracranial embolism is a medical condition that occurs when a blood clot or other foreign material (embolus) forms elsewhere in the body and travels to the blood vessels within the brain. This embolus then blocks the flow of blood in the cerebral arteries, leading to potential damage or death of brain tissue. Common sources of intracranial emboli include heart conditions such as atrial fibrillation, valvular heart disease, or following a heart attack; or from large-vessel atherosclerosis in the carotid arteries. Symptoms can vary depending on the location and size of the obstruction, but may include sudden weakness or numbness, confusion, difficulty speaking, vision loss, severe headache, or even loss of consciousness. Immediate medical attention is required to diagnose and treat intracranial embolism, often involving anticoagulation therapy, endovascular procedures, or surgery.

A fatal outcome is a term used in medical context to describe a situation where a disease, injury, or illness results in the death of an individual. It is the most severe and unfortunate possible outcome of any medical condition, and is often used as a measure of the severity and prognosis of various diseases and injuries. In clinical trials and research, fatal outcome may be used as an endpoint to evaluate the effectiveness and safety of different treatments or interventions.

Factor V deficiency is a rare bleeding disorder that is caused by a mutation in the gene that produces coagulation factor V, a protein involved in the clotting process. This condition can lead to excessive bleeding following injury or surgery, and may also cause menorrhagia (heavy menstrual periods) in women.

Factor V deficiency is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene (one from each parent) in order to develop the condition. People who inherit only one copy of the mutated gene are carriers and may have a milder form of the disorder or no symptoms at all.

Treatment for factor V deficiency typically involves replacement therapy with fresh frozen plasma or clotting factor concentrates, which can help to reduce bleeding episodes and prevent complications. In some cases, medications such as desmopressin or antifibrinolytics may also be used to manage the condition.

Fibrinopeptide A is a small protein molecule that is cleaved and released from the larger fibrinogen protein during the blood clotting process. Specifically, it is removed by the enzyme thrombin as part of the conversion of fibrinogen to fibrin, which is the main structural component of a blood clot. The measurement of Fibrinopeptide A in the blood can be used as a marker for ongoing thrombin activation and fibrin formation, which are key events in coagulation and hemostasis. Increased levels of Fibrinopeptide A may indicate abnormal or excessive blood clotting, such as in disseminated intravascular coagulation (DIC) or deep vein thrombosis (DVT).

Angiography is a medical procedure in which an x-ray image is taken to visualize the internal structure of blood vessels, arteries, or veins. This is done by injecting a radiopaque contrast agent (dye) into the blood vessel using a thin, flexible catheter. The dye makes the blood vessels visible on an x-ray image, allowing doctors to diagnose and treat various medical conditions such as blockages, narrowing, or malformations of the blood vessels.

There are several types of angiography, including:

* Cardiac angiography (also called coronary angiography) - used to examine the blood vessels of the heart
* Cerebral angiography - used to examine the blood vessels of the brain
* Peripheral angiography - used to examine the blood vessels in the limbs or other parts of the body.

Angiography is typically performed by a radiologist, cardiologist, or vascular surgeon in a hospital setting. It can help diagnose conditions such as coronary artery disease, aneurysms, and peripheral arterial disease, among others.

Hemostasis is the physiological process that occurs to stop bleeding (bleeding control) when a blood vessel is damaged. This involves the interaction of platelets, vasoconstriction, and blood clotting factors leading to the formation of a clot. The ultimate goal of hemostasis is to maintain the integrity of the vascular system while preventing excessive blood loss.

Oral hormonal contraceptives, also known as "birth control pills," are a type of medication that contains synthetic hormones (estrogen and/or progestin) that are taken by mouth to prevent pregnancy. They work by preventing ovulation (the release of an egg from the ovaries), thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant.

There are several different types of oral hormonal contraceptives, including combined pills that contain both estrogen and progestin, and mini-pills that only contain progestin. These medications are usually taken daily for 21 days, followed by a seven-day break during which menstruation occurs. Some newer formulations may be taken continuously with no break.

It's important to note that while oral hormonal contraceptives are highly effective at preventing pregnancy when used correctly, they do not protect against sexually transmitted infections (STIs). Therefore, it is still important to use barrier methods of protection, such as condoms, during sexual activity to reduce the risk of STIs.

As with any medication, oral hormonal contraceptives can have side effects and may not be suitable for everyone. It's important to discuss any medical conditions, allergies, or medications you are taking with your healthcare provider before starting to take oral hormonal contraceptives.

A registry in the context of medicine is a collection or database of standardized information about individuals who share a certain condition or attribute, such as a disease, treatment, exposure, or demographic group. These registries are used for various purposes, including:

* Monitoring and tracking the natural history of diseases and conditions
* Evaluating the safety and effectiveness of medical treatments and interventions
* Conducting research and generating hypotheses for further study
* Providing information to patients, clinicians, and researchers
* Informing public health policy and decision-making

Registries can be established for a wide range of purposes, including disease-specific registries (such as cancer or diabetes registries), procedure-specific registries (such as joint replacement or cardiac surgery registries), and population-based registries (such as birth defects or cancer registries). Data collected in registries may include demographic information, clinical data, laboratory results, treatment details, and outcomes.

Registries can be maintained by a variety of organizations, including hospitals, clinics, academic medical centers, professional societies, government agencies, and industry. Participation in registries is often voluntary, although some registries may require informed consent from participants. Data collected in registries are typically de-identified to protect the privacy of individuals.

An embolism is a medical condition that occurs when a substance, such as a blood clot or an air bubble, blocks a blood vessel. This can happen in any part of the body, but it is particularly dangerous when it affects the brain (causing a stroke) or the lungs (causing a pulmonary embolism). Embolisms can cause serious harm by preventing oxygen and nutrients from reaching the tissues and organs that need them. They are often the result of underlying medical conditions, such as heart disease or deep vein thrombosis, and may require immediate medical attention to prevent further complications.

I'm sorry for any confusion, but "United States" is a geopolitical entity, specifically the name of the country consisting of 50 states, and it is not a medical term or concept. Therefore, I can't provide a medical definition for it. If you have any questions related to health, medicine, or biology, I would be happy to try to help answer those!

Estrogen Replacement Therapy (ERT) is a medical treatment in which estrogen hormones are administered to replace the estrogen that is naturally produced by the ovaries but declines, especially during menopause. This therapy is often used to help manage symptoms of menopause such as hot flashes, night sweats, and vaginal dryness. It can also help prevent bone loss in postmenopausal women. ERT typically involves the use of estrogen alone, but in some cases, a combination of estrogen and progestin may be prescribed for women with a uterus to reduce the risk of endometrial cancer. However, ERT is associated with certain risks, including an increased risk of breast cancer, blood clots, and stroke, so it's important for women to discuss the potential benefits and risks with their healthcare provider before starting this therapy.

The odds ratio (OR) is a statistical measure used in epidemiology and research to estimate the association between an exposure and an outcome. It represents the odds that an event will occur in one group versus the odds that it will occur in another group, assuming that all other factors are held constant.

In medical research, the odds ratio is often used to quantify the strength of the relationship between a risk factor (exposure) and a disease outcome. An OR of 1 indicates no association between the exposure and the outcome, while an OR greater than 1 suggests that there is a positive association between the two. Conversely, an OR less than 1 implies a negative association.

It's important to note that the odds ratio is not the same as the relative risk (RR), which compares the incidence rates of an outcome in two groups. While the OR can approximate the RR when the outcome is rare, they are not interchangeable and can lead to different conclusions about the association between an exposure and an outcome.

Heart disease is a broad term for a class of diseases that involve the heart or blood vessels. It's often used to refer to conditions that include:

1. Coronary artery disease (CAD): This is the most common type of heart disease. It occurs when the arteries that supply blood to the heart become hardened and narrowed due to the buildup of cholesterol and other substances, which can lead to chest pain (angina), shortness of breath, or a heart attack.

2. Heart failure: This condition occurs when the heart is unable to pump blood efficiently to meet the body's needs. It can be caused by various conditions, including coronary artery disease, high blood pressure, and cardiomyopathy.

3. Arrhythmias: These are abnormal heart rhythms, which can be too fast, too slow, or irregular. They can lead to symptoms such as palpitations, dizziness, and fainting.

4. Valvular heart disease: This involves damage to one or more of the heart's four valves, which control blood flow through the heart. Damage can be caused by various conditions, including infection, rheumatic fever, and aging.

5. Cardiomyopathy: This is a disease of the heart muscle that makes it harder for the heart to pump blood efficiently. It can be caused by various factors, including genetics, viral infections, and drug abuse.

6. Pericardial disease: This involves inflammation or other problems with the sac surrounding the heart (pericardium). It can cause chest pain and other symptoms.

7. Congenital heart defects: These are heart conditions that are present at birth, such as a hole in the heart or abnormal blood vessels. They can range from mild to severe and may require medical intervention.

8. Heart infections: The heart can become infected by bacteria, viruses, or parasites, leading to various symptoms and complications.

It's important to note that many factors can contribute to the development of heart disease, including genetics, lifestyle choices, and certain medical conditions. Regular check-ups and a healthy lifestyle can help reduce the risk of developing heart disease.

Impedance plethysmography is a non-invasive method used to measure changes in blood volume or flow in a particular area of the body. It works by passing a small electrical current through the tissue and measuring the opposition (impedance) to that current, which varies with the amount of blood present in the area.

In impedance cardiography, this technique is used to estimate cardiac output, stroke volume, and other hemodynamic parameters. The changes in impedance are measured across the chest wall, which correlate with the ventricular ejection of blood during each heartbeat. This allows for the calculation of various cardiovascular variables, such as the amount of blood pumped by the heart per minute (cardiac output) and the resistance to blood flow in the systemic circulation (systemic vascular resistance).

Impedance plethysmography is a safe and reliable method for assessing cardiovascular function, and it has been widely used in clinical settings to evaluate patients with various cardiovascular disorders, including heart failure, hypertension, and peripheral arterial disease.

Proportional hazards models are a type of statistical analysis used in medical research to investigate the relationship between covariates (predictor variables) and survival times. The most common application of proportional hazards models is in the Cox regression model, which is named after its developer, Sir David Cox.

In a proportional hazards model, the hazard rate or risk of an event occurring at a given time is assumed to be proportional to the hazard rate of a reference group, after adjusting for the covariates. This means that the ratio of the hazard rates between any two individuals remains constant over time, regardless of their survival times.

Mathematically, the hazard function h(t) at time t for an individual with a set of covariates X can be expressed as:

h(t|X) = h0(t) \* exp(β1X1 + β2X2 + ... + βpXp)

where h0(t) is the baseline hazard function, X1, X2, ..., Xp are the covariates, and β1, β2, ..., βp are the regression coefficients that represent the effect of each covariate on the hazard rate.

The assumption of proportionality is crucial in the interpretation of the results from a Cox regression model. If the assumption is violated, then the estimated regression coefficients may be biased and misleading. Therefore, it is important to test for the proportional hazards assumption before interpreting the results of a Cox regression analysis.

Comorbidity is the presence of one or more additional health conditions or diseases alongside a primary illness or condition. These co-occurring health issues can have an impact on the treatment plan, prognosis, and overall healthcare management of an individual. Comorbidities often interact with each other and the primary condition, leading to more complex clinical situations and increased healthcare needs. It is essential for healthcare professionals to consider and address comorbidities to provide comprehensive care and improve patient outcomes.

Conduction anesthesia is a type of local anesthesia in which an anesthetic agent is administered near a peripheral nerve to block the transmission of painful stimuli. It is called "conduction" anesthesia because it works by blocking the conduction of nerve impulses along the nerve fibers.

There are several types of conduction anesthesia, including:

1. Infiltration anesthesia: In this technique, the anesthetic agent is injected directly into the tissue where the surgical procedure will be performed. This type of anesthesia can be used for minor surgeries such as wound closure or repair of simple lacerations.
2. Nerve block anesthesia: In this technique, the anesthetic agent is injected near a specific nerve or bundle of nerves to block sensation in a larger area of the body. For example, a brachial plexus block can be used to numb the arm and hand for procedures such as shoulder surgery or fracture reduction.
3. Field block anesthesia: In this technique, the anesthetic agent is injected around the periphery of the surgical site to create a "field" of anesthesia that blocks sensation in the area. This type of anesthesia is often used for procedures such as hernia repair or circumcision.

Conduction anesthesia has several advantages over general anesthesia, including reduced risk of complications, faster recovery time, and lower cost. However, it may not be appropriate for all types of surgical procedures or patients, and its effectiveness can vary depending on the skill of the practitioner and the individual patient's response to the anesthetic agent.

Logistic models, specifically logistic regression models, are a type of statistical analysis used in medical and epidemiological research to identify the relationship between the risk of a certain health outcome or disease (dependent variable) and one or more independent variables, such as demographic factors, exposure variables, or other clinical measurements.

In contrast to linear regression models, logistic regression models are used when the dependent variable is binary or dichotomous in nature, meaning it can only take on two values, such as "disease present" or "disease absent." The model uses a logistic function to estimate the probability of the outcome based on the independent variables.

Logistic regression models are useful for identifying risk factors and estimating the strength of associations between exposures and health outcomes, adjusting for potential confounders, and predicting the probability of an outcome given certain values of the independent variables. They can also be used to develop clinical prediction rules or scores that can aid in decision-making and patient care.

The heart atria are the upper chambers of the heart that receive blood from the veins and deliver it to the lower chambers, or ventricles. There are two atria in the heart: the right atrium receives oxygen-poor blood from the body and pumps it into the right ventricle, which then sends it to the lungs to be oxygenated; and the left atrium receives oxygen-rich blood from the lungs and pumps it into the left ventricle, which then sends it out to the rest of the body. The atria contract before the ventricles during each heartbeat, helping to fill the ventricles with blood and prepare them for contraction.

An "aircraft" is not a medical term, but rather a general term used to describe any vehicle or machine designed to be powered and operated in the air. This includes fixed-wing aircraft such as airplanes and gliders, as well as rotary-wing aircraft such as helicopters and autogyros.

However, there are some medical conditions that can affect a person's ability to safely operate an aircraft, such as certain cardiovascular or neurological disorders. In these cases, the individual may be required to undergo medical evaluation and obtain clearance from aviation medical examiners before they are allowed to fly.

Additionally, there are some medical devices and equipment that are used in aircraft, such as oxygen systems and medical evacuation equipment. These may be used to provide medical care to passengers or crew members during flight.

Early ambulation, also known as early mobilization or early rehabilitation, refers to the practice of encouraging patients to get out of bed and start moving around as soon as possible after a surgical procedure or medical event such as a stroke. The goal of early ambulation is to prevent complications associated with prolonged bed rest, including muscle weakness, joint stiffness, blood clots, pneumonia, and pressure ulcers. It can also help improve patients' overall recovery, strength, and functional ability.

The specific timeline for early ambulation will depend on the individual patient's medical condition and healthcare provider's recommendations. However, in general, it is recommended to start mobilizing patients as soon as they are medically stable and able to do so safely, often within the first 24-48 hours after surgery or an event. This may involve sitting up in bed, standing, taking a few steps with assistance, or walking a short distance with the help of a walker or other assistive device.

Healthcare providers such as physicians, nurses, and physical therapists work together to develop a safe and effective early ambulation plan for each patient, taking into account their individual needs, abilities, and limitations.

Protein S is a vitamin K-dependent protein found in the blood that functions as a natural anticoagulant. It plays a crucial role in regulating the body's clotting system by inhibiting the activation of coagulation factors, thereby preventing excessive blood clotting. Protein S also acts as a cofactor for activated protein C, which is another important anticoagulant protein.

Protein S exists in two forms: free and bound to a protein called C4b-binding protein (C4BP). Only the free form of Protein S has biological activity in inhibiting coagulation. Inherited or acquired deficiencies in Protein S can lead to an increased risk of thrombosis, or abnormal blood clot formation, which can cause various medical conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Regular monitoring of Protein S levels is essential for patients with a history of thrombotic events or those who have a family history of thrombophilia.

A chronic disease is a long-term medical condition that often progresses slowly over a period of years and requires ongoing management and care. These diseases are typically not fully curable, but symptoms can be managed to improve quality of life. Common chronic diseases include heart disease, stroke, cancer, diabetes, arthritis, and COPD (chronic obstructive pulmonary disease). They are often associated with advanced age, although they can also affect children and younger adults. Chronic diseases can have significant impacts on individuals' physical, emotional, and social well-being, as well as on healthcare systems and society at large.

The Kaplan-Meier estimate is a statistical method used to calculate the survival probability over time in a population. It is commonly used in medical research to analyze time-to-event data, such as the time until a patient experiences a specific event like disease progression or death. The Kaplan-Meier estimate takes into account censored data, which occurs when some individuals are lost to follow-up before experiencing the event of interest.

The method involves constructing a survival curve that shows the proportion of subjects still surviving at different time points. At each time point, the survival probability is calculated as the product of the conditional probabilities of surviving from one time point to the next. The Kaplan-Meier estimate provides an unbiased and consistent estimator of the survival function, even when censoring is present.

In summary, the Kaplan-Meier estimate is a crucial tool in medical research for analyzing time-to-event data and estimating survival probabilities over time while accounting for censored observations.

Pipicolic acid is not a term that refers to a specific medical condition or disease. Instead, it is a metabolite that is involved in the body's metabolic processes.

Pipicolic acid is a type of organic compound called a cyclic amino acid, which is derived from the amino acid lysine. It is produced in the liver and is excreted in urine. Pipicolic acid has been found to have various functions in the body, including regulating the metabolism of lipids and bile acids.

Abnormal levels of pipicolic acid in the body may be associated with certain medical conditions, such as liver disease or genetic disorders that affect amino acid metabolism. However, pipicolic acid is not typically used as a diagnostic marker for these conditions.

In summary, pipicolic acid is a cyclic amino acid produced in the liver and involved in various metabolic processes in the body. Abnormal levels of pipicolic acid may be associated with certain medical conditions but are not typically used as diagnostic markers.

Ethinyl estradiol is a synthetic form of the hormone estrogen that is often used in various forms of hormonal contraception, such as birth control pills. It works by preventing ovulation and thickening cervical mucus to make it more difficult for sperm to reach the egg. Ethinyl estradiol may also be used in combination with other hormones to treat menopausal symptoms or hormonal disorders.

It is important to note that while ethinyl estradiol can be an effective form of hormonal therapy, it can also carry risks and side effects, such as an increased risk of blood clots, stroke, and breast cancer. As with any medication, it should only be used under the guidance and supervision of a healthcare provider.

Chemoprevention is a medical term that refers to the use of chemical agents, usually in the form of drugs or dietary supplements, to prevent or delay the development of cancer. These agents are typically designed to interfere with the molecular processes involved in cancer initiation, promotion, or progression.

There are several different approaches to chemoprevention, depending on the specific type of cancer and the individual patient's risk factors. Some chemopreventive agents work by blocking the action of hormones that can promote cancer growth, while others may inhibit the activity of enzymes involved in DNA damage or repair.

Chemoprevention is often used in individuals who are at high risk of developing cancer due to inherited genetic mutations, a history of precancerous lesions, or other factors. However, it is important to note that chemopreventive agents can have side effects and may not be appropriate for everyone. Therefore, they should only be used under the close supervision of a healthcare provider.

Multivariate analysis is a statistical method used to examine the relationship between multiple independent variables and a dependent variable. It allows for the simultaneous examination of the effects of two or more independent variables on an outcome, while controlling for the effects of other variables in the model. This technique can be used to identify patterns, associations, and interactions among multiple variables, and is commonly used in medical research to understand complex health outcomes and disease processes. Examples of multivariate analysis methods include multiple regression, factor analysis, cluster analysis, and discriminant analysis.

Pregnancy is a physiological state or condition where a fertilized egg (zygote) successfully implants and grows in the uterus of a woman, leading to the development of an embryo and finally a fetus. This process typically spans approximately 40 weeks, divided into three trimesters, and culminates in childbirth. Throughout this period, numerous hormonal and physical changes occur to support the growing offspring, including uterine enlargement, breast development, and various maternal adaptations to ensure the fetus's optimal growth and well-being.

Prevalence, in medical terms, refers to the total number of people in a given population who have a particular disease or condition at a specific point in time, or over a specified period. It is typically expressed as a percentage or a ratio of the number of cases to the size of the population. Prevalence differs from incidence, which measures the number of new cases that develop during a certain period.

Norethynodrel is a synthetic progestin, which is a type of female sex hormone. It is not commonly used in modern medicine. In the past, it was used in some oral contraceptives to prevent pregnancy by inhibiting ovulation and altering the cervical mucus and endometrium. Norethynodrel is no longer widely used due to the development of newer and more effective progestins.

I'm sorry for any confusion, but "Japan" is not a medical term. Japan is the name of a country, officially known as Nippon-koku or Nihon-koku in Japanese, and is located in East Asia. It is an island nation in the Pacific Ocean with a population of about 126 million people.

If you have any medical questions or terms that you would like me to define, please let me know!

An autopsy, also known as a post-mortem examination or obduction, is a medical procedure in which a qualified professional (usually a pathologist) examines a deceased person's body to determine the cause and manner of death. This process may involve various investigative techniques, such as incisions to study internal organs, tissue sampling, microscopic examination, toxicology testing, and other laboratory analyses. The primary purpose of an autopsy is to gather objective evidence about the medical conditions and factors contributing to the individual's demise, which can be essential for legal, insurance, or public health purposes. Additionally, autopsies can provide valuable insights into disease processes and aid in advancing medical knowledge.

Intracranial hemorrhage (ICH) is a type of stroke caused by bleeding within the brain or its surrounding tissues. It's a serious medical emergency that requires immediate attention and treatment. The bleeding can occur in various locations:

1. Epidural hematoma: Bleeding between the dura mater (the outermost protective covering of the brain) and the skull. This is often caused by trauma, such as a head injury.
2. Subdural hematoma: Bleeding between the dura mater and the brain's surface, which can also be caused by trauma.
3. Subarachnoid hemorrhage: Bleeding in the subarachnoid space, which is filled with cerebrospinal fluid (CSF) and surrounds the brain. This type of ICH is commonly caused by the rupture of an intracranial aneurysm or arteriovenous malformation.
4. Intraparenchymal hemorrhage: Bleeding within the brain tissue itself, which can be caused by hypertension (high blood pressure), amyloid angiopathy, or trauma.
5. Intraventricular hemorrhage: Bleeding into the brain's ventricular system, which contains CSF and communicates with the subarachnoid space. This type of ICH is often seen in premature infants but can also be caused by head trauma or aneurysm rupture in adults.

Symptoms of intracranial hemorrhage may include sudden severe headache, vomiting, altered consciousness, confusion, seizures, weakness, numbness, or paralysis on one side of the body, vision changes, or difficulty speaking or understanding speech. Rapid diagnosis and treatment are crucial to prevent further brain damage and potential long-term disabilities or death.

Sick Sinus Syndrome (SSS) is a term used to describe a group of abnormal heart rhythm disturbances that originates in the sinoatrial node (the natural pacemaker of the heart). This syndrome is characterized by impaired functioning of the sinoatrial node, resulting in various abnormalities such as sinus bradycardia (abnormally slow heart rate), sinus arrest (complete cessation of sinus node activity), and/or sinoatrial exit block (failure of the electrical impulse to leave the sinus node and spread to the atria).

People with SSS may experience symptoms such as palpitations, dizziness, fatigue, shortness of breath, or syncope (fainting) due to inadequate blood supply to the brain caused by slow heart rate. The diagnosis of SSS is typically made based on the patient's symptoms and the results of an electrocardiogram (ECG), Holter monitoring, or event recorder that shows evidence of abnormal sinus node function. Treatment options for SSS may include lifestyle modifications, medications, or implantation of a pacemaker to regulate the heart rate.

Thromboplastin is a substance that activates the coagulation cascade, leading to the formation of a clot (thrombus). It's primarily found in damaged or injured tissues and blood vessels, as well as in platelets (thrombocytes). There are two types of thromboplastin:

1. Extrinsic thromboplastin (also known as tissue factor): This is a transmembrane glycoprotein that is primarily found in subendothelial cells and released upon injury to the blood vessels. It initiates the extrinsic pathway of coagulation by binding to and activating Factor VII, ultimately leading to the formation of thrombin and fibrin clots.
2. Intrinsic thromboplastin (also known as plasma thromboplastin or factor III): This term is used less frequently and refers to a labile phospholipid component present in platelet membranes, which plays a role in the intrinsic pathway of coagulation.

In clinical settings, the term "thromboplastin" often refers to reagents used in laboratory tests like the prothrombin time (PT) and activated partial thromboplastin time (aPTT). These reagents contain a source of tissue factor and calcium ions to initiate and monitor the coagulation process.

The inferior vena cava (IVC) is the largest vein in the human body that carries deoxygenated blood from the lower extremities, pelvis, and abdomen to the right atrium of the heart. It is formed by the union of the left and right common iliac veins at the level of the fifth lumbar vertebra. The inferior vena cava is a retroperitoneal structure, meaning it lies behind the peritoneum, the lining that covers the abdominal cavity. It ascends through the posterior abdominal wall and passes through the central tendon of the diaphragm to enter the thoracic cavity.

The inferior vena cava is composed of three parts:

1. The infrarenal portion, which lies below the renal veins
2. The renal portion, which receives blood from the renal veins
3. The suprahepatic portion, which lies above the liver and receives blood from the hepatic veins before draining into the right atrium of the heart.

The inferior vena cava plays a crucial role in maintaining venous return to the heart and contributing to cardiovascular function.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

The mitral valve, also known as the bicuspid valve, is a two-leaflet valve located between the left atrium and left ventricle in the heart. Its function is to ensure unidirectional flow of blood from the left atrium into the left ventricle during the cardiac cycle. The mitral valve consists of two leaflets (anterior and posterior), the chordae tendineae, papillary muscles, and the left atrial and ventricular myocardium. Dysfunction of the mitral valve can lead to various heart conditions such as mitral regurgitation or mitral stenosis.

I'm sorry for any confusion, but "Massachusetts" is not a medical term. It is the name of a state located in the northeastern region of the United States. If you have any questions about medical terms or concepts, I would be happy to help clarify those for you.

Sagittal sinus thrombosis is a medical condition that refers to the formation of a blood clot (thrombus) in the sagittal sinus, which is a venous structure located in the brain. The sagittal sinus runs along the midline of the brain and receives blood from the superficial veins of the brain.

Sagittal sinus thrombosis can occur as a result of various conditions, such as head trauma, infection, cancer, or certain medical disorders that cause hypercoagulability (an increased tendency to form blood clots). The formation of a blood clot in the sagittal sinus can obstruct the flow of blood from the brain, leading to symptoms such as headache, seizures, altered consciousness, and focal neurological deficits.

Diagnosis of sagittal sinus thrombosis typically involves imaging studies such as computed tomography (CT) or magnetic resonance imaging (MRI) scans, which can show the presence of a blood clot in the sagittal sinus. Treatment may involve administering anticoagulant medications to prevent further growth of the blood clot and reduce the risk of complications such as pulmonary embolism or cerebral infarction. In some cases, surgical intervention may be necessary to remove the blood clot or alleviate pressure on the brain.

Elective surgical procedures are operations that are scheduled in advance because they do not involve a medical emergency. These surgeries are chosen or "elective" based on the patient's and doctor's decision to improve the patient's quality of life or to treat a non-life-threatening condition. Examples include but are not limited to:

1. Aesthetic or cosmetic surgery such as breast augmentation, rhinoplasty, etc.
2. Orthopedic surgeries like knee or hip replacements
3. Cataract surgery
4. Some types of cancer surgeries where the tumor is not spreading or causing severe symptoms
5. Gastric bypass for weight loss

It's important to note that while these procedures are planned, they still require thorough preoperative evaluation and preparation, and carry risks and benefits that need to be carefully considered by both the patient and the healthcare provider.

I'm not sure I understand your question. "Denmark" is a country located in Northern Europe, and it is not a medical term or concept. It is the southernmost of the Nordic countries, and it consists of the Jutland peninsula and several islands in the Baltic Sea. The capital city of Denmark is Copenhagen.

If you are looking for information about a medical condition that may be associated with Denmark, could you please provide more context or clarify your question? I would be happy to help you with more specific information if I can.

Progestins are a class of steroid hormones that are similar to progesterone, a natural hormone produced by the ovaries during the menstrual cycle and pregnancy. They are often used in hormonal contraceptives, such as birth control pills, shots, and implants, to prevent ovulation and thicken the cervical mucus, making it more difficult for sperm to reach the egg. Progestins are also used in menopausal hormone therapy to alleviate symptoms of menopause, such as hot flashes and vaginal dryness. Additionally, progestins may be used to treat endometriosis, uterine fibroids, and breast cancer. Different types of progestins have varying properties and may be more suitable for certain indications or have different side effect profiles.

A hip fracture is a medical condition referring to a break in the upper part of the femur (thigh) bone, which forms the hip joint. The majority of hip fractures occur due to falls or direct trauma to the area. They are more common in older adults, particularly those with osteoporosis, a condition that weakens bones and makes them more prone to breaking. Hip fractures can significantly impact mobility and quality of life, often requiring surgical intervention and rehabilitation.

Tertiary prevention in a medical context refers to measures aimed at managing or reducing the negative impact of an existing disease or disorder, with the goal of improving the patient's quality of life and preventing further complications or disability. It involves rehabilitation, long-term supportive care, and management of symptoms or complications associated with chronic conditions.

Tertiary prevention strategies may include:

1. Rehabilitation programs to help patients regain lost function, mobility, or skills.
2. Symptom management through medications, therapies, or surgical interventions.
3. Education and counseling on lifestyle modifications to minimize the risk of complications.
4. Regular monitoring and follow-up care to detect and address any new issues early.
5. Supportive care to help patients cope with chronic conditions and maintain their independence.

Examples of tertiary prevention include physical therapy for someone recovering from a stroke, pain management strategies for individuals with chronic pain, or regular monitoring and treatment of complications in people with diabetes.

Heart valve diseases are a group of conditions that affect the function of one or more of the heart's four valves (tricuspid, pulmonic, mitral, and aortic). These valves are responsible for controlling the direction and flow of blood through the heart. Heart valve diseases can cause the valves to become narrowed (stenosis), leaky (regurgitation or insufficiency), or improperly closed (prolapse), leading to disrupted blood flow within the heart and potentially causing symptoms such as shortness of breath, fatigue, chest pain, and irregular heart rhythms. The causes of heart valve diseases can include congenital defects, age-related degenerative changes, infections, rheumatic heart disease, and high blood pressure. Treatment options may include medications, surgical repair or replacement of the affected valve(s), or transcatheter procedures.

Evidence-Based Medicine (EBM) is a medical approach that combines the best available scientific evidence with clinical expertise and patient values to make informed decisions about diagnosis, treatment, and prevention of diseases. It emphasizes the use of systematic research, including randomized controlled trials and meta-analyses, to guide clinical decision making. EBM aims to provide the most effective and efficient care while minimizing variations in practice, reducing errors, and improving patient outcomes.

Primary prevention in a medical context refers to actions taken to prevent the development of a disease or injury before it occurs. This is typically achieved through measures such as public health education, lifestyle modifications, and vaccinations. The goal of primary prevention is to reduce the risk of a disease or injury by addressing its underlying causes. Examples of primary prevention strategies include smoking cessation programs to prevent lung cancer, immunizations to prevent infectious diseases, and safety regulations to prevent accidents and injuries.

Thrombocytopenia is a medical condition characterized by an abnormally low platelet count (thrombocytes) in the blood. Platelets are small cell fragments that play a crucial role in blood clotting, helping to stop bleeding when a blood vessel is damaged. A healthy adult typically has a platelet count between 150,000 and 450,000 platelets per microliter of blood. Thrombocytopenia is usually diagnosed when the platelet count falls below 150,000 platelets/µL.

Thrombocytopenia can be classified into three main categories based on its underlying cause:

1. Immune thrombocytopenia (ITP): An autoimmune disorder where the immune system mistakenly attacks and destroys its own platelets, leading to a decreased platelet count. ITP can be further divided into primary or secondary forms, depending on whether it occurs alone or as a result of another medical condition or medication.
2. Decreased production: Thrombocytopenia can occur when there is insufficient production of platelets in the bone marrow due to various causes, such as viral infections, chemotherapy, radiation therapy, leukemia, aplastic anemia, or vitamin B12 or folate deficiency.
3. Increased destruction or consumption: Thrombocytopenia can also result from increased platelet destruction or consumption due to conditions like disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or severe bacterial infections.

Symptoms of thrombocytopenia may include easy bruising, prolonged bleeding from cuts, spontaneous nosebleeds, bleeding gums, blood in urine or stools, and skin rashes like petechiae (small red or purple spots) or purpura (larger patches). The severity of symptoms can vary depending on the degree of thrombocytopenia and the presence of any underlying conditions. Treatment for thrombocytopenia depends on the cause and may include medications, transfusions, or addressing the underlying condition.

The popliteal vein is the continuation of the tibial and fibular (or anterior and posterior tibial) veins, forming in the lower leg's back portion or popliteal fossa. It carries blood from the leg towards the heart. The popliteal vein is located deep within the body and is accompanied by the popliteal artery, which supplies oxygenated blood to the lower leg. This venous structure is a crucial part of the venous system in the lower extremities and is often assessed during physical examinations for signs of venous insufficiency or deep vein thrombosis (DVT).

A biological marker, often referred to as a biomarker, is a measurable indicator that reflects the presence or severity of a disease state, or a response to a therapeutic intervention. Biomarkers can be found in various materials such as blood, tissues, or bodily fluids, and they can take many forms, including molecular, histologic, radiographic, or physiological measurements.

In the context of medical research and clinical practice, biomarkers are used for a variety of purposes, such as:

1. Diagnosis: Biomarkers can help diagnose a disease by indicating the presence or absence of a particular condition. For example, prostate-specific antigen (PSA) is a biomarker used to detect prostate cancer.
2. Monitoring: Biomarkers can be used to monitor the progression or regression of a disease over time. For instance, hemoglobin A1c (HbA1c) levels are monitored in diabetes patients to assess long-term blood glucose control.
3. Predicting: Biomarkers can help predict the likelihood of developing a particular disease or the risk of a negative outcome. For example, the presence of certain genetic mutations can indicate an increased risk for breast cancer.
4. Response to treatment: Biomarkers can be used to evaluate the effectiveness of a specific treatment by measuring changes in the biomarker levels before and after the intervention. This is particularly useful in personalized medicine, where treatments are tailored to individual patients based on their unique biomarker profiles.

It's important to note that for a biomarker to be considered clinically valid and useful, it must undergo rigorous validation through well-designed studies, including demonstrating sensitivity, specificity, reproducibility, and clinical relevance.

In the context of medicine and healthcare, 'probability' does not have a specific medical definition. However, in general terms, probability is a branch of mathematics that deals with the study of numerical quantities called probabilities, which are assigned to events or sets of events. Probability is a measure of the likelihood that an event will occur. It is usually expressed as a number between 0 and 1, where 0 indicates that the event is impossible and 1 indicates that the event is certain to occur.

In medical research and statistics, probability is often used to quantify the uncertainty associated with statistical estimates or hypotheses. For example, a p-value is a probability that measures the strength of evidence against a hypothesis. A small p-value (typically less than 0.05) suggests that the observed data are unlikely under the assumption of the null hypothesis, and therefore provides evidence in favor of an alternative hypothesis.

Probability theory is also used to model complex systems and processes in medicine, such as disease transmission dynamics or the effectiveness of medical interventions. By quantifying the uncertainty associated with these models, researchers can make more informed decisions about healthcare policies and practices.

Operative surgical procedures refer to medical interventions that involve manual manipulation of tissues, structures, or organs in the body, typically performed in an operating room setting under sterile conditions. These procedures are carried out with the use of specialized instruments, such as scalpels, forceps, and scissors, and may require regional or general anesthesia to ensure patient comfort and safety.

Operative surgical procedures can range from relatively minor interventions, such as a biopsy or the removal of a small lesion, to more complex and extensive surgeries, such as open heart surgery or total joint replacement. The specific goals of operative surgical procedures may include the diagnosis and treatment of medical conditions, the repair or reconstruction of damaged tissues or organs, or the prevention of further disease progression.

Regardless of the type or complexity of the procedure, all operative surgical procedures require careful planning, execution, and postoperative management to ensure the best possible outcomes for patients.

Rheumatic Heart Disease (RHD) is defined as a chronic heart condition caused by damage to the heart valves due to untreated or inadequately treated streptococcal throat infection (strep throat). The immune system's response to this infection can mistakenly attack and damage the heart tissue, leading to inflammation and scarring of the heart valves. This damage can result in narrowing, leakage, or abnormal functioning of the heart valves, which can further lead to complications such as heart failure, stroke, or infective endocarditis.

RHD is a preventable and treatable condition if detected early and managed effectively. It primarily affects children and young adults in developing countries where access to healthcare and antibiotics for strep throat infections may be limited. Long-term management of RHD typically involves medications, regular monitoring, and sometimes surgical intervention to repair or replace damaged heart valves.

The term "lower extremity" is used in the medical field to refer to the portion of the human body that includes the structures below the hip joint. This includes the thigh, lower leg, ankle, and foot. The lower extremities are responsible for weight-bearing and locomotion, allowing individuals to stand, walk, run, and jump. They contain many important structures such as bones, muscles, tendons, ligaments, nerves, and blood vessels.

Bleeding time is a medical test that measures the time it takes for a small blood vessel to stop bleeding after being cut. It's used to evaluate platelet function and the effectiveness of blood clotting. The most common method used to measure bleeding time is the Ivy method, which involves making a standardized incision on the forearm and measuring the time it takes for the bleeding to stop. A normal bleeding time ranges from 2 to 9 minutes, but this can vary depending on the specific method used. Prolonged bleeding time may indicate an impairment in platelet function or clotting factor deficiency.

A bioprosthesis is a type of medical implant that is made from biological materials, such as heart valves or tendons taken from animals (xenografts) or humans (allografts). These materials are processed and sterilized to be used in surgical procedures to replace damaged or diseased tissues in the body.

Bioprosthetic implants are often used in cardiac surgery, such as heart valve replacement, because they are less likely to cause an immune response than synthetic materials. However, they may have a limited lifespan due to calcification and degeneration of the biological tissue over time. Therefore, bioprosthetic implants may need to be replaced after several years.

Bioprostheses can also be used in other types of surgical procedures, such as ligament or tendon repair, where natural tissue is needed to restore function and mobility. These prostheses are designed to mimic the properties of native tissues and provide a more physiological solution than synthetic materials.

Left atrial function refers to the role and performance of the left atrium in the heart. The left atrium is the upper chamber on the left side of the heart that receives oxygenated blood from the lungs via the pulmonary veins and then contracts to help pump it into the left ventricle, which is the lower chamber that pumps blood out to the rest of the body.

The main functions of the left atrium include:

1. Receiving oxygen-rich blood from the lungs: The left atrium receives oxygenated blood from the pulmonary veins and acts as a reservoir for this blood before it is pumped into the left ventricle.
2. Contracting to help pump blood into the left ventricle: During atrial contraction, also known as atrial kick, the left atrium contracts and helps push blood into the left ventricle, increasing the amount of blood that can be ejected with each heartbeat.
3. Relaxing to receive more blood: Between heartbeats, the left atrium relaxes and fills up with more oxygenated blood from the lungs.
4. Contributing to heart rate regulation: The left atrium contains specialized cells called pacemaker cells that can help regulate the heart rate by initiating electrical impulses that trigger heart contractions.

Left atrial function is crucial for maintaining efficient cardiac output and overall cardiovascular health. Various conditions, such as heart failure, atrial fibrillation, and hypertension, can negatively impact left atrial function and contribute to the development of complications like stroke and reduced exercise tolerance.

Fibrin clot lysis time, also known as fibrinolytic time, is the measurement of the amount of time it takes for a blood clot to dissolve or lyse. This is typically measured in a laboratory setting using specialized tests such as the thromboelastography (TEG) or rotational thromboelastometry (ROTEM) assays. These tests measure the viscoelastic properties of a clot and can provide information about the rate of fibrinolysis, which is the natural process by which the body breaks down and removes blood clots.

Increased fibrin clot lysis time may indicate an impaired fibrinolytic system, which can lead to an increased risk of thrombosis or blood clot formation. Decreased fibrin clot lysis time may indicate an overactive fibrinolytic system, which can lead to an increased risk of bleeding.

It's important to note that the fibrin clot lysis time is just one factor among many that are considered when evaluating a patient's coagulation status and risk of thrombosis or bleeding. Other factors, such as platelet function, coagulation factor levels, and the presence of inhibitors or anticoagulants, must also be taken into account.

Hyperhomocysteinemia is a medical condition characterized by an excessively high level of homocysteine, an amino acid, in the blood. Generally, a level of 15 micromoles per liter (μmol/L) or higher is considered elevated.

Homocysteine is a byproduct of methionine metabolism, an essential amino acid obtained from dietary proteins. Normally, homocysteine gets converted back to methionine with the help of vitamin B12 and folate (vitamin B9), or it can be converted to another amino acid, cysteine, with the aid of vitamin B6.

Hyperhomocysteinemia can occur due to genetic defects in these enzymes, nutritional deficiencies of vitamins B12, B6, or folate, renal insufficiency, or aging. High homocysteine levels are associated with increased risks of cardiovascular diseases, including atherosclerosis, thrombosis, and stroke. It may also contribute to neurodegenerative disorders like Alzheimer's disease and cognitive decline.

It is essential to diagnose and manage hyperhomocysteinemia early to prevent potential complications. Treatment typically involves dietary modifications, supplementation of the deficient vitamins, and, in some cases, medication.

Fibrin is defined as a protein that is formed from fibrinogen during the clotting of blood. It plays an essential role in the formation of blood clots, also known as a clotting or coagulation cascade. When an injury occurs and bleeding starts, fibrin threads form a net-like structure that entraps platelets and red blood cells to create a stable clot, preventing further loss of blood.

The process of forming fibrin from fibrinogen is initiated by thrombin, another protein involved in the coagulation cascade. Thrombin cleaves fibrinogen into fibrin monomers, which then polymerize to form long strands of fibrin. These strands cross-link with each other through a process catalyzed by factor XIIIa, forming a stable clot that protects the wound and promotes healing.

It is important to note that abnormalities in fibrin formation or breakdown can lead to bleeding disorders or thrombotic conditions, respectively. Proper regulation of fibrin production and degradation is crucial for maintaining healthy hemostasis and preventing excessive clotting or bleeding.

Prognosis is a medical term that refers to the prediction of the likely outcome or course of a disease, including the chances of recovery or recurrence, based on the patient's symptoms, medical history, physical examination, and diagnostic tests. It is an important aspect of clinical decision-making and patient communication, as it helps doctors and patients make informed decisions about treatment options, set realistic expectations, and plan for future care.

Prognosis can be expressed in various ways, such as percentages, categories (e.g., good, fair, poor), or survival rates, depending on the nature of the disease and the available evidence. However, it is important to note that prognosis is not an exact science and may vary depending on individual factors, such as age, overall health status, and response to treatment. Therefore, it should be used as a guide rather than a definitive forecast.

Traumatic Intracranial Hemorrhage (TIH) is a type of bleeding that occurs within the skull or inside the brain parenchyma as a result of traumatic injury. It can be further classified based on the location and type of bleeding, which includes:

1. Epidural hematoma (EDH): Bleeding between the dura mater and the inner table of the skull, usually caused by arterial bleeding from the middle meningeal artery after a temporal bone fracture.
2. Subdural hematoma (SDH): Bleeding in the potential space between the dura mater and the arachnoid membrane, often due to venous sinus or bridging vein injury. SDHs can be acute, subacute, or chronic based on their age and clinical presentation.
3. Subarachnoid hemorrhage (SAH): Bleeding into the subarachnoid space, which is filled with cerebrospinal fluid (CSF). SAH is commonly caused by trauma but can also be secondary to aneurysmal rupture or arteriovenous malformations.
4. Intraparenchymal hemorrhage (IPH): Bleeding directly into the brain parenchyma, which can result from contusions, lacerations, or shearing forces during traumatic events.
5. Intraventricular hemorrhage (IVH): Bleeding into the cerebral ventricles, often as a complication of IPH, SAH, or EDH. IVH can lead to obstructive hydrocephalus and increased intracranial pressure (ICP).

TIHs are medical emergencies requiring prompt diagnosis and management to prevent secondary brain injury and reduce morbidity and mortality. Imaging modalities such as computed tomography (CT) or magnetic resonance imaging (MRI) are used for the detection and characterization of TIHs, while neurosurgical intervention may be necessary in specific cases.

Beta-thromboglobulin is a type of protein that is released from platelets (a component of blood) when they are activated. It is often used as a marker for platelet activation, which can occur in various physiological and pathological conditions such as hemostasis, thrombosis, inflammation, and atherosclerosis.

Beta-thromboglobulin is a member of the thromboglobulin family, which also includes platelet factor 4 (PF4) and other proteins that are involved in hemostasis and thrombosis. These proteins play important roles in the regulation of blood clotting and wound healing, but their excessive release or activation can contribute to the development of various cardiovascular diseases, such as myocardial infarction (heart attack) and stroke.

Elevated levels of beta-thromboglobulin have been found in patients with thromboembolic disorders, inflammatory bowel disease, cancer, and other conditions associated with platelet activation. Therefore, the measurement of beta-thromboglobulin can be useful in the diagnosis and monitoring of these diseases.

Pulmonary hypertension is a medical condition characterized by increased blood pressure in the pulmonary arteries, which are the blood vessels that carry blood from the right side of the heart to the lungs. This results in higher than normal pressures in the pulmonary circulation and can lead to various symptoms and complications.

Pulmonary hypertension is typically defined as a mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest, as measured by right heart catheterization. The World Health Organization (WHO) classifies pulmonary hypertension into five groups based on the underlying cause:

1. Pulmonary arterial hypertension (PAH): This group includes idiopathic PAH, heritable PAH, drug-induced PAH, and associated PAH due to conditions such as connective tissue diseases, HIV infection, portal hypertension, congenital heart disease, and schistosomiasis.
2. Pulmonary hypertension due to left heart disease: This group includes conditions that cause elevated left atrial pressure, such as left ventricular systolic or diastolic dysfunction, valvular heart disease, and congenital cardiovascular shunts.
3. Pulmonary hypertension due to lung diseases and/or hypoxia: This group includes chronic obstructive pulmonary disease (COPD), interstitial lung disease, sleep-disordered breathing, alveolar hypoventilation disorders, and high altitude exposure.
4. Chronic thromboembolic pulmonary hypertension (CTEPH): This group includes persistent obstruction of the pulmonary arteries due to organized thrombi or emboli.
5. Pulmonary hypertension with unclear and/or multifactorial mechanisms: This group includes hematologic disorders, systemic disorders, metabolic disorders, and other conditions that can cause pulmonary hypertension but do not fit into the previous groups.

Symptoms of pulmonary hypertension may include shortness of breath, fatigue, chest pain, lightheadedness, and syncope (fainting). Diagnosis typically involves a combination of medical history, physical examination, imaging studies, and invasive testing such as right heart catheterization. Treatment depends on the underlying cause but may include medications, oxygen therapy, pulmonary rehabilitation, and, in some cases, surgical intervention.

In medical terms, the leg refers to the lower portion of the human body that extends from the knee down to the foot. It includes the thigh (femur), lower leg (tibia and fibula), foot, and ankle. The leg is primarily responsible for supporting the body's weight and enabling movements such as standing, walking, running, and jumping.

The leg contains several important structures, including bones, muscles, tendons, ligaments, blood vessels, nerves, and joints. These structures work together to provide stability, support, and mobility to the lower extremity. Common medical conditions that can affect the leg include fractures, sprains, strains, infections, peripheral artery disease, and neurological disorders.

Thalidomide is a pharmaceutical drug that was initially developed and marketed as a sedative and treatment for morning sickness in pregnant women. However, it was later found to cause severe birth defects when given during pregnancy, particularly damage to the limbs, ears, and eyes of the developing fetus. As a result, thalidomide was banned in many countries in the 1960s.

In recent years, thalidomide has been reintroduced as a treatment for certain medical conditions, including multiple myeloma (a type of cancer that affects plasma cells) and leprosy. It is also being studied as a potential treatment for other diseases, such as rheumatoid arthritis and Crohn's disease.

Thalidomide works by suppressing the immune system and inhibiting the formation of new blood vessels (angiogenesis). However, its use is tightly regulated due to its teratogenic effects, meaning it can cause birth defects if taken during pregnancy. Women who are pregnant or planning to become pregnant should not take thalidomide, and healthcare providers must follow strict guidelines when prescribing the drug to ensure that it is used safely and effectively.

Cell-derived microparticles (CDMs), also known as microvesicles or microparticles, are small membrane-bound particles that are released from the cell surface upon activation or apoptosis of various cell types, including platelets, leukocytes, endothelial cells, and red blood cells. CDMs range in size from 0.1 to 1.0 micrometers in diameter and contain a variety of bioactive molecules, such as lipids, proteins, and nucleic acids, which can be transferred to neighboring or distant cells, thereby modulating their function.

CDMs have been implicated in various physiological and pathological processes, including coagulation, inflammation, immune response, angiogenesis, and cancer progression. They have also emerged as potential biomarkers for various diseases, such as cardiovascular disease, sepsis, and cancer, due to their distinct molecular signature and abundance in body fluids, such as blood, urine, and cerebrospinal fluid.

The mechanisms of CDM formation and release are complex and involve several cellular processes, including cytoskeletal rearrangement, membrane budding, and vesicle shedding. The molecular composition of CDMs reflects their cellular origin and activation state, and can be analyzed by various techniques, such as flow cytometry, proteomics, and transcriptomics, to gain insights into their biological functions and clinical relevance.

Arterial thromboembolism occurs suddenly and is very painful. The blockage of the terminal portion of the aorta results in an ... Feline arterial thromboembolism is a rare disease, accounting for approximately 0.1-0.3% of the total number of feline patients ... Less frequently, thromboembolism of the vessels of the arm, upper mesenteric artery or renal arteries (renal infarction) occurs ... Feline arterial thromboembolism (FATE syndrome) (German: Feline arterielle Thromboembolie) is a disease of the domestic cat in ...
The Estrogen in Venous Thromboembolism Trial (EVTET) was a randomized controlled trial (RCT) of menopausal hormone therapy in ... Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM (August 2018). "Risk of venous thromboembolism events in ... Lobo RA (May 2011). "Risk of venous thromboembolism by route of administration of estrogen". Menopause. 18 (5): 469-70. doi: ... Scarabin PY (August 2018). "Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal ...
Virchow is also known for elucidating the mechanism of pulmonary thromboembolism (a condition of blood clotting in the blood ... Dalen, James E. (2003). Venous Thromboembolism. New York: Marcel Decker, Inc. ISBN 978-0-8247-5645-1. Reese, DM (1998). " ...
2007). "Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of ... Khan, Faizan; Tritschler, Tobias; Kahn, Susan R; Rodger, Marc A (2021). "Venous thromboembolism". The Lancet. 398 (10294): 64- ... such as venous thromboembolism. While a negative result practically rules out thrombosis, a positive result can indicate ... A negative D-dimer test will virtually rule out thromboembolism: the degree to which the D-dimer reduces the probability of ...
"Venous thromboembolism". Royal College of Nursing. Retrieved 4 September 2012. "Mission Statement". Lifeblood, the Thrombosis ... campaign aims to ensure that every adult patient admitted to hospital across the UK receives a venous thromboembolism risk ... They also strive to improve the clinical diagnosis of venous thromboembolism in the community ('Spot the Clots'). Thrombosis UK ... they campaign for governments in the UK to prioritise venous thromboembolism (VTE) prevention in the National Health Service (' ...
Clinical guideline 92: Venous thromboembolism: reducing the risk: Reducing the risk of venous thromboembolism (deep vein ... Venous thromboembolism (VTE), a common risk factor, is present at much higher rates in those over the age of 70 (three times ... The conditions are generally regarded as a continuum known as a venous thromboembolism (VTE).[citation needed] VTE is much more ... Together, deep vein thrombosis and PE are known as venous thromboembolism (VTE). Efforts to prevent PE include beginning to ...
"Venous thromboembolism (VTE) , McMaster Pathophysiology Review". www.pathophys.org. 26 September 2012. Retrieved 2018-11-03. ... all of which contribute to increased risk for venous thromboembolism and other cardiovascular diseases. Virchow's triad ...
Thromboembolism (blood clots; including pulmonary embolism and deep vein thrombosis) Rhabdomyolysis (breakdown of muscle tissue ...
"What is Venous Thromboembolism?". Centers for Disease Control and Prevention. 14 March 2019. Retrieved 6 January 2020. Anderson ... DVT and PE are the two manifestations of the cardiovascular disease venous thromboembolism (VTE). VTE can occur as DVT only, ... Lee LH, Gallus A, Jindal R, Wang C, Wu CC (December 2017). "Incidence of venous thromboembolism in Asian populations: a ... "Venous thromboembolism". Disease Management Project. Cleveland Clinic. Archived from the original on 23 February 2011. ...
This can result in issues such as a relatively higher risk of thromboembolism. Estrogens can be administered via a variety of ... An example is history of thromboembolism (blood clots). The most common side effects of estrogens in general include breast ... Heit JA, Spencer FA, White RH (2016). "The epidemiology of venous thromboembolism". J. Thromb. Thrombolysis. 41 (1): 3-14. doi: ... 665-. ISBN 978-0-323-29738-7. Ralli E, Zezza L, Caserta D (2014). "Pregnancy and venous thromboembolism". Curr. Opin. Obstet. ...
Venous thromboembolism (VTE) consists of deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is a blood clot in a deep ... Beyer-Westendorf J, Werth S, Halbritter K, Weiss N (April 2010). "Cancer in males and risk of venous thromboembolism". Thromb. ... Seaman HE, Langley SE, Farmer RD, de Vries CS (June 2007). "Venous thromboembolism and cyproterone acetate in men with prostate ... Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H (October 2018). "Sex hormones and venous thromboembolism - ...
Thrombophilia and Venous Thromboembolism and The prevention of Venous Thromboembolism. Nicolaides A. (1975). Thromboembolism - ... 1994). Prevention of Venous Thromboembolism, Med-Orion Publishing. ISBN 978-9963-592-52-4 Belcaro G. et al. (1995). Venous ... Nicolaides has undertaken research on venous thromboembolism, noninvasive vascular investigations with particular emphasis on ... ISBN 978-1-86094-213-6 Nicolaides A. (2002). Prevention of Venous Thromboembolism, International Consensus Statement ( ...
"Venous Thromboembolism (Blood Clots) Facts". Division of Blood Disorders National Center on Birth Defects and Developmental ... "Venous Thromboembolism (VTE)" (PDF). National Center on Birth Defects and Developmental Disabilities. Archived from the ... "Patients with Venous Thromboembolism ) Registry". RIETE. Retrieved 2016-12-20. Moliterno D (2013). Therapeutic advances in ... Most hospitalized medical patients have at least 1 risk factor for thrombosis that progresses to thromboembolism and this risk ...
Member of European Association for the Study of Diabetes Long COVID-19: A Systematic Review HIV infection and thromboembolism. ... "HIV infection and thromboembolism". The Journal of the Association of Physicians of India. 59: 380-382. ISSN 0004-5772. PMID ...
air embolism, thromboembolism, etc.) CPR use in ACLS (Advanced Cardiovascular Life Support) Procedural Sedation Monitoring ...
"Management of Venous Thromboembolism". ACS Surgery. American College of Surgeons. Archived from the original on January 27, ...
Venography in iliofemoral venous thromboembolism. Surg Gynecol Obstet 1969;129:57. Wolf, GL; Arenson, RL; Cross, AP. A ...
Heit JA, Spencer FA, White RH (2016). "The epidemiology of venous thromboembolism". J. Thromb. Thrombolysis. 41 (1): 3-14. doi: ... Sehovic N, Smith KP (May 2010). "Risk of venous thromboembolism with drospirenone in combined oral contraceptive products". Ann ... Toni I, Neubert A, Botzenhardt S, Gratzki N, Rascher W (September 2013). "Venous thromboembolism in adolescents associated with ... Birth control pills containing ethinylestradiol and a progestin are associated with an increased risk of venous thromboembolism ...
Having a DVT or PE and a strong family history of venous thromboembolism. The use of hormones, such as oral contraceptive pills ... Despite the increased risk of venous thromboembolisms, people with one copy of this gene have not been found to have shorter ... Implications for venous thromboembolism screening". JAMA. 277 (16): 1305-7. doi:10.1001/jama.277.16.1305. PMID 9109469. Gregg ... November 2019). "Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with ...
In comparison, venous thromboembolism occurs in 100-200 per 100.000 pregnant women every year. One study showed more than a 600 ... The risk of thromboembolism varies with different types of birth control pills; compared with combined oral contraceptives ... All COCP users have a small increase in the risk of venous thromboembolism compared with non-users; this risk is greatest ... Combined oral contraceptives increase the risk of venous thromboembolism (including deep vein thrombosis (DVT) and pulmonary ...
"Venous thromboembolism - reducing the risk". Guidance.nice.org.uk. 2013-11-07. Retrieved 2014-01-16. "VTE prevention". Guidance ... She is a member of "The Independent Expert Panel on Venous Thromboembolism" 2005/6, and co-author on the "International ... She has a specialist clinical and research interest in venous thromboembolism, thromboprophylaxis, antiphospholipid syndrome, ... "Acute management of venous thromboembolism" published in 2012. On behalf of Thrombosis UK, she was also a member of the ...
Reitsma PH, Versteeg HH, Middeldorp S (2012). "Mechanistic view of risk factors for venous thromboembolism". Arterioscler ... Zakai, NA; McClure, LA (October 2011). "Racial differences in venous thromboembolism". Journal of Thrombosis and Haemostasis ( ... prothrombin G20210A is one of the most common genetic risk factors for venous thromboembolism (VTE). Increased production of ... mutations in adults with a history of idiopathic venous thromboembolism and their adult family members". Genetics in Medicine. ...
Renoux C, Dell'Aniello S, Suissa S (May 2010). "Hormone replacement therapy and the risk of venous thromboembolism: a ... 157-. ISBN 978-92-832-1291-1. Heit JA, Spencer FA, White RH (January 2016). "The epidemiology of venous thromboembolism". ... in women and does not increase the risk of venous thromboembolism (VTE) (RRTooltip Rate ratio = 0.92), which would not be ...
ISBN 978-3-319-65226-9. Ro A, Kageyama N, Mukai T (June 2017). "Pathophysiology of Venous Thromboembolism with Respect to the ... Heit JA, Spencer FA, White RH (January 2016). "The epidemiology of venous thromboembolism". Journal of Thrombosis and ...
November 2021). "Milvexian for the Prevention of Venous Thromboembolism". The New England Journal of Medicine. 385 (23): 2161- ... "Abelacimab for Prevention of Venous Thromboembolism". New England Journal of Medicine. 385 (7): 609-617. doi:10.1056/ ...
An estimated 64 percent of patients with venous thromboembolism may have APC resistance.[needs update] The disorder can be ... Sheppard DR (2000). "Activated protein C resistance: the most common risk factor for venous thromboembolism". J Am Board Fam ... Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J (2021). "Combined Oral Contraceptives and Venous Thromboembolism: Review ... Douxfils J, Morimont L, Bouvy C (November 2020). "Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May ...
Recurrent thromboembolism, or thrombosis in unusual sites (e.g. the hepatic vein in Budd-Chiari syndrome), is a generally ... When venous thromboembolism occurs when a patient is experiencing transient major risk factors such as prolonged immobility, ... Comp PC, Esmon CT (December 1984). "Recurrent venous thromboembolism in patients with a partial deficiency of protein S". N. ... Prandoni P, Falanga A, Piccioli A (June 2005). "Cancer and venous thromboembolism". Lancet Oncol. 6 (6): 401-10. doi:10.1016/ ...
Bińkowska M (October 2014). "Menopausal hormone therapy and venous thromboembolism". Prz Menopauzalny. 13 (5): 267-72. doi: ... Scarabin PY (December 2014). "Hormones and venous thromboembolism among postmenopausal women". Climacteric. 17 (Suppl 2): 34-7 ... incidence of venous thromboembolism. In a small study comparing high-dosage 320 mg/month intramuscular polyestradiol phosphate ... "Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills ...
Massimo, F.; Mannucci, P.M (2016). "Direct oral anticoagulants and venous thromboembolism". European Respiratory Review. 25 ( ... was granted marketing authorization for the prevention of venous thromboembolism in Europe and Canada in September 2008. ...
This type of embolism is known as a thromboembolism. Complications can arise when a venous thromboembolism (commonly called a ... Some people have a higher risk of developing thrombosis and its possible development into thromboembolism. Some of these risk ... Clinical guideline 46: Venous thromboembolism (surgical). London, April 2007. Geerts WH, Pineo GF, Heit JA, et al. (September ... Clinical guideline 92: Venous thromboembolism: reducing the risk for patients in hospital. London, January 2010. Hunt BJ (March ...
Arterial thromboembolism occurs suddenly and is very painful. The blockage of the terminal portion of the aorta results in an ... Feline arterial thromboembolism is a rare disease, accounting for approximately 0.1-0.3% of the total number of feline patients ... Less frequently, thromboembolism of the vessels of the arm, upper mesenteric artery or renal arteries (renal infarction) occurs ... Feline arterial thromboembolism (FATE syndrome) (German: Feline arterielle Thromboembolie) is a disease of the domestic cat in ...
Venous thromboembolism (VTE), also known as blood clots, is an underdiagnosed and serious, but preventable medical condition. ... Venous thromboembolism (VTE), also known as blood clots, is an underdiagnosed and serious, but preventable medical condition. ... Free continuing education for healthcare providers: Learn about venous thromboembolism in this e-learning course. Learn more ... NewE-learning course on the treatment and management of venous thromboembolism. Learn more and register ...
Trousseau is considered to be the first to have recognised a relation between venous thromboembolism (VTE) and malignancy. ... Venous thromboembolism and occult malignancy Thromb Res. 2001 Jun 15;102(6):V187-94. doi: 10.1016/s0049-3848(01)00235-3. ... Trousseau is considered to be the first to have recognised a relation between venous thromboembolism (VTE) and malignancy. ...
Thromboembolism, or the development of a clot within blood vessels, can occur in arteries or veins, but arterial ... Although the incidence of venous thromboembolism, a leading cause of adult morbidity and mortality, is lower in children than ... encoded search term (Pediatric Thromboembolism) and Pediatric Thromboembolism What to Read Next on Medscape ... Pediatric Thromboembolism Differential Diagnoses. Updated: Jun 08, 2023 * Author: Scott C Howard, MD; Chief Editor: Hassan M ...
The NHLBI leads and supports many studies on venous thromboembolism. See whether you or someone you love is eligible to join a ...
... especially if you are at risk of venous thromboembolism (VTE). ... Venous thromboembolism (VTE) refers to a blood clot in a vein. ... By learning about how to prevent an treat venous thromboembolism, communicating with your health care team, and surrounding ... especially if you are at risk of venous thromboembolism (VTE). There are important treatment decisions to make, emotional ...
Are you familiar with the presentation and treatment of venous thromboembolism? Test yourself with this short quiz. ... Venous thromboembolism (VTE) comprises two types of serious blood clots: deep venous thrombosis (DVT) and pulmonary embolism ( ... Quick Lesson on Pediatric Venous Thromboembolism Management 0.25 CME / CE / ABIM MOC Credits ... Fast Five Quiz: Test Your Knowledge of Venous Thromboembolism - Medscape - Dec 03, 2018. ...
... of patients having recurrent venous thromboembolism in the first 2 months after discontinuing oral anticoagulants. ... Cite this: Clinical Evidence for Rebound Hypercoagulability After Discontinuing Oral Anticoagulants for Venous Thromboembolism ... Clinical Evidence for Rebound Hypercoagulability After Discontinuing Oral Anticoagulants for Venous Thromboembolism ... for venous thromboembolism (VTE).. Objective: Assess the extent to which rebound hypercoagulability-related VTE recurrences ...
One in five cancer patients more likely to develop venous thromboembolism An analysis of more than 30,000 cancer patients has ... Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the ... Patients with SVT more likely to develop venous thromboembolism Patients with clinically diagnosed superficial vein thrombosis ... known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of ...
... data from two Womens Health Initiative trials that assessed factors that indicate increased risk of venous thromboembolism ( ... Risk Factors For Blood Clots, Venous Thromboembolism, In Women Identified. Date:. January 13, 2008. Source:. University of ... 1, 2020 A new review provides an in-depth analysis of the risk of venous thromboembolism (VTE) in patients hospitalized for ... 16, 2019 Researchers report that a new nuclear medicine tracer may allow better diagnosis of acute venous thromboembolism (VTE ...
Abdominal ultrasonography confirmed aortic thromboembolism (ATE), and surgical histopathology diagnosed necrotizing ... Surgical Removal of a Canine Aortic Thromboembolism Secondary to Pancreatitis. Jill Narak. ,1Emily C. Graff. ,2Katrin Saile. ,1 ... Aortic thromboembolism (ATE) is a relatively rare occurrence in the dog. Compared to the syndrome in cats, it typically results ... Prognosis for acute thromboembolism in cats is poor to grave when seen with underlying cardiac conditions; however, in dogs, ...
Venous thromboembolism (VTE) can affect men and women of all ages, races and ethnicities. People at the highest risk include ... Risk Factors for Venous Thromboembolism. Venous thromboembolism (VTE) can affect men and women of all ages, races and ...
... travel and risk for venous thromboembolism. Download Prime PubMed App to iPhone, iPad, or Android ... Prolonged travel and venous thromboembolism findings from the RIETE registry.. *Chemoprophylaxis for Venous Thromboembolism in ... HumansPublication BiasResearch DesignRisk AssessmentSelection BiasTime FactorsTravelVenous Thromboembolism ... Chandra D, Parisini E, Mozaffarian D. Meta-analysis: Travel and Risk for Venous Thromboembolism. Ann Intern Med. 2009 Aug 4;151 ...
Recurrent pulmonary thromboembolism presenting with cardiac arrhythmias. Message subject: (Your Name) has forwarded a page to ...
To predict the clinical risk of Pulmonary thromboembolism according to Wells score, click here. ... Venous Thromboembolism in Adult Hospitalizations - United States, 2007-2009 *↑ 19.0 19.1 19.2 Beckman MG, Hooper WC, Critchley ... Abbreviations: LDUH: low dose unfractionated heparin; LMWH: low molecular weight heparin; VTE: Venous thromboembolism ... Venous thromboembolism (VTE) may be classified into deep vein thrombosis (DVT) and pulmonary embolism (PE). Pulmonary embolism ...
Category Archives: Venous Thromboembolism. American College of Chest Physicians (CHEST) The American College of Chest ... Posted in Hematology, Venous Thromboembolism and tagged American College of Chest Physicians, CHEST on February 5, 2019. by han ...
ASH Releases New Guidelines for Management of Venous Thromboembolism in Latin America ... Venous thromboembolism (VTE) includes deep-vein thrombosis (DVT), a blood clot that typically forms in the deep veins of the ... ASH Clinical Practice Guidelines on Venous Thromboembolism. The American Society of Hematology (ASH) (www.hematology.org) is ... ASH Releases New Clinical Practice Guidelines for Management of Venous Thromboembolism in Latin America. Aug 10 ...
Hospital acquired venous thromboembolism (VTE) is a major source of morbidity and mortality, yet proven prevention measures are ... Hospital acquired venous thromboembolism (VTE) is a major source of morbidity and mortality, yet proven prevention measures are ... Designing and implementing effective venous thromboembolism prevention protocols: lessons from collaborative efforts J Thromb ...
When a blood clot breaks loose and travels in the blood, it is called a venous thrombo- embolism (VTE). ... Newer Contraceptive Pills Has Blood Clot Risk; Could Lead to Venous Thrombo-Embolism Personalised Printable Document (PDF). ... Newer Contraceptive Pills Has Blood Clot Risk; Could Lead to Venous Thrombo-Embolism. ...
Arixtra administered the morning after orthopedic surgery prevented venous thromboembolism with low risk of bleeding. ... Venous thromboembolism is a common complication of total knee or hip replacement surgery. The routine use of VTE prophylaxis is ... Arixtra is approved in the United States (U.S.) for the prevention of venous thromboembolism (VTE), which includes deep vein ... 3. Raskob GE, Hirsh J: Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism ...
... and treatment for venous thromboembolism with this short quiz. ... Quick Lesson on Pediatric Venous Thromboembolism Management ...
Venous thromboembolism (VTE) is often asymptomatic, mis-diagnosed, and unrecognized at death, and there is a lack of routine ... Venous thromboembolism (VTE) is often asymptomatic, mis-diagnosed, and unrecognized at death, and there is a lack of routine ... Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *November 2007 ...
Schulman S, Wåhlander K, Lundström T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin ... Ximelagatran v placebo for secondary prevention of venous thromboembolism (VTE) at 18 months* ... ximelagatran reduced recurrent venous thromboembolism and did not increase bleeding. ... and safety of ximelagatran after 6 months of standard anticoagulant therapy for secondary prevention of venous thromboembolism ...
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ... For high-risk patients, does prophylaxis against venous thromboembolism (VTE) with the combined modalities of leg intermittent ... Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann ... Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in ...
Genetic testing could help identify breast cancer patients with high risk of experiencing venous thromboembolism (VTE), a ... "The risk for venous thromboembolism is increased in cancer patients, particularly in those receiving chemotherapy," explained ... Genetic Testing to Identify Breast Cancer Patients at Risk for Venous Thromboembolism ...
Clinical validation of the AHRQ postoperative venous thromboembolism patient safety indicator.. Citation Text:. Henderson KE, ... Clinical validation of the AHRQ postoperative venous thromboembolism patient safety indicator. Jt Comm J Qual Patient Saf. 2009 ... Clinical validation of the AHRQ postoperative venous thromboembolism patient safety indicator. Jt Comm J Qual Patient Saf. 2009 ... Just what the doctor ordered: missed ordering of venous thromboembolism chemoprophylaxis is associated with increased VTE ...
Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol2007;110:587 ... Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. Can Med ... Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol2012;156:366-73. ... Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol2000;49:591-6. ...
Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism: a cohort study. ... Risk factor model to predict venous thromboembolism in hospitalized medical patients. J Hosp Med 2011;6:202-9. doi:10.1002/jhm. ... Hospital-acquired venous thromboembolism (VTE) is a leading cause of preventable death in hospitalised patients and its ... Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American ...
Idiopathic venous thromboembolism is associated with a 5-7 % increased risk of recurrence after an initial six months of ... Extended prevention of venous thromboembolism following an initial six month period of warfarin therapy An article from the e- ... Schulman et al showed that oral ximelagatran was superior to placebo for the extended prevention of venous thromboembolism and ... Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thrombo-embolism. N Engl J Med 2003; 348: 1425 ...
  • In about half of the recovered cats, thromboembolism recurs despite anticoagulation prophylaxis. (wikipedia.org)
  • ThromboGenics NV and co-development partner BioInvent International announce today that they have completed the enrolment of a 632-patient Phase IIb trial with their novel long-acting anticoagulant TB-402 for the prophylaxis of venous thromboembolism (VTE) after total hip surgery. (news-medical.net)
  • Arixtra is approved in the United States (U.S.) for the prevention of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients undergoing surgery for hip fracture (including extended prophylaxis), knee replacement, hip replacement, and in abdominal surgery patients who are at risk for thromboembolic complications. (webwire.com)
  • For high-risk patients, does prophylaxis against venous thromboembolism (VTE) with the combined modalities of leg intermittent pneumatic compression (IPC) and pharmacologic prophylaxis provide more protection than either treatment alone? (aafp.org)
  • Hospital-acquired venous thromboembolism (VTE) is a leading cause of preventable death in hospitalised patients and its prevention with pharmacological prophylaxis has been rated a top patient safety practice. (bmj.com)
  • This drug and the new very low molecular weight heparins - the pentasaccharides - are currently being evaluated in patients with ischaemic heart disease, atrial fibrillation and as prophylaxis and treatment of venous thromboembolism. (escardio.org)
  • At the time the CLOTS Trial Collaboration was reported, work was near completion on NICE guidance for venous thromboembolism (VTE) prophylaxis in all hospitalised patients. (bmj.com)
  • BACKGROUND: Evidence-based guidelines recommend that acutely ill hospitalized medical patients who are at risk of venous thromboembolism (VTE) should receive prophylaxis. (mcmaster.ca)
  • Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE). (mcmaster.ca)
  • Khokhar A, Chari A, Murray D, McNally M, Pandit H. Venous thromboembolism and its prophylaxis in elective knee arthroplasty: An international perspective. (medscape.com)
  • Venous thromboembolism (VTE) comprises two types of serious blood clots: deep venous thrombosis (DVT) and pulmonary embolism (PE). (medscape.com)
  • In patients with deep venous thrombosis or pulmonary embolism receiving standard anticoagulant therapy for 6 months, ximelagatran reduced recurrent venous thromboembolism and did not increase bleeding. (bmj.com)
  • Comparison of Low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. (escardio.org)
  • The Ottawa score is a clinical prediction rule designed for this purpose, stratifying patients according to their risk of recurrent venous thromboembolism during the first six months of anticoagulation. (haematologica.org)
  • The original score classified 49.3% of the patients as high-risk, with a sensitivity of 0.7 [95% confidence interval (CI): 0.6-0.8], a 6-month pooled rate of recurrent venous thromboembolism of 18.6% (95%CI: 13.9-23.9). (haematologica.org)
  • The modified score classified 19.8% of the patients as low-risk, with a sensitivity of 0.9 (95%CI: 0.4-1.0) and a 6-month pooled rate of recurrent venous thromboembolism of 2.2% (95%CI: 1.6-2.9). (haematologica.org)
  • Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. (umassmed.edu)
  • First episode and recurrent venous thromboembolism: who is identifiably at risk? (medscape.com)
  • Philadelphia, PA, February 3, 2006 Results from a new study of Arixtra (fondaparinux sodium) called FLEXTRA (Flexibility in Administration of Fondaparinux for Prevention of Symptomatic Venous Thromboembolism in Orthopaedic Surgery) showed the anti-thrombotic drug was generally well tolerated and effective in the prevention of symptomatic venous thromboembolism (VTE) when administered to patients the morning after orthopedic surgery. (webwire.com)
  • The frequency of symptomatic venous thromboembolism was 2.8 percent among those receiving ximelagatran, a rate that was 78 percent lower than in the placebo group. (escardio.org)
  • The characteristics of human genomics and cellular immune function between clinically symptomatic venous thromboembolism (VTE) and controls were systematically compared to explore the immunologic pathogenesis of VTE. (scienceopen.com)
  • Rivaroxaban has been found to be effective in the prevention of venous thromboembolism (VTE) after orthopedic surgery, for the prevention of stroke in AF (Atrial fibrillation) patients, and as additional therapy to conventional antiplatelet therapy in ACS (Acute coronary syndrome) patients. (news-medical.net)
  • WASHINGTON, August 10, 2021) - Today, the American Society of Hematology (ASH), the world's largest professional society dedicated to furthering the understanding, diagnosis, treatment, and prevention of blood disorders, announced the publication of adapted guidelines for the management of venous thromboembolism in Latin America, in partnership with 12 Latin American hematology societies representing 10 countries. (hematology.org)
  • Hospital acquired venous thromboembolism (VTE) is a major source of morbidity and mortality, yet proven prevention measures are often underutilized. (nih.gov)
  • Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. (bmj.com)
  • Q What is the long term efficacy and safety of ximelagatran after 6 months of standard anticoagulant therapy for secondary prevention of venous thromboembolism (VTE)? (bmj.com)
  • Oral ximelagatran is superior to placebo for extended prevention of venous thromboembolism in patients initially treated with warfarin (INR 2.0-3.0) for six months. (escardio.org)
  • Schulman et al showed that oral ximelagatran was superior to placebo for the extended prevention of venous thromboembolism and that there was no significant increase in the frequencies of bleeding complications (4). (escardio.org)
  • However, a direct comparison of ximelagatran and warfarin based on efficacy of the drugs, inconveniences in laboratory monitoring (INR, ALAT) and costs, is warranted, before any conclusion can be drawn as to the drug of choice in long-term prevention of venous thromboembolism. (escardio.org)
  • While waiting for such comparisons, extended prevention of venous thromboembolism with oral ximelagatran might be an option in some patients. (escardio.org)
  • 4) Schulman S, WÃ¥hlander K, Lundström T, Clason S B, Erikson H, for the THRIVE III Investigators: Secondary prevention of venous thromboembolism with oral direct thrombin inhibitor Ximelagatran. (escardio.org)
  • We discuss in-hospital and post-discharge venous thromboembolism (VTE) prevention, treatment of suspected but unconfirmed VTE, laboratory monitoring of COVID-19, associated anticoagulant therapies, and essential elements for optimized transitions of care specific to patients with COVID-19. (springer.com)
  • Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (scienceopen.com)
  • This article discusses the prevention of venous thromboembolism (VTE) and is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (scienceopen.com)
  • Agnelli G, Sonaglia F, Becattini C. Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. (medscape.com)
  • Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? (medscape.com)
  • Recurrent pulmonary thromboembolism presenting with cardiac arrhythmias. (bmj.com)
  • Venous thromboembolism (VTE) may be classified into deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ). (wikidoc.org)
  • Venous thromboembolism (VTE) includes deep-vein thrombosis (DVT), a blood clot that typically forms in the deep veins of the leg, and pulmonary embolism (PE), a life-threatening condition that occurs when a blood clot breaks free and becomes lodged in the arteries of the lung. (hematology.org)
  • Venous thromboembolism (VTE) events, which manifest as deep vein thrombosis (DVT) and/or pulmonary embolism (PE), cause considerable mortality and morbidity. (ajmc.com)
  • When used in the outpatient setting, anticoagulants (blood thinners) probably reduce venous thromboembolism (VTE) and pulmonary embolism (PE) when compared with placebo or no treatment in people with COVID-19. (cochrane.org)
  • Olivares Ortiz J, Botija Arcos G, Rupérez Lucas M, Cano Dorao F. Pulmonary thromboembolism: a not so unexpected diagnosis. (pap.es)
  • Samantha Pettigrew, MD, second-year pulmonary critical care fellow at Temple University Hospital, participated in a video interview with Healio Pulmonology on the recent CHEST update on venous thromboembolism and anti-coagulation. (templehealth.org)
  • Ishola T, Kirk SE, Guffey D, Voigt K, Shah MD, Srivaths L. Risk factors and co-morbidities in adolescent thromboembolism are different than those in younger children. (medscape.com)
  • Risk Factors for Venous Thromboembolism in Pediatric Trauma Patients and Validation of a Novel Scoring System: The Risk of Clots in Kids With Trauma Score. (medscape.com)
  • Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study. (medscape.com)
  • Cancer is one of the most frequent risk factors for venous thromboembolism (VTE) and for VTE recurrence while on anticoagulation. (haematologica.org)
  • Analysis of incidence and risk factors for postoperative venous thromboembolism in patients with stageâ…  a non-small-cell lung cancer]. (physiciansweekly.com)
  • To analyze the incidence and risk factors for postoperative venous thromboembolism(VTE) in patients with stage â… a non-small-cell lung cancer(NSCLC), so as to find evidence for further research of prophylactic anticoagulation. (physiciansweekly.com)
  • Up to 17% of cats with HCM experience arterial thromboembolism, but cats with other cardiomyopathies are also at increased risk. (wikipedia.org)
  • Preliminary data from two Women's Health Initiative trials that assessed factors that indicate increased risk of venous thromboembolism (VTE) with postmenopausal hormone therapy is now available. (sciencedaily.com)
  • Current exposure to any combined oral contraceptive was associated with an increased risk of venous thromboembolism (adjusted odds ratio 2.97, 95% confidence interval 2.78 to 3.17) compared with no exposure in the previous year. (bmj.com)
  • Idiopathic venous thromboembolism is associated with a 5-7 % increased risk of recurrence after an initial six months of anticoagulation with conventional-intensity warfarin (INR 2.0-3.0), but can be reduced with the use of extended warfarin therapy (1). (escardio.org)
  • Many patients with COVID-19 are at increased risk of venous thromboembolism (VTE). (springer.com)
  • Venous thromboembolism (VTE) in patients with AAV is common with previous studies identifying a 4-fold increased risk in AAV compared with the general population. (researchsquare.com)
  • Clinical validation of the AHRQ postoperative venous thromboembolism patient safety indicator. (ahrq.gov)
  • ABSTRACT To assess the risk of venous thromboembolism (VTE) associated with hyperhomocystein- aemia (hyper-Hcy) and hyperlipidaemia, we performed a case-control study. (who.int)
  • A diagnosis of cancer can leave you and your loved ones feeling uncertain, anxious and overwhelmed, especially if you are at risk of venous thromboembolism (VTE). (cancercare.org)
  • Participants Women aged 15-49 years with a first diagnosis of venous thromboembolism in 2001-13, each matched with up to five controls by age, practice, and calendar year. (bmj.com)
  • Feline arterial thromboembolism (FATE syndrome) (German: Feline arterielle Thromboembolie) is a disease of the domestic cat in which blood clots (thrombi) block arteries, causing severe circulatory problems. (wikipedia.org)
  • Heart disease is the most common underlying cause of arterial thromboembolism. (wikipedia.org)
  • Arterial thromboembolism occurs suddenly and is very painful. (wikipedia.org)
  • The mortality of arterial thromboembolism in cats is very high. (wikipedia.org)
  • Feline arterial thromboembolism is a rare disease, accounting for approximately 0.1-0.3% of the total number of feline patients. (wikipedia.org)
  • Conservative treatment of arterial thromboembolism in cats is also based on this endogenous dissolution of the clot (see below). (wikipedia.org)
  • In humans, heart disease (especially atrial fibrillation), increased blood clotting, and atherosclerosis are the most common underlying diseases for the development of arterial thromboembolism. (wikipedia.org)
  • Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients. (medscape.com)
  • Pharmacological treatment of arterial thromboembolism. (who.int)
  • The risk for venous thromboembolism is increased in cancer patients, particularly in those receiving chemotherapy," explained the study's lead author, Judith S. Brand, PhD, a postdoctoral researcher in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Stockholm, Sweden. (nursingcenter.com)
  • Recently, Schulman and co-workers assessed a new treatment option, namely the effects of the oral direct thrombin inhibitor ximelagatran 24 mg twice daily or placebo in patients who had completed 6 months of anticoagulant therapy for an episode of venous thromboembolism. (escardio.org)
  • Over 8 million acute medically ill patients each year in the United States are at risk for experiencing venous thromboembolism (VTE) events, with up to 900,000 patients developing blood clots for the first time. (ajmc.com)
  • We know that we need to take a good history and do a physical exam in patients with venous thromboembolism. (oncologynurseadvisor.com)
  • In patients with cancer-associated venous thromboembolism, knowledge of the estimated rate of recurrent events is important for clinical decision-making regarding anticoagulant therapy. (haematologica.org)
  • We conclude that new therapeutic strategies are needed in patients at high risk for recurrent cancer-associated venous thromboembolism. (haematologica.org)
  • The sequelae associated with long COVID were notably different among male vs female patients and patients above vs under 55 years old, with the hair loss enrichment found primarily in females and the thromboembolism enrichment in males. (medrxiv.org)
  • Venous thromboembolism (VTE) is a common complication in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) and confers significant morbidity and mortality. (researchsquare.com)
  • Venous thromboembolism in orthopedic trauma patients. (medscape.com)
  • Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. (medscape.com)
  • Venous thromboembolism (VTE) as the most common cancer -associated complication has become the second death -causing reason among cancer patients . (bvsalud.org)
  • In vitro studies and anecdotal clinical reports have suggested that clinically significant rebound hypercoagulability may occur after discontinuation of oral anticoagulants (OACs), such as vitamin K antagonists and ximelagatran, for venous thromboembolism (VTE). (medscape.com)
  • Thrombocytosis in asplenia syndrome with congenital heart disease: A previously unrecognized risk factor for thromboembolism. (medscape.com)
  • Venous thromboembolism is a common complication of total knee or hip replacement surgery. (webwire.com)
  • Fast Five Quiz: Thromboembolism - Medscape - Oct 20, 2023. (medscape.com)
  • Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the labeling only listed cerebral vascular accidents. (cdc.gov)
  • Venous thromboembolism (VTE) in childhood is uncommon and clinically variable. (pap.es)
  • Because thromboembolism is uncommon and its symptoms are often nonspecific in children, a high index of suspicion is required. (medscape.com)
  • Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. (unboundmedicine.com)
  • TY - JOUR T1 - Meta-analysis: travel and risk for venous thromboembolism. (unboundmedicine.com)
  • Venous thromboembolism (VTE) refers to a blood clot in a vein. (cancercare.org)
  • Venous thromboembolism (VTE) refers to DVT, PE, or both. (cdc.gov)
  • Trousseau is considered to be the first to have recognised a relation between venous thromboembolism (VTE) and malignancy. (nih.gov)
  • E-learning course on the treatment and management of venous thromboembolism. (cdc.gov)
  • Venous thromboembolism in adult hospitalizations - United States, 2007-2009. (medscape.com)
  • Title : Trends in venous thromboembolism among pregnancy-related hospitalizations, United States, 1994-2009 Personal Author(s) : Ghaji, Nafisa;Boulet, Sheree L.;Tepper, Naomi;Hooper, William C. (cdc.gov)
  • Conclusions In these population based, case-control studies using two large primary care databases, risks of venous thromboembolism associated with combined oral contraceptives were, with the exception of norgestimate, higher for newer drug preparations than for second generation drugs. (bmj.com)
  • Venous thromboembolism (VTE), also known as blood clots, is an underdiagnosed and serious, but preventable medical condition. (cdc.gov)
  • Venous thromboembolism, which includes both deep vein thrombosis (DVT) and PE, is a condition where a blood clot forms in a vein and may migrate to another location (e.g. the lung). (cochrane.org)
  • Venous thromboembolism, or VTE, is a condition in which blood clots form in veins that are deep inside the body. (planetdrugsdirect.com)
  • Learn more about thromboembolism in pregnancy. (medscape.com)
  • Although combined oral contraceptives are generally effective in preventing pregnancy, they have measurable side effects such as venous thromboembolism (VTE). (bmj.com)
  • Unfortunately, venous thromboembolism is very common. (planetdrugsdirect.com)
  • OBJECTIVES: Venous thromboembolism (VTE) is a common worldwide disease. (lu.se)
  • Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. (medscape.com)
  • Main outcome measures Odds ratios for incident venous thromboembolism and use of combined oral contraceptives in the previous year, adjusted for smoking status, alcohol consumption, ethnic group, body mass index, comorbidities, and other contraceptive drugs. (bmj.com)
  • Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. (medscape.com)